CURRICULUM VITAE - Harvard Medical School · Chair, Search Committee for Director, Office of Cancer...

CURRICULUM VITAE

NAME: James H. Doroshow, M.D., F.A.C.P.

ADDRESS AND PHONE NUMBER:

HOME: 6001 Corewood Lane

Bethesda, MD 20816

(301) 320-3260

OFFICE: Division of Cancer Treatment and Diagnosis

National Cancer Institute

Building 31, Room 3A44

31 Center Drive

Bethesda, MD 20892

(301) 496-4291

PERSONAL AND FAMILY:

Date of Birth: August 19, 1948

Place of Birth: Lynwood, CA

Citizenship: U.S.A.

Marital Status: Married

Wife's Name: Robin Winkler Doroshow, M.D.

Children: Deborah Blythe Doroshow, M.D., Ph.D.

EDUCATION:

1965-1969 A.B. (History and Science, Magna cum laude)

Harvard University, Cambridge, Massachusetts

1969-1973 M.D. Harvard Medical School, Boston, Massachusetts

MILITARY SERVICE:

Lieutenant Commander, U.S. Public Health Service, 1975-1978

PROFESSIONAL EXPERIENCE:

2011-Present Deputy Director for Clinical and Translational Research

National Cancer Institute, Bethesda, MD

2004-Present Director, Division of Cancer Treatment and Diagnosis,


Senior Investigator (Full NIH Tenure), Developmental Therapeutics Branch,

Center for Cancer Research, National Cancer Institute, Bethesda, MD

2

Dr. J. H. Doroshow - Curriculum Vitae, contd.

1983-2004 Chairman, Department of Medical Oncology and Therapeutics Research

City of Hope National Medical Center, Duarte, CA

Associate Director for Clinical Research

City of Hope Comprehensive Cancer Center

1983-2004 Leader, Clinical and Experimental Therapeutics Program, City of Hope

Cancer Center and Director, Medical Oncology Fellowship Program

1987-1989; Director, City of Hope Comprehensive Cancer Center

2000-2001

1996-1998 Director, Department of Physician Relations and Community Oncology


1981-1983 Head, Section of Pharmacology, and Physician, Dept. of Medical Oncology,


1978-1981 Assistant Professor of Medicine, Division of Medical Oncology,

University of Southern California School of Medicine. Attending Staff,

Los Angeles County-University of Southern California Medical Center

1977-1978 Investigator, Clinical Pharmacology Branch, National Cancer Institute,

Bethesda, MD

1976-1977 Clinical Associate, Clinical Pharmacology Branch,


1975-1976 Clinical Associate, Medicine Branch, National Cancer Institute, Bethesda, MD

1974-1975 Resident in Medicine, Massachusetts General Hospital, Boston, MA

1973-1974 Intern in Medicine, Massachusetts General Hospital, Boston, MA

1973-1975 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA

MEDICAL LICENSURE:

California Certificate # G-28765, 1/21/75

Massachusetts Certificate # 37308, 11/7/74

District of Columbia Certificate # 8506, 12/5/75

BOARD CERTIFICATION:

Diplomate, National Board of Medical Examiners, 1974

Diplomate, American Board of Internal Medicine, 1976

Diplomate, American Board of Internal Medicine, Subspecialty of Medical Oncology, 1977

3


PROFESSIONAL SOCIETIES:

American Federation for Medical Research

American Association for Cancer Research

American Society of Clinical Oncology

Society for Free Radical Research/Oxygen Society

American Society of Hematology

American Society for Pharmacology and Experimental Therapeutics

American College of Physicians

Association of Hematology and Oncology Program Directors

American Society for Blood and Marrow Transplantation

HONORS AND AWARDS:

National Merit Scholar, 1965-1969

John Harvard Scholarship, 1968

Detur Prize, Harvard University, 1968

Phi Beta Kappa, 1969

Alpha Omega Alpha, 1973

Richard Cabot Prize, Harvard Medical School, 1973

Special Fellow of the Leukemia Society of America, 1980-1982

Scholar of the Leukemia Society of America, 1982-1987

Fellow of the American College of Physicians, 1984

Member, National Institutes of Health Experimental Therapeutics II Study Section, 1987-1992

Chairman, National Institutes of Health Experimental Therapeutics II Study Section, 1990-1992

National Institutes of Health Reviewers Reserve, 1992-96

Member, National Cancer Institute, Cancer Collaborative Research Review Committee,

Subcommittee D--Pharmacology, 1993-95

Member, Subspecialty Board on Medical Oncology, American Board of Internal Medicine,

1995-2001

Seventh Annual Charles L. Spurr Lectureship, Comprehensive Cancer Center of Wake Forest

University, 1996

Florence Lockhart Nimick Memorial Oncology Lectureship, Pittsburgh Cancer Institute, 1996

Gallery of Scientific and Medical Achievement, City of Hope, 1997

Best Doctors in America, 1992-2013

Member, National Cancer Institute, Scientific Review Group A--Cancer Centers, 1997-2000

Chairman, National Cancer Institute, Scientific Review Group A--Cancer Centers, 1999-2000

Chair, Southwest Oncology Group Early Therapeutics Committee, 2001-2004

America=s Top Doctors, 3rd

Edition, 2003; 4th

Edition, 2004; 5th

Edition, 2005; 6th

Edition, 2006;

7th

Edition, 2007; 8th

Edition, 2008; 9th

Edition, 2009; 10th

Edition, 2010;

11th

Edition, 2011; 12th

Edition, 2012; 13th

Edition, 2013; 14th

Edition, 2014

Member, Oncologic Drugs Advisory Committee, US Food and Drug Administration, 2003-2007

Gerhard Schmidt Memorial Lectureship in Transplantation Biology, City of Hope Comprehensive

Cancer Center, 2005

America’s Top Doctors for Cancer, 1st Edition, 2005; 2

nd Edition, 2006; 3

rd Edition, 2007;

4th

Edition, 2008; 5th

Edition, 2009; 6th

Edition, 2010; 7th

Edition, 2011; 8th

Edition, 2012;

9th

Edition, 2013

Eleventh Annual Maurice M. Burkholder Lectureship in Oncology, Mountain States Tumor

Institute, 2006

4


HONORS AND AWARDS (contd.):

Stanley Balcerzak Annual Lectureship, Department of Internal Medicine, The Ohio State

University School of Medicine, 2007

Who’s Who in America, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014

Scott Wadler, M.D. Memorial Lectureship, New York Cancer Consortium and Albert Einstein

College of Medicine, 2008

NIH Individual Award of Merit: “For Leadership of NCI’s Early Drug Discovery and

Development Program, and for Transforming Clinical Cancer Research Across the Entire

Spectrum of Therapeutic Oncology”, 2008

President David Hardesty Lectureship, Mary Babb Randolph Cancer Center, West Virginia

University, 2009

National Institutes of Health Director’s Award: “For Outstanding Initiative and Leadership in

Promoting New Approaches to Shorten the Time Frame in Which NCI-Sponsored Clinical

Trials Are Implemented”, 2009

Who’s Who in Medicine and Health Care, 2009, 2010, 2011, 2012, 2013

Lois O’Grady, M.D. Lectureship, University of California Davis School of Medicine, 2011

NIH Award of Merit: “For the Development of the NCI Pharmacodynamics Program”, 2011

City of Hope Scientific Research Portrait Gallery of Achievement, 2013

RESEARCH SUPPORT:

Current: NIH ZIA BC010677-08; NADPH Oxidase 1: A Novel Target for Colon Cancer

Therapy; ZIA BC011076-05; Roles of NADPH Oxidase 5 and Dual Oxidase

2 in Cancer; PI 10/1/05-9/30/17; ZIA BC 011078; Phase 0/1 Clinical Trials;

PI 10/1/05-9/30/17

Previous: NIH Research Grant # CA 62505; Phase I Molecular and Clinical

Pharmacodynamic Trials; 2/1/94 - 1/31/08; 15% effort; PI

NIH Contract # CM 17101; Early Therapeutics Development with

Phase II Emphasis; 2/1/01 - 12/31/05; 15% effort; PI

NIH Research Grant # CA 01727; COH Clinical Oncology Research

Development Program; 9/1/92 - 6/30/08; 10% effort; PI

NIH Research Grant # CA 46368; COH Southwest Oncology Group Trials;

8/1/86 - 12/31/09; 10% effort; PI

NIH Research Grant # CA 33572; City of Hope Cancer Center Support Grant;

12/1/84 - 8/31/07; 20% effort; Associate Director; PI 1/87-9/89; 9/00-4/01

NIH Research Grant # CA 95260; Simultaneous Care: Linking Palliation to

Clinical Trials; 4/01/02-3/31/07; 5% effort; PI

NIH Research Grant # CA 43904; Bio-Engineered Antibodies in Cancer

Imaging and Therapy; 7/1/88 - 9/30/06; 3% effort; Co-Investigator

NIH Research Grant # CA 71866; MDR1 Selection in CD34+ Cells and

SCID-Hu Mice; 7/1/96-6/30/03; Co-Investigator

NIH Research Grant # CA 63265; Pharmacodynamic Phase II Breast, Lung, and

Ovary Trials; 4/1/94 - 1/31/01; 10% effort; PI

NIH Research Grant # CA 65767; Molecular Breast Cancer Therapy and

Carcinogenesis; 10/1/94 - 9/30/99; PI

NIH Research Grant # CA 59308; Gene Therapy of Marrow Cells During

Cancer Treatment; 10/1/92 - 9/30/97; Project Leader

5


RESEARCH SUPPORT:

Previous: American Cancer Society Grant DHP-67656; Modulation of Pyrimidine

Antagonists in Acute Leukemia; 1/1/93 - 12/31/96; Co-Investigator

NIH Research Grant # GM 46565; Cloned Human Carbonyl Reductase:

Molecular Pharmacology; 8/1/92 - 7/31/95; Co-Investigator

American Cancer Society Clinical Oncology Fellowship Awards;

7/1/83 - 6/30/95; PI

NIH Research Grant # CA 09477; Surgical Oncology; 9/1/84 - 6/30/93;

Co-Investigator

NIH Contract # CM 73703; Clinical Trials of Activated Human Leukocytes;

2/1/86 - 6/29/91; PI

NIH Research Grant # CA 31788; Oxygen Radicals and Anticancer Quinones;

12/80 - 5/88; PI

Scholarship of the Leukemia Society of America; 10/82 - 9/87; PI

NIH Research Grant # CA 43595; NSABP Trials; 4/87-1/92; Co-Investigator

Special Fellowship of the Leukemia Society of America; 7/80 - 6/82; PI

American Heart Association Grant 622-G3; 7/79 - 6/82; PI

EDITORIAL BOARDS: Free Radical Biology and Medicine, 1985-1993

The Oncologist, 1996-2001

Section Editor for Medical Oncology, Annals of Surgical Oncology,

1998-2001

Research Communications in Molecular Pathology

and Pharmacology, 1988-2003

Cancer Chemotherapy and Pharmacology, 1990-2003

Associate Editor, UICC (International Union Against Cancer)

Manual of Clinical Oncology, 7th

Edition, c.1999; 8th

Edition, c.2004

Associate Editor, Clinical Cancer Research, 1999-2004

Oncology, 2002-2007

International Journal of Oncology, 2002-2009

Senior Editor for Pharmacology, Clinical Cancer Research, 2005-Present

Technology in Cancer Research and Treatment, 2001-Present

Pharmacology and Drug Discovery Faculty, Faculty of 1000

Biology/Medicine, 2006-2007; 2013-Present

Guest Editor, Clinical Cancer Research Focus on Phase 0 Clinical

Trials, 2008

Associate Editor, Abeloff’s Clinical Oncology, 5th

Edition, 2014

Associate Editor for Oncology, Cecil Textbook of Medicine,

25th

Edition, 2015

Seminars in Oncology, 2013-Present

Cardio-Oncology, 2015-Present

COMMITTEE MEMBERSHIPS:

Current National Activities:

Member, Forum on Drug Discovery, Development, and Translation, Institute of

Medicine of the National Academies of Science, 2007-2015

6


COMMITTEE MEMBERSHIP (contd.)

Current National Activities (contd.):

Member, Life Sciences Consortium Task Force, CEO Roundtable on Cancer,

2008-2015

Scientific Committee and Co-Organizer, 26th

AACR-NCI-EORTC International

Conference: “Molecular Targets and Cancer Therapeutics” Boston, MA,

November 2015

Member, NCATS (NIH National Center for Advancing Translational Sciences)

Clinical and Translational Science Awards (CTSA) Steering Committee,

2015-Present

Member, National Cancer Policy Forum, Institute of Medicine of the National

Academies of Science, 2015-Present

Current Local Activities:

Scientific Program Leadership Committee, National Cancer Institute, 2004-Present

Co-Chair, Molecular Targets Faculty, Center for Cancer Research, National

Cancer Institute, 2004-Present

Co-Chair, Senior Advisory Committee, NCI Experimental Therapeutics Program,

2010-Present

Member, Clinical Trials & Translational Research Operations Committee, NCI,

2005-Present; Chair, 2011-Present

Member, Clinical Trials & Translational Research Advisory Committee, NCI,

2006-Present

Member, Cancer Steering Committee, NIH Foundation, 2007-Present

Member, NIH Workgroup on Supporting Clinical Center and Extramural

Collaborations, 2012-Present

Chair, Search Committee for Director, Office of Cancer Centers, NCI 2015

Previous National and Local Activities:

AACR 2014 Annual Meeting Program Committee

Member, CEO Life Sciences Consortium Dr. Charles A. Sanders Award, 2013

Scientific Committee and Co-Organizer, 25th


Conference: “Molecular Targets and Cancer Therapeutics” Barcelona,

Spain, November 2014

Co-Chair, Organizing Committee, 24th


Conference: “Molecular Targets and Cancer Therapeutics”, Boston, MA

October 2013

Co-Chair, Trans-NIH Task Force on Clinical Trials, 2012-2013

Member, Search Committee, Division of Clinical Innovation,

NCATS, NIH, 2012-3

AACR 2013 Annual Meeting Clinical Trials Committee

Trans-NIH Advisory Group for the Therapeutics for Rare and Neglected Diseases

Program, 2010-2013

7



Previous National and Local Activities (contd.):

Member, NCI Lung Cancer Steering Committee, 2007-2013

Member, NCI Center for Cancer Research Molecular Oncology Center of

Excellence Steering Committee, 2007-2013

Member, Trans-NIH Inventory of Programs and Initiatives Relevant to

Therapeutics Development Task Force, 2010-2012

Member, NIH-FDA Leadership Council Working Group on Clinical Research and

Trials, 2011-2013

Co-Chair, Scientific Organizing Committee, 23rd


Conference: “Molecular Targets and Cancer Therapeutics: Discovery,

Biology, and Clinical Applications,” Dublin, IR, November 2012

Board of Directors, Clinical Trials Network of the Cancer Prevention & Research

Institute of the State ofTexas, 2011-2013

Member, Organizing Committee, Targeted Anticancer Therapies 2012, European

Society of Medical Oncology and the NDDO Research Foundation

Co-Chair, Scientific Organizing Committee, 22nd



Biology, and Clinical Applications,” San Francisco, CA November 2011

Co-Chair, Scientific Organizing Committee, 21st AACR-NCI-EORTC International


Biology, and Clinical Applications,” Berlin, FRG November 2010

Member, NCI-FDA Biomarkers Think Tank, 2007-2011

Co-Chair, Operational Efficiency Working Group, NCI, 2008-2010

Co-Chair, AACR-FDA-NCI Cancer Biomarkers Collaborative, 2006-2010



Member, American Association for Cancer Research Clinical Translational

Research Steering Committee, 2006-2009

Co-Chair, Joint Therapeutics Development Committee, Center for Cancer

Research and Division of Cancer Treatment and Diagnosis, NCI, 2005-09

Member, Organizing Committee, Institute of Medicine, National Academies of

Science Workshop: “Transforming Clinical Research in the US,” 2009

Co-Chair, Scientific Organizing Committee, AACR-NCI-EORTC International


Biology, and Clinical Applications,” Boston, MA November 2009

Member, American Society of Clinical Oncology, Cancer Research Committee,

2005-2008

Executive Secretary, Clinical Investigations Subcommittee, National

Cancer Advisory Board, NCI, 2004-2008

Member, Planning Committee, National Cancer Policy Forum, Institute of

Medicine Workshop: “Improving Multisite Cancer Clinical Trials,” 2008

Co-Chair, Scientific Organizing Committee, 20th

EORTC-NCI-AACR Symposium

on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland

October 2008

8

Dr. J.H. Doroshow - Curriculum Vitae, contd.





Member, Source Selection Evaluation Group—NCI Frederick Contract, 2008

Co-Chair, Scientific Organizing Committee, AACR-NCI-EORTC International


Biology, and Clinical Applications,” San Francisco, CA 10/2007

Member, Neurosurgery Search Committee, National Institute for Neurologicial

Disease and Stroke, 2007-2008

Co-Chair, Oncology Biomarkers Qualification Initiative, FDA-NCI

Interagency Task Force, 2005 to 2007

Member, American Association for Cancer Research, Special Conferences

Committee, 2004-2007

Member, American Association for Cancer Research Program Committee,

2006-2007

Member, Planning Committee, National Cancer Policy Forum, Institute of

Medicine Workshop: “Improving the Quality of Cancer Clinical Trials,”

2007

Member, American Association for Cancer Research, Jeannik M. Littlefield—

AACR Grants for Metastatic Colon Cancer Selection Committee, 2007

Member, Oncologic Drugs Advisory Committee, US Food and Drug

Administration, 2004-2007

Member, Translational Research Working Group, NCI, 2005-2007

Member, Scientific Organizing Committee, AACR-NCI-EORTC International


Biology, and Clinical Applications,” Prague, Czech Republic, 11/06

Co-Chair, AACR-NCI-FDA-ASCO 2006 Workshop: “Accelerating Anticancer

Agent Development and Validation,” Bethesda, MD, May 2006

Chair, Search Committee for Scientific Director for Clinical Research, Center for

Cancer Research, National Cancer Institute, 2006

National Institutes of Health Roadmap Clinical Research Networks Efficiency


National Institutes of Health Roadmap Translational Core Services Committee,

2004-2006

Co-Chair, AACR-NCI-FDA-ASCO 2005 Workshop: “Accelerating Anticancer

Agent Development and Validation,” Bethesda, MD, June 2005

Member, Scientific Organizing Committee, AACR-NCI-EORTC International


Biology, and Clinical Applications,” Philadelphia, PA, November 2005

Member, American Association for Cancer Research, Clinical Cancer Research


Chair, Clinical Trials Working Group, National Cancer Advisory Board, NCI

2004-2005

National Cancer Institute Search Committee for NCI “Physician-in-Chief,”

2004

9




Chair, Southwest Oncology Group Early Therapeutics Committee, 2001-2004

Member, American Board of Internal Medicine, Recent Advances in Medical

Oncology Committee, 2002-2004

National Comprehensive Cancer Network Colorectal Cancer Panel, 1995-2004

National Comprehensive Cancer Network Clinical Research

Advisory Committee, 1998-2004

Board of Governors, Southwest Oncology Group, 1986-2004

Chairman, Clinical Cancer Committee, City of Hope National Medical Center,

1983-2004; Chair, Cancer Protocol Review Committee, 1993-2004

Executive Committee, City of Hope Cancer Research Center, 1983-2004

Executive Committee, Division of Medicine, City of Hope National Medical

Center, 1984-2004

Member, Medical Staff Executive Committee, City of Hope National Medical

Center, 1988-2004

Member, City of Hope Medical Group Board of Directors, 1995-2004

Member, City of Hope Gene Therapy Coordinating Committee, 1992-2004

Board of Directors, Wellness Community of Southern California, 1989-2004

Member, City of Hope Clinical and Scientific Executive Team, 2000-2004

Southwest Oncology Group Chair Nominating Committee, 2001-2002

National Institutes of Health Oncology Study Section Boundaries Team, 2001-

2002

Member, American Association for Cancer Research, California State Legislative


Member, Scientific Advisory Board, Roswell Park Cancer Institute, 1998-2002

Member, Subspecialty Board on Medical Oncology, American Board

of Internal Medicine, 1995-2001

National Comprehensive Cancer Network Board of Directors, 2000-2001

Member, National Institutes of Health, Center for Scientific Review, Advisory

Committee for the Oncology Initial Review Group, 1999-2000

Member, National Cancer Institute, Scientific Review Group A--Cancer Centers,

1997-2000; Chairman, 1999-2000

Member, External Scientific Advisory Board, Dana Farber Cancer Institute, 2000

Member, American Association for Cancer Research, Gertrude Elion Research

Award Committee, 1998-1999

External Scientific Advisory Panel, Specialized Research Center on Malignant

Human Gliomas, Duke University School of Medicine, 1993-1999

Member, Medical and Scientific Advisory Board, Immunex, Corp., 1995-1999

External Scientific Review Panel, Univ. of Iowa Cancer Center, 1995-1998

Member, American Association for Cancer Research Program Committee,

Clinical Research Subcommittee, 1997-1998

Member, National Cancer Institute Board of Scientific Advisors Cancer Control

Program Review Group, 1996-1997

10




Member, Program Committee, American Society of Clinical Oncology, 1995-96

Member, National Cancer Institute, Cancer Collaborative Research Review

Committee, Subcommittee D--Pharmacology, 1993-1995

Member, Experimental Therapeutics and Pharmacology Committee, American

Society of Clinical Oncology, 1993-1994

Member, National Institutes of Health Experimental Therapeutics II

Study Section, 1987-1992

Member, Tumor Biology Subcommittee, Gynecologic Oncology, Southwest

Oncology Group, 1991-1997

Member, City of Hope Oncology Network Board of Directors, 1995-1999

Chairman, City of Hope Oncology Network Clinical Research Committee,

1995-1999

Chairman, City of Hope Oncology Network Guidelines Committee, 1995-1999

Member, City of Hope Patient Care Council, 1997-1999

Member, City of Hope Research Council, 1997-2000

Member, City of Hope Oncology Network Management Services Organization

Board of Directors, 1995-1998

Member, Scientific and Medical Advisory Committee, City of Hope National

Medical Center, 1993-1994

Member, City of Hope Promotions Committee, 1992-1996

Member, City of Hope Institutional Review Board, 1988-1996

Member, City of Hope Managed Care Task Force, 1994-1996

Member, City of Hope Quality Council, 1992-1994

Technical Review Panel, State of Nebraska Department of Health, Cancer and

Smoking Disease Research Program, 1992-1994

Member, City of Hope Faculty Senate/Executive Committee, 1990-92

Chairman, Search Committee, Radiation Oncology Chairmanship, 1991

Member, City of Hope Faculty Appointment and Review Committee, 1990

Board of Directors, Cancer Management Network of Southern California,

1987-1991

Capital Budget Committee, City of Hope National Medical Center,

Member 1986-1996, Chairman 1991-1996

Peer Review Committee, Arizona Disease Control Research Commission,

State of Arizona Department of Health Services, 1985-1988

Organizing Committee, Fifth Biennnial Meeting of the International Society for

Free Radical Research, November 14-20, 1990, Pasadena, CA

Chairman, Local Arrangements Committee, American Society of

Clinical Oncology, 1985-1986

Scientific Advisory Committee, UCLA Clinical Nutrition Research Unit,

University of California, Los Angeles, 1986-1990

Executive Committee, Northern California Oncology Group, 1984-1990

11




Chairman, Search Committee, Executive Vice President for Medical and

Scientific Affairs, City of Hope National Medical Center, 1986-1988

Chairman, Search Committee, Director of Dept. of Biostatistics, City of Hope

National Medical Center, 1986

Chairman, Research Space Committee, City of Hope, 1986-1989

Vice Chairman, Medical Management Council, City of Hope, 1986-1988

Acting Director, Department of Biostatistics, City of Hope National Medical

Center, 1987-88

Member, Search Committee, Chairman, Division of Pathology, City of Hope

National Medical Center, 1986

City of Hope Organizational Task Force, 1985-1986

City of Hope Pharmacy & Therapeutics Committee, 1981-1985; Chair, 1983-1985

Scientific Review Committee, University of Southern California Comprehensive

Cancer Center, 1978-1981

12


INVITED LECTURES AND REVIEW ACTIVITIES (Since 2000):

Chair, Fox Chase Comprehensive Cancer Center Site Visit, National Cancer Institute, 2/00

Cancer Center of Santa Barbara Symposium: Guidelines for Women=s Cancer Treatment in the New

Millenium, Santa Barbara, CA

ASystemic Cancer Therapy in the Next Decade@ 3/00

American Association for Cancer Research Symposium: NIH Grants: View from Peer Review,

San Francisco, CA

AHow to Get a Clinical Grant@ 4/00

Arizona Clinical Oncology Society, Phoenix, AZ

AHigh-Dose Chemotherapy for Metastatic Breast Cancer@ 4/00

Sixth International NCI/NINDS Blood-Brain Disruption Consortium Meeting: Importance of Dose

Intensity in Neuro-Oncology Clinical Trials, Mt. Hood, OR

Keynote Lecture: AImportance of Dose Intensity in Oncologic Therapy@ 4/00

Chair, University of Colorado Comprehensive Cancer Center Site Visit, National Cancer Institute, 5/00

Southern California Academy of Clinical Oncology, Los Angeles, CA

AASCO Update: Novel Therapeutic Agents@ 6/00

National Cancer Institute, Ad Hoc Member, Scientific Review Group D--Clinical Research

Studies, 7/00

M.D. Anderson Cancer Center, Division of Medicine Grand Rounds, Houston, TX

AReactive Oxygen Metabolism and the Anthracycline Antibiotic Cell Death Program@ 8/00

National Cancer Institute, Cancer Therapy Evaluation Program Drug Development Meeting,

Bethesda, MD

APhase I Study of Oxaliplatin in Patients with Advanced Malignancies and Varying Degrees of

Liver Dysfunction@ 9/00

National Cancer Institute, Ad Hoc Member, Study Section to Review Proposals in Response to

RFA CA-00-002: AMolecular Target Drug Discovery for Cancer,@ Rockville, MD 11/00

Visiting Professor, Departments of Pharmacology and Oncology, Mayo Clinic and Mayo Comprehensive

Cancer Center, Rochester, MN

AThe Anthracycline Antibiotic Cell Death Program@ 12/00

National Institutes of Health, Chairman Ad Hoc Experimental Therapeutics I Study Section, 1/01

Chair, Northwestern Univ. Comprehensive Cancer Center Site Visit, National Cancer Institute, 3/01

13


INVITED LECTURES AND REVIEW ACTIVITIES (contd.)

Lombardi Comprehensive Cancer Center of Georgetown University, Grand Rounds,

Washington, D.C.

AThe Anthracycline Antibiotic Cell Death Program@ 4/01

Visiting Professor, University of Virginia Cancer Center, Charlottesville, VA

ARole of Reactive Oxygen Species in Anthracycline-Related Apoptosis@ 5/01

American Society of Clinical Oncology Annual Meeting Symposium: AStrategies for a Successful Career

in Academic Oncology,@ San Francisco, CA 5/01

Norris Comprehensive Cancer Center of the University of Southern California, Grand Rounds,

Los Angeles, CA

AOncologic Clinical Pharmacology@ 12/01

Co-Chair, National Institutes of Health, Oncology Study Section Boundaries Team,

Bethesda, MD 12/01

National Institutes of Health, Chairman Ad Hoc Experimental Therapeutics I Study Section, 1/02

City of Hope Comprehensive Cancer Center Symposium: AMeeting the Challenge of Abdomino-Pelvic

Malignancies in the New Millenium,@ Carlsbad, CA

AChanging Paradigms in the Systemic Treatment of Colorectal Cancer@ 3/02

Chairman, National Cancer Institute, Ad Hoc Study Section to Review Proposals in Response to

RFA CA-02-503: APediatric Phase I/Pilot Consortium,@ Bethesda, MD 4/02

Univ. of California, Irvine Comprehensive Cancer Center Symposium: AAdvances in the Therapy of

Cancer,@ Irvine, CA

AAdvances in the Treatment of Colon Cancer@ 6/02

National Cancer Institute, Ad Hoc Committee on Development of Radiation and Hypoxic Cell Sensitizers,

Bethesda, MD 6/02

Visiting Professor, Cleveland Clinic Foundation Taussig Cancer Center, Cleveland, OH

AAnthracycline Antibiotic Cell Death Program@ 8/02

Sanofi-Synthelabo Symposium, Chicago, IL

APharmacodynamics of Oxaliplatin in Solid Tumor Patients with Hepatic Dysfunction@ 9/02

Cancer Education Consortium, AClinical Pharmacology of Anticancer Agents,@ Leesburg, VA

AAnthracycline Antibiotics@ 10/02

Norris Comprehensive Cancer Center of the University of Southern California, Grand Rounds,

Los Angeles, CA

AOncologic Clinical Pharmacology@ 1/03

14



National Institutes of Health, Ad Hoc Member Experimental Therapeutics II Study Section,

Bethesda, MD 3/03

Second Annual California Cancer Consortium Conference, ARecent Advances and New Directions in

Cancer Therapy,@ San Francisco, CA

ANew Approaches to Metastatic Breast Cancer@ 4/03

University of Minnesota Comprehensive Cancer Center, External Scientific Advisory Board Ad Hoc

Member, Minneapolis, MN 5/03

University of Nebraska/Eppley Cancer Center, External Scientific Advisory Board Ad Hoc Member,

Omaha, NE 6/03

Children’s National Medical Center Cardiology Grand Rounds, Washington, DC

“Anthracycline Cardiac Toxicity” 3/04

American Association for Cancer Research Annual Meeting: ACareers in Clinical and Translational

Research,” Orlando, FL 3/04

Third Annual California Cancer Consortium Conference, ARecent Advances and New Directions in

Cancer Therapy,@ Santa Monica, CA

ANew Directions in Cancer Research@ 4/04

National Cancer Advisory Board, National Cancer Institute, Bethesda, MD

“NCI Clinical Trials Working Group,” 6/04

Board of Scientific Advisors, National Cancer Institute, Bethesda, MD

“NCI Clinical Trials Working Group,” 6/04

National Institute on Drug Abuse, Medications Development Work Group, Silver Spring, MD

“Drug Development at the NCI,” 6/04

Roswell Park Cancer Institute: ASCO Update 2004, Buffalo, NY

“Pharmacology and New Agents,” 7/04

ASCO—AACR—AACI Joint Meeting: “Designing a Smart Clinical Trials System for the 21st Century:

Optimizing the Interactions between Basic and Clinical Science,” Leesburg, VA

“Update from the NCI Clinical Trials Working Group,” 9/04

Advances in the Multidisciplinary Treatment of Gastrointestinal Neoplasms, San Diego, CA

“Targeted Promiscuity: The Case for Combination Molecular-Targeted Therapy,” 9/04



15



American College of Radiology Imaging Network Annual Meeting, Arlington, VA

“NCI Clinical Trials Working Group” 10/04

National Cancer Institute Center for Cancer Research Grand Rounds, Bethesda, MD

“The Anthracycline Antibiotic Cell Death Program” 10/04

Arizona Cancer Center: Arizona Cancer Research Symposium Plenary Lecture, Phoenix, AZ

“Reactive Oxygen and the Anthracycline Antibiotic Cell Death Program” 11/04

National Cancer Institute Combined Intramural Principal Investigator Retreat Plenary Lecture,

Bethesda, MD

“Re-inventing Drug Development at the NCI” 1/05

Fourth Annual California Cancer Consortium Conference, ARecent Advances and New Directions in

Cancer Therapy@ Yountville, CA

AThe Art of Linking Correlative Science to Clinical Trials@ 3/05

Sixth Annual NCI-Industry National Forum on Biomedical Imaging in Oncology, Bethesda, MD

“Update on the NCI Review of the Clinical Trials Process” 4/05


Cancer Research Symposium,” Anaheim, CA

“Chasing Free Radicals from Coast to Coast” 4/05

American Association of Cancer Research Presentation to Board of Directors, Anaheim, CA

“Draft Recommendations of the NCI Clinical Trials Working Group” 4/05

City of Hope National Medical Center Gerhard Schmidt Memorial Lecture in Transplantation Biology,

Duarte, CA

“Re-Inventing Cancer Drug Development: A View from the National Cancer Institute” 4/05

City of Hope Comprehensive Cancer Center Symposium: “Aromatase and Breast Cancer Therapy”

Duarte, CA

“Developing Anticancer Drugs” 4/05

National Cancer Institute, Cancer Center Directors’ Retreat, Bethesda, MD

“Recommendations from the NCI Clinical Trials Working Group” 5/05

National Cancer Institute Symposium for Practicing Physicians, “Vaccines and Molecular Targets in

Clinical Oncology” Bethesda, MD

“Novel Trial Designs to Accelerate New Drug Evaluation” 5/05

American Society of Clinical Oncology Annual Meeting, Orlando, FL

“ASCO/NCI Strategic Initiatives in Clinical Research” 5/05

16



Duke University Comprehensive Cancer Center, American Association for Cancer Research, American

Society of Clinical Oncology, National Cancer Institute, and US Food and Drug Administration

2005 Workshop, “Accelerating Anticancer Agent Development and Validation” Bethesda, MD

“Re-Inventing Drug Development: A View from the NCI” 6/05

NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host

Disease, Bethesda, MD

“New Approaches to Drug Development at the NCI” 6/05

Department of Defense Breast Cancer Research Program Meeting, Philadelphia, PA

“Restructuring the National Cancer Clinical Trials Enterprise” 6/05

Roswell Park Cancer Institute: Highlights from ASCO 2005, Buffalo, NY

“Pharmacology/New Agents” 6/05

Aspen Cancer Conference, Aspen, CO

“Re-inventing Drug Development: A View from the NCI” 7/05

Advances in the Multidisciplinary Treatment of Gastrointestinal Neoplasms, Third Annual Conference,

San Diego, CA

“Restructuring the National Cancer Institute’s Clinical Trials System” 9/05

Summit Series on Cancer Clinical Trials IX: On the Brink of the Tipping Point?, Chantilly, VA

“Report of the Clinical Trials Working Group: Restructuring the National Cancer Clinical Trials

Enterprise” 9/05

Office of Oncology Drug Products, United States Food and Drug Administration, Bethesda, MD

“Accelerating Cancer Drug Development” 10/05

Massey Cancer Center of the Medical College of Virginia, Grand Rounds, Richmond, VA


University of California, Davis Cancer Center, Eleventh Annual Cancer Research Symposium

Keynote Address, Sacramento, CA

“The Art of Linking Correlative Science to Clinical Trials” 10/05



Florida Society of Clinical Oncology Annual Meeting, Tampa, FL

“Cancer Clinical Trials of the Future” 11/05

Center for Biologics Evaluation and Research, United States Food and Drug Administration,

Bethesda, MD


17



Gynecologic Oncology Group Annual Meeting Plenary Lecture, San Diego, CA

“Restructuring the National Cancer Clinical Trials Enterprise: A Report from the Clinical Trials

Working Group of the National Cancer Advisory Board” 1/06

University of California, San Francisco Comprehensive Cancer Center Breast Cancer Program Annual

Meeting, San Francisco, CA

“Re-inventing Anticancer Drug Development: A View from the NCI” 1/06

Case Comprehensive Cancer Center Blood Club, Cleveland, OH

“Restructuring the National Cancer Clinical Trials Enterprise” 3/06

National Academy of Sciences National Cancer Policy Forum Workshop on Developing Biomarker-

Based Tools for Cancer Screening, Diagnosis, and Treatment, Washington, D.C.

“Role of the NCI in Cancer Drug Development” 3/06

Mountain States Tumor Institute, Boise, ID

“Reactive Oxygen Metabolism and the Anthracycline Antibiotic Cell Death Program” 4/06


Cancer Research Symposium,” Washington, DC 4/06

University of Maryland Greenebaum Cancer Center, Experimental Therapeutics Program,

Baltimore, MD

“Epithelial NADPH Oxidase 1: A Novel Therapeutic Target for Colon Cancer” 5/06

UICC World Cancer Congress Symposium: Global Strategies in Drug Development and Research,

Washington, D.C.

“Role of the National Cancer Institute in Drug Development” 7/06

Roswell Park Cancer Institute: Highlights from ASCO 2006, Buffalo, NY

“Pharmacology/New Agents” 7/06

Advances in the Multidisciplinary Treatment of Gastrointestinal Neoplasms, Fourth Annual Conference,

San Diego, CA

“Recommendations from the NCI’s Clinical Trials Working Group” 9/06

The 34th

Meeting of the International Society for Oncodevelopmental Biology and Medicine: Tumor

Biology, Detection, and Therapy, Pasadena, CA

“New Paradigms for Cancer Drug Development” 9/06

Patient-Reported Outcomes Assessment in Cancer Trials: Evaluating and Enhancing the Payoff to

Decision Making, Bethesda, MD

“National Cancer Institute’s Clinical Trials Working Group and Its Implementation Process” 9/06

18



Plenary Session, Southwest Oncology Group Fall 2006 Meeting, Seattle, WA

“Clinical Trials Re-Engineering: One Year Later” 10/06

American Association of Cancer Institutes Annual Meeting, Chicago, IL

“Update: Clinical Trials Working Group” 10/06

National Cancer Institute Symposium: Fundamentals of Oncology Treatment Clinical Trials,

Bethesda, MD

“Phase 0 Clinical Trials” 10/06

Multiple Myeloma Research Foundation Symposium: Combination Strategies in the Treatment of

Multiple Myeloma, Tampa, FL

“Re-inventing Oncologic Drug Development at the NCI” 1/07

European Society of Medical Oncology Fifth International Symposium on Targeted Anticancer

Therapies: TAT 2007, Amsterdam, The Netherlands

“Phase 0 Clinical Trials” 3/07

The Ohio State University School of Medicine, Department of Internal Medicine Grand Rounds,

Columbus, OH

“Current and Future Challenges in the Development of Targeted Cancer Therapeutics” 3/07

NIH Pharmacogenetics Research Network External Scientific Panel, Baltimore, MD

“NCI Clinical Trials Cooperative Groups” 4/07


Cancer Research Symposium,” Los Angeles, CA 4/07

Bio International Annual Meeting, Symposium on Exploratory INDs—Phase 0 Trials: New Tools

Accelerating Drug Development, Boston, MA

“Role of Phase ‘0’ Trials in Cancer Drug Development: A Case Study from the NCI” 5/07

American Society of Clinical Oncology Annual Meeting, Discussant: Translational Oncology Oral

Session, Chicago, IL

“Development and Validation of Predictive Biomarkers” 6/07

MD Anderson Cancer Center, Division of Medicine Grand Rounds, Houston, TX

“Phase 0 Clinical Trials: From Concept to Practice” 8/07

National Cancer Policy Forum, Institute of Medicine of the National Academies of Science,

Improving the Quality of Cancer Clinical Trials: A Workshop, Washington, D.C.

“Phase 0 Clinical Trials in Practice” 10/07

19



AACR Centennial Conference, Translational Cancer Medicine: Technologies to Treatment, Singapore,

Singapore

“Culture, Policy, and Economics of Cancer Research and Cancer Care: A Global Perspective”

Panel Discussion, 11/07

AACR Centennial Conference, Translational Cancer Medicine: Technologies to Treatment, Singapore,

Singapore


University of Pennsylvania Abramson Comprehensive Cancer Center, Anticancer Drug Discovery and

Development Retreat, Philadelphia, PA

“Cancer Drug Discovery Resources at the NCI for Academic Investigators” 12/07

American Enterprise Institute for Public Policy Research, Oncology Drug Development: Rethinking

FDA Oversight, Washington, D.C.

“Early Phase Clinical Trials Design: Changing the Model” 3/08

Methodology for the Development of Innovative Cancer Therapies Task Force, NDDO Research

Foundation, Bethesda, MD

“Phase 0 Clinical Trials in Cancer Drug Development: Conceptions and Misconceptions” 3/08

Group on Research Advancement and Development (GRAND) 2008 Annual Meeting, Association of

American Medical Colleges, Bethesda, MD

“Coordinating Clinical and Translational Science: Developing an Interoperative Support System

for Research from Late Discovery Through Randomized Clinical Trials” 4/08

Third Annual Developmental Therapeutics Symposium, New York Cancer Consortium and Albert

Einstein School of Medicine, New York, NY

“The Phase II Trial: Time to Change the Model” 5/08

Beatson Institute for Cancer Research, University of Glasgow, Second Annual International Beatson

Cancer Centre Symposium: Translation of Preclinical Science into Early Clinical Trials,

Glasgow, UK

“Phase 0 Trials in Oncology” 6/08

Institute of Medicine of the National Academies of Science, National Cancer Policy Forum Workshop:

Multi-Center Phase III Clinical Trials and NCI Cooperative Groups, Washington, D.C.

“Data Collection Standards to Establish Safety and Efficacy in Cancer Clinical Trials: How Much

Data Is Enough?” 7/08

City of Hope Comprehensive Cancer Center Medical and Scientific Symposium: Cancer Immunotherapy

and Clinical Trials, Los Angeles, CA

“New Approaches to Clinical Trials in the Era of Targeted Agents” 7/08

20



AACR Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine,

Monterey, CA

“Careers in Clinical and Translational Cancer Research” 7/08

AACR Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine,

Monterey, CA

“Cancer Drug Development: Shortening Timelines to the Clinic” 7/08

CEO Roundtable on Cancer—VIII, Cary, NC

“Standardization and Harmonization of Clinical Trial Agreement Terms” 9/08

Division of Cancer Prevention, National Cancer Institute, Phase II Consortia Scientific Meeting: Agents,

Biomarkers, and Resources, Gaithersburg, MD

“Innovative Trial Design—Phase 0 Clinical Trials” 9/08

Brookings Institution Conference on Clinical Cancer Research, Improved Insights into Effects of Cancer

Therapies, Washington, DC

“Proposals for the Use of Audits to Assess Progression Free Survival” 9/08

American Academy of Orthopedic Surgeons Research Symposium: Molecular Biology and Therapeutics

in Musculoskeletal Oncology, Salt Lake City, UT

“Strategies for Combining Targeted Agents in Oncology” 9/08

American Society for Therapeutic Radiology and Oncology, Translational Advances in Radiation

Oncology and Cancer Imaging Plenary Lecture, Arlington, VA

“Targeted Combination Therapy in Oncology: Challenges and Strategies” 10/08

Chair, 20th

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Workshop,

“Phase 0 Trials: Are They Necessary?” Geneva, Switzerland 10/08

Institute of Medicine, National Academies of Science, Forum on Drug Discovery, Development, and

Translation, Washington, DC

“Standardization and Harmonization of Clinical Trial Agreement Terms” 11/08

NCI Translates: NCI Translational Sciences Meeting, Washington, DC

“Translational Research Interface with the NCI-Supported Clinical Trials System” 11/08

Clinical Trials Transformation Initiative Steering Committee, Bethesda, MD

“Transforming the National Cancer Institute’s Clinical Trials System” 3/09

8th

Annual Recent Advances and New Directions in Cancer Therapy, University of California Davis

Comprehensive Cancer Center and the California Cancer Consortium, San Francisco, CA

“Pharmacodynamic Markers in Early Phase Clinical Trials” 3/09

21



Inaugural David C. and Susan B. Hardesty Lectureship, West Virginia University, Mary Babb Randolph

Cancer Center, Morgantown, WV

“Cancer Clinical Trials: Speeding the Development of New Treatments for Our Patients” 4/09

Co-Chair, AACR-FDA-NCI Cancer Biomarkers Collaborative Special Session: Towards a More Efficient

Biomarker Development Process—Right On the Path of the Critical Path, Denver, CO 4/09

Emory University School of Medicine, Winship Cancer Institute, Drug Development and

Pharmacogenomics Academy, Atlanta, GA

“Resources for Drug Development at the National Cancer Institute” 5/09

NCI-Frederick/SAIC Research Conference, NCI-Frederick, Frederick, MD


AACR-FDA-NCI Cancer Biomarkers Collaborative Leadership Meeting, Philadelphia, PA

“The American Recovery and Reinvestment Act: A Resource for Biomarker Development and

Validation” 6/09

Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation, Bethesda, MD

“NCI’s Vision for Personalized Cancer Treatment” 7/09

Life Sciences Consortium of the CEO Roundtable on Cancer Meeting, Research Triangle Park, NC

“Pharmacodynamic Approaches to the Development of Novel Cancer Therapies” 8/09

NCI Chemical Biology Consortium Inaugural Meeting, Bethesda, MD

“The NCI Experimental Therapeutics Platform” 8/09

American Chemical Society 2009 Annual Meeting, Small Molecule Therapeutic Agents Symposium,

Washington, DC

“National Cancer Institute’s Chemical Biology Consortium: An Academic/Private Partnership

for the Discovery of Novel Cancer Therapeutics” 8/09

National Cancer Center of Korea Forum on Bridging and Development Program for Cancer Therapeutics,

Seoul, South Korea

“United States National Cancer Institute Drug Development Program: Overview and Future

Directions” 10/09

Cleveland Clinic 2009 Medical Innovation Summit: Cancer Cures Through Innovation, Cleveland, OH

“Enabling New Technologies and New Therapies for Cancer” 10/09

United States and United Kingdom Collaborative Initiatives in Cancer Research, Tyson’s Corner, VA

“A Vision for Clinical Cancer Research in 5 Years Time” 10/09

National Cancer Institute Translational Science Meeting, Vienna, VA

“The NCI’s Experimental Therapeutics Program (NExT)” 11/09

22



AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, Boston, MA

“Proof of Concept Clinical Trial Design: From Precinical Concept to Man” 11/09

Keynote Address, International Symposium on Trends in Drug Discovery and Development, Chemistry

Department, Delhi University, Delhi, India

“The US National Cancer Institute’s Chemical Biology Consortium and Experimental Therapeutics

Program” 1/10

Keynote Address, AACR Special Conference Cell Death Mechanisms and Cancer Therapy,

San Diego, CA

“From Novel Target to Novel Therapeutic: Compressing the Timeline from Discovery to the

Clinic” 2/10

Melanoma Research Alliance 2nd

Annual Scientific Retreat, Las Vegas, NV

“Developing Experimental Drug Combinations: Opportunities and Challenges” 2/10

AACR 2010 Annual Meeting Meet the Expert Session, Washington, DC

“Reducing Attrition and Enhancing Efficiency in Cancer Drug Development” 4/10

AACR 2010 Annual Meeting Forum: Oncology Drug Discovery in Academia: Key Strategies and

Challenges, Washington, DC

“NCI’s Experimental Therapeutics Program” 4/10

ASCO-NCI Symposium: Cancer Trial Accrual: Science and Solutions, Bethesda, MD

“Revitalizing the Cancer Trials Research Enterprise” 4/10

NCI Cancer Center Director’s Annual Retreat, Washington, DC

“Assessing the Impact of a Cancer Center’s Clinical and Translational Research Programs” 5/10

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Leadership Retreat, Baltimore, MD

“Challenges to Increasing the Efficiency of Initiating Innovative Clinical Research” 5/10

American Society of Clinical Oncology 2010 Annual Meeting Opening Session, Chicago, IL

“Clinical Cancer Research and the NCI: Improving the Effectiveness of Scientifically-Driven

Clinical Investigation” 6/10

American Society of Clinical Oncology 2010 Annual Meeting Clinical Science Symposium: PARP

Inhibition: DNA Repair as the Target, Chicago, IL

“State of Development for PARP Inhibition” 6/10

Chair, American Society of Clinical Oncology 2010 Annual Meeting Education Session: Improving the

Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the NCI’s

Clinical Trials and Translational Research Advisory Committee, Chicago, IL

“Operational Efficiency Working Group Final Report: Compressing the Timeline for Cancer

Clinical Trial Activation” 6/10

23



Drug Information Association 2010 Annual Meeting, Preclinical and Clinical Development of Anticancer

Pharmaceuticals Session, Washington, DC

“Phase 0 Trials for Anticancer Pharmaceuticals” 6/10

Beckman Research Institute of the City of Hope Comprehensive Cancer Center, 2010 Clinical Residency

and Fellowship Programs Commencement, Duarte, CA

“What You ‘Know’ Depends on When You Learned It: Why You Need to Make a Career-Long

Commitment to Clinical and Translational Cancer Research” 6/10

National Center for Research Resources, National Institutes of Health, Clinical and Translational Science

Award Clinical Research Management Workshop, Bethesda, MD

“NCI-NIH Expectations for Academic Health Centers in Clinical Research Management of NIH

Sponsored Trials” 6/10

American College of Clinical Pharmacology 39th

Annual Meeting, Symposium on International Drug

Development and Collaboration, Baltimore, MD

“The National Cancer Institute’s Drug Development Program” 9/10

NIH Scientific Management Review Board: NIH Resources and Programs for a New Paradigm in

Translational Research, Bethesda, MD

“NCI’s Experimental Therapeutics Program” 9/10

President’s Cancer Panel, Boston, MA

“Changing the NCI’s Clinical Trials System to Meet the Needs of the 21st Century: Focus on

Molecular Characterization of Tumors for Patients Entered on Clinical Studies” 9/10

American Association of Cancer Institutes 2010 Annual Meeting, Chicago, IL

“NCI’s Experimental Therapeutics Program: A Status Report” 10/10

American Association of Cancer Institutes 2010 Annual Meeting, Chicago, IL

“Changing the NCI’s Clinical Trials System to Meet the Needs of the 21st Century: Implementation

of the Clinical Trials Working Group and the Institute of Medicine Recommendations” 10/10

Center for Cancer Research, National Cancer Institute Gastrointestinal Cancer Faculty Seminar,

Bethesda, MD

“Developing Experimental Targeted Agent Combinations: Opportunities and Challenges” 10/10

Keynote Lecture, International Conference on Translational Medicine in Cancer, Zhejiang University

School of Medicine, Hangzhou, China

“From Novel Target to Novel Therapeutic: Compressing the Timeline from Discovery to the

Clinic” 10/10

Forum on Drug Discovery, Development, and Translation of the Institute of Medicine, “The US Clinical

Trials Enterprise: Approvals Relating to Protection of Research Subjects” Washington, DC

“NCI’s Central IRB: An Update” 10/10

24



AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, Berlin, FRG

“Re-Inventing the Methodology of Early Drug Development” 11/10

Life Sciences Consortium of the CEO Roundtable, Washington, DC

“Pharmacodynamic Approaches to the Development of Novel Cancer Therapies” 11/10

Institute of Medicine of the National Academies of Science, National Cancer Policy Forum and American

Society of Clinical Oncology Workshop: Implementing a National Cancer Clinical Trials System

for the 21st Century, Washington, D.C.

“NCI Perspective and Current Implementation Activities” 3/11

Chairman, AACR 2011 Annual Meeting Session: NCI’s Clinical Trials Cooperative Group Program:

Infrastructure in Transition, Orlando, FL

“NCI’s Cooperative Group Program” 4/11

Alexandria Summit: Oncology 2011, New York, NY

“The Era of Collaboration: Why Collaboration is the Path to Innovation in Oncology” 4/11

University of California, Irvine Chao Family Comprehensive Cancer Center Symposium: Translational

Approaches to Cancer Therapeutics, Irvine, CA

“How Do You Move Your Favorite Molecule from Lab to Clinic: Early Steps” 4/11

The Ohio State University Comprehensive Cancer Center Symposium: Cancer Drug Development

Roundtable at Ohio State, Columbus, OH


Board of Directors, Statewide Cancer Clinical Trials Network of Texas, Dallas, TX

“Implementing the Institute of Medicine Report on a National Clinical Trials System for the 21st

Century” 5/11

American Society of Clinical Oncology 2011 Annual Meeting Clinical Science Symposium: PK/PD

According to Dr. Merrill Egorin: A Tribute to a Great Translational Scientist, Chicago, IL

“Discussion of a Phase I Study of Veliparib in Combination with Irinotecan in Patients with

Advanced Solid Tumors” 6/11

Institute of Medicine of the National Academies of Science Workshop: Facilitating Collaborations to

Develop Combination Investigational Cancer Therapies, Washington, D.C.

“Perspectives on Preclinical Issues in Co-Development from the NCI” 6/11

Tisch Cancer Institute of the Mt. Sinai School of Medicine Grand Rounds, New York, NY

“Re-inventing the Methodology of Early Cancer Drug Development” 6/11

NCI Workshop on Criteria for Use of ‘Omics-Based Predictors in Clinical Trials, Bethesda, MD

Keynote Address: “Opportunities and Challenges in Translating Omics Discoveries to Useful

Clinical Tests” 6/11

25



Cancer Leadership Council, Washington, DC

“Transforming NCI’s Clinical Trials System” 7/11

American College of Clinical Pharmacology Annual Meeting: Symposium on the Evolving Landscape of

First-in-Human Clinical Trials, Chicago, IL

“Phase 0 Pharmacodynamic Trials in Oncology” 9/11

Second Annual Lois O’Grady, M.D. Lectureship, University of California Davis School of Medicine,

Sacramento, CA

“Transforming the National Cancer Institute’s Clinical Trials System” 9/11

University of California Davis Cancer Center: 12th

Annual Advances in Oncology 2011, Sacramento, CA


Keynote Presentation, Robert H. Lurie Comprehensive Cancer Center and the Center for Molecular

Innovation & Drug Discovery, Northwestern University School of Medicine, 16th

Annual Drug

Discovery Symposium, Chicago, IL

“Re-engineering Early Phase Cancer Drug Development: Decreasing the Time from Novel Target

to Novel Therapeutic” 10/11

National Coalition for Cancer Survivorship: Cancer Policy Roundtable, Washington, DC

“Transforming the NCI Clinical Trials System” 10/11

Coalition of Cancer Cooperative Groups: Patient Advocate Leadership Forum, Washington, DC

“Transforming the NCI Clinical Trials System” 10/11

Keynote Lecture, 2011 Chabner Colloquium: Collaboration in Cancer Drug Trials, Massachusetts General

Hospital Cancer Center and the Society for Translational Oncology, Cambridge, MA

“Decreasing the Time from Novel Target to Novel Cancer Therapeutic” 10/11

Brookings Institution and Friends of Cancer Research Conference on Clinical Cancer Research,

Washington, DC

“Alternative Trial Designs Based on Tumor Genetics or Pathway Characteristics Instead of

Histology” 11/11

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference,

San Francisco, CA

“New Paradigms for Early-Phase Clinical Trials” 11/11

Institute of Medicine of the National Academies of Science Workshop on Envisioning a Transformed

Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020, Washington, DC

“Lessons Learned from the Transformation of the National Cancer Institutes Clinical Trials

System” 11/11

26



Radiation Therapy Clinical Trials Workshop, Radiation Research Program, NCI, Bethesda, MD

“New Paradigms for Early-Phase Clinical Trials” 12/11

2012 ASCO Gastrointestinal Cancers Symposium, General Session II: Cancers of the Colon and Rectum:

Translational Research, San Francisco, CA

“Vision of Molecularly Targeted Therapies in Colon Cancer in 2012” 1/12

Tulane Cancer Center Grand Rounds, Tulane University School of Medicine, New Orleans, LA


Society of Chairs of Academic Radiation Oncology Programs, American Society for Radiation Oncology

Annual Meeting, Washington, DC

“Re-inventing NCI-Supported Clinical Trials” 3/12

American Association for Cancer Research Roundtable: Careers in Clinical and Translational Cancer

Research, 2012 Annual Meeting, Chicago, IL

“Pharmacological Perspectives on Translational Research Careers” 3/12

American Association for Cancer Research Annual Meeting, Meet-the-Expert Session, Chicago, IL

“Principles and Practice of Molcular Pharmacodynamics in Cancer Drug Discovery” 4/12

WIN 2012 Syposium: Efficacy of Biomarkers and Personalized Cancer Therapeutics, Paris, FR

“Shortening the Timeline for Cancer Drug Development” 6/12

NIH Clinical and Translational Science Awards Consortium Steering Committee Meeting, Bethesda, MD

“Transforming the NCI’s Clinical Trials System” 10/12

National Cancer Institute, Early Drug Development Meeting, Bethesda, MD

“NCI’s Early Drug Development Program: Scanning the Horizon” 10/12

NCI Workshop: Evidence Needed to Support Clinical Utility of Molecular Diagnostics, Bethesda, MD

“Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests” 1/13

Institute of Medicine of the National Academies of Science, National Cancer Policy Forum and American

Society of Clinical Oncology Workshop: Implementing a National Cancer Clinical Trials System

for the 21st Century, Washington, DC

“NCI Update on Implementation Activities for the NCI Clinical Trials Network” 2/13

Chairman, American Association for Cancer Research 2013 Annual Meeting Minisymposium: Biomarkers

in Clinical Response, Washington, DC 4/13

American Association for Cancer Research Annual Meeting Symposium: “Predictive Modeling of Single

Patients (N of 1)”, Washington, DC

“Genomic Clinical Trials” 4/13

St. Jude Children’s Research Hospital Chemical Biology and Therapeutics Seminar, Memphis, TN

“Shortening the Timeline for Cancer Drug Discovery” 4/13

27



Cancer Immunotherapy Consortium, 2013 Scientific Colloquium, Washington, DC


Oncology Nursing Society 2013 Annual Meeting, Washington, DC

“NCI Initiatives: Beyond the Sequester” 4/13

Massachusetts General Hospital Cancer Center Grand Rounds, Boston, MA

“Shortening the Cancer Drug Discovery Timeline: Role of Molecular Pharmacodynamics” 5/13

Case Comprehensive Cancer Center of Case Western Reserve University, Cleveland, OH

Impact of Genomics on Cancer Diagnosis and Treatment: Open Drug Policy Forum:

“Implementing Proper Use of Genomic Tests to Select Therapeutics” 6/13

City of Hope Comprehensive Cancer Center Centennial Scientific Program: 100 Years of Compassionate

Care, Keynote Speaker, Duarte, CA

“100 Years of Progress in Cancer: Refocusing on Patients as the ‘Model’ for Drug Discovery” 9/13

Chair, Seventeenth European Cancer Congress, Scientific Symposium: Outcome Measures in Clinical

Trial Design, Amsterdam, The Netherlands

“Impact of Biomarkers on the Value of Crossover Designs in Cancer Clinical Trials” 9/13

NYU School of Medicine Fourth Annual Innovations in Health Care Symposium: Clinical Research at the

Crossroads: New Paradigms for New Challenges, New York, NY

“Clinical Cancer Research and the NCI: Improving the Effectiveness of Scientifically-Driven

Clinical Investigation” 10/13

Institute of Medicine of the National Academies of Science, 2013 National Cancer Policy Summit: New

Opportunities and Challenges in Cancer Research and Care, Washington, DC

“Converting Novel Therapeutic Models into Early Phase Clinical Trials” 11/13

Society for Melanoma Research Annual Meeting, Philadelphia, PA

“Facilitating Small Molecule Combinations and Biological Agents in Cancer Therapy” 11/13

Society for Free Radical Biology and Medicine 20th

Annual Meeting, San Antonio, TX

“Effect of Stable Knockdown of Nox1 Gene Expression with siRNA on Colon Cancer Cells In

Vitro and In Vivo” 11/13

American Association for Cancer Research Annual Meeting Clinical Trials Workshop: Insights in the Era

of Personalized Cancer Therapy and Targeted Therapies: Definitive Advanced Stage Clinical

Trials, San Diego, CA

“Ongoing and Planned Genomic Based Trials” 4/14

Moderator, American Association for Cancer Research 2014 Annual Meeting Forum: Putting Molecular

Science into Clinical Trials, San Diego, CA

“NCI-Supported Genomic-Based Clinical Trials” 4/14

28



Gordon Research Conference: NOX Family NADPH Oxidases, NOX Enzymes and Cancer Session

Plenary Lecture; Lucca, Italy

“Epithelial NADPH Oxidases and Cancer” 5/14

American Society of Clinical Oncology 2014 Annual Meeting New Drugs in Oncology Seminar,

Chicago, IL

“NCI-Supported Early Therapeutics Programs: Are Classic Phase I Trials Obsolete?” 6/14

Cincinnati Children’s Hospital Cancer and Blood Diseases Institute Translational Cancer Research

Seminar Series, Cincinnati, OH

“Shortening the Timeline for Cancer Drug Discovery” 7/14

American Association for Cancer Research Special Conference on Hematologic Malignancies,

Philadelphia, PA

Chair, Panel on Cancer Clinical Research: Now and in the Future 9/14

Cold Spring Harbor Laboratories, Banbury Conference: ROS in Biology and Cancer,

Cold Spring Harbor, NY

“NADPH Oxidases and Cancer” 10/14

Levine Cancer Institute, Carolinas Healthcare, Grand Rounds, Charleston, SC

“Shortening the Timeline for Cancer Drug Development: Role of Molecular

Pharmacodynamics” 12/14

Mayo Clinic Comprehensive Cancer Center All-SPORE Retreat, Rochester, MN

“The NCI Chemical Biology Consortium” 2/15

29


PATENTS, EMPLOYEE INVENTIONS, & WORKING GROUP REPORTS:

1. Myers, C.E., Doroshow, J., and Locker, G.: N-Acetyl-Cysteine Protects Against Cardiac Damage from

Subsequently Administered Cardiotoxic Anthracycline in Cancer Therapy. United States Department of

Commerce Patent No. 4,331,648; Granted May 25, 1982.

(Assignee: United States Government).

2. Chu, F.-F., Esworthy, R.S., and Doroshow, J.H.: Mice with Combined Disruption of Gpx1 and Gpx2

Genes Have Growth Retardation, Hyperthermia, and Colitis and Provide a Mouse Model for Cancer.

United States Department of Commerce Patent No. 6,762,343; Granted July 13, 2004.

(Assignee: City of Hope, Duarte, CA)

3. Doroshow, J.H. et al.: Report of the Clinical Trials Working Group of the National Cancer Advisory

Board: “Restructuring the National Cancer Clinical Trials Enterprise,” June, 2005. Available at:

http://restructuringtrials.cancer.gov/files/ctwg-report.pdf

4. Doroshow, J.H., Hortobagyi, G., et al.: Report of the Operational Efficiency Working Group of the

Clinical Trials and Translational Research Advisory Committee: “Compressing the Timeline for Cancer

Clinical Trial Activation,” March, 2010. Available at: http://ccct.cancer.gov/files/OEWG-Report.pdf

5. Doroshow, J., Roy, K., Antony, S., and Wu, Y.: Design, Production, and Characterization of Human

Monoclonal Dual Oxidase (DUOX2) Antibody for the Detection of DUOX2 in Organs, Tumors, and

Infammatory Reactions. Employee Invention Report No. E-278-2011 (9/6/2011). Licensed to EMD

Millipore, Inc., 2013.

6. Doroshow, J., Roy, K., and Antony, S.: Design, Generation, and Characterization of a Monoclonal

Antibody Against NADPH Oxidase 5 Protein. Employee Invention Report No. E-149-2011 (4/4/2012).

U.S. Patent Application No.: 61/471,596; Filed April 4, 2011.

7. Doroshow, J., Roy, K., Juhasz, A., and Antony, S.: Generation and Preliminary Characterization of

Mouse Monoclonal Antibodies to Human NADPH Oxidase 1 (NOX1) Enzyme. Employee Invention

Report No. E-097-2012 (2/15/2012).

8. Pfister, T., Parchment, R., and Doroshow, J.: Development of a Rabbit Anti-pT1989 ATR Monoclonal

Antibody for Use in IFA and Other Immunoassays. Employee Invention Report No. E-001-2014

(10/18/2013). U.S. Patent Application No.: 61/893,070.

9. Doroshow, J., Risbood, P., Lu, J.: Development of Analogs of Diphenylene Iodonium and Di-Thienyl-

Iodonium as Inhibitors of NADPH Oxidase and Other Flavin Dehydrogenases for the Treatment and

Prevention of Cancer and Inflammatory Disorders. Employee Invention Report No. E-116-2014

(4/7/2014). U.S. Patent Application No.: 61/976,362.

10. Pfister, T., Parchement, R., Kinders, R., and Doroshow, J.: Development of Recombinant Proteins for

Pharmacodynamic Targets. Employee Invention Report No. E-024-2015 (10/24/2014).

11. Kinders, R., Parchment, R., and Doroshow, J.: Development of Monoclonal Antibodies and

Recombinant Protein Reagents for EMT/Stem Cell Targets for Application in Clinical Immuoassays.

Employee Invention Report No. E-023-2015 (10/24/2014).

http://restructuringtrials.cancer.gov/files/ctwg-report.pdf

http://ccct.cancer.gov/files/OEWG-Report.pdf

30


PUBLICATIONS:

1. Vaage, J., Doroshow, J.H., and Dubois, T.T.: Radiation-Induced Changes in Established Tumor

Immunity. Cancer Res. 34: 129-137, 1974.

2. Bender, R., Zwelling, L., Doroshow, J.H., Locker, G.Y., Hande, K.R., Murinson, D.S., Cohen, M.,

Myers, C.E., and Chabner, B.A.: Antineoplastic Drugs: Clinical Pharmacology and Therapeutic Use.

Drugs 16: 46-87, 1978.

3. Locker, G.Y., Doroshow, J.H., Zwelling, L., and Chabner, B.: The Clinical Features of Hepatic

Angiosarcoma: A Report of Four Cases and a Review of the English Literature. Medicine 58: 48-64,

1979.

4. Ozols, R.F., Locker, G.Y., Doroshow, J.H., Grotzinger, K.R., Myers, C.E., Fisher, R.I., and Young,

R.C.: Chemotherapy for Murine Ovarian Cancer: A Rationale for Ip Therapy with Adriamycin. Cancer

Treat. Rep. 63: 269-273, 1979.

5. Locker, G.Y., Doroshow, J.H., Baldinger, J.C., and Myers, C.E.: The Relationship Between Dietary

Tocopherol and Glutathione Peroxidase Activity in Murine Cardiac Tissue. Nutrit. Rep. Int. 19: 671-678,

1979.

6. Ozols, R.F., Locker, G.Y., Doroshow, J.H., Grotzinger, K.R., Myers, C.E., and Young, R.C.:

Pharmacokinetics of Adriamycin and Tissue Penetration in Murine Ovarian Cancer. Cancer Res. 39:

3209-3214, 1979.

7. Doroshow, J.H., Locker, G.Y., and Myers, C.E.: Experimental Animal Models of Doxorubicin Cardiac

Toxicity. Cancer Treat. Rep. 63: 855-860, 1979.

8. Doroshow, J.H., Locker, G.Y., Baldinger, J., and Myers, C.E.: The Effect of Doxorubicin on Hepatic

and Cardiac Glutathione. Res. Commun. Chem. Path. Pharmacol. 26: 285-295, 1979.

9. Doroshow, J.H., Locker, G.Y., and Myers, C.E.: Enzymatic Defenses of the Mouse Heart Against

Reactive Oxygen Metabolites: Alterations Produced by Doxorubicin. J. Clinical Investigation 65: 128-

135, 1980.

10. Doroshow, J.H., Sears, H., Myers, C., and Anderson, T.: Biliary Colic Heralding Systemic Relapse in

Non-Hodgkin Lymphoma. J. Surg. Oncology 14: 255-259, 1980.

11. Doroshow, J.H. and Reeves, J.: Daunorubicin-Stimulated Reactive Oxygen Metabolism in Cardiac

Sarcosomes. Biochem. Pharmacol. 30: 259-262, 1981.

12. Doroshow, J.: Mitomycin C-Enhanced Superoxide and Hydrogen Peroxide Formation in Rat Heart. J.

Pharmacol. Exp. Therapeutics 218: 206-211, 1981.

13. Doroshow, J.H., Locker, G.Y., Gaasterland, D., Hubbard, S., Young, R., and Myers, C.E.: Ocular

Irritation from High-Dose Methotrexate: Pharmacokinetics of Drug in the Tear Film. Cancer 48: 2158-

2162, 1981.

31


PUBLICATIONS (contd.)

14. Doroshow, J.: The Usefulness of Noninvasive Cardiac Monitoring in Prevention and Detection of

Anthracycline Cardiomyopathy. In Medical Oncology: Controversies in Cancer Treatment. M.B. Van

Scoy-Mosher, ed., G.K. Hall Medical Publishers, Boston, MA, pp. 255-264, c. 1981.

15. Doroshow, J.H., Locker, G.Y., Ifrim, I., and Myers, C.E.: Prevention of Doxorubicin Cardiac Toxicity

in the Mouse by N-Acetylcysteine. J. Clinical Investigation 68: 1053-1064, 1981.

16. Doroshow, J. and Hochstein, P.: Redox Cycling and the Mechanism of Action of Antibiotics in

Neoplastic Diseases. In Pathology of Oxygen. A.P. Autor, ed., Academic Press, New York, NY, pp. 245-

259, c. 1982.

17. Doroshow, J.H., Locker, G.Y., Gaasterland, D.E., Hubbard, S.P., Young, R.C., and Myers, C.E.:

Ophthalmic Side Effects from Methotrexate. Cancer 50: 605, 1982.

18. Doroshow, J.H. and Locker, G.Y.: Role of Oxygen Radical Formation in Anthracycline Cardiac

Toxicity. In Anthracycline Antibiotics in Cancer Therapy. F.M. Muggia, C.W. Young, and S.K. Carter

eds., Martinus Nijhoff Publishers, Boston, MA, pp. 317-330, c. 1982.

19. Doroshow, J.H.: Effect of Anthracycline Antibiotics on Oxygen Radical Formation in Rat Heart.

Cancer Res. 43: 460-472, 1983.

20. Davies, K.J.A., Doroshow, J.H., and Hochstein, P.: Mitochondrial NADH Dehydrogenase-Catalyzed

Oxygen Radical Production by Adriamycin, and the Relative Inactivity of 5-Iminodaunorubicin. Fed. Eur.

Biochem. Soc. Lett. 153: 227-230, 1983.

21. Myers, C., Bonow, R., Palmeri, S., Jenkins, J., Corden, B., Locker, G., Doroshow, J., and Epstein, S.:

A Randomized Controlled Trial Assessing the Prevention of Doxorubicin Cardiomyopathy by N-

Acetylcysteine. Semin. Oncol. Suppl. 1, 10: 53-56, 1983.

22. Doroshow, J.H., Davies, K.J.A., and Hochstein, P.: Adriamycin Cardiac Toxicity: The Role of

Mitochondrial Reactive Oxygen Metabolites. In Oxy-Radicals and Their Scavenger Systems: Cellular and

Medical Aspects. R. Greenwald and G. Cohen, eds., Vol. 2, Elsevier Science Publishing Co., Inc., New

York, NY, pp. 113-118, c. 1983.

23. Davies, K.J.A., Doroshow, J.H., Chan, T.P., and Hochstein, P.: Mitochondrial Reduction of

Anthracyclines: Oxygen Radical Production at the Expense of ATP. In Oxy-Radicals and Their

Scavenger Systems: Cellular and Medical Aspects. R. Greenwald and G. Cohen, eds., Vol. 2, Elsevier

Science Publishing Co., Inc., New York, NY, pp. 313-316, c. 1983.

24. Doroshow, J.H.: Anthracycline Antibiotic-Stimulated Superoxide, Hydrogen Peroxide, and Hydroxyl

Radical Production by NADH Dehydrogenase. Cancer Res. 43: 4543-4551, 1983.

25. Doroshow, J.H. and Davies, K.J.A.: Comparative Cardiac Oxygen Radical Metabolism by

Anthracycline Antibiotics, Mitoxantrone, Bisantrene, 4'-(9-Acridinylamino)-Methanesulfon-m-Anisidide,

and Neocarzinostatin. Biochem. Pharmacol. 32: 2935-2940, 1983.

32



26. Doroshow, J.H.: Evaluation of Free Radical Formation by Anthracycline Antibiotics, Bisantrene, and

Mitoxantrone. In Proc. 13th Internat. Congress of Chemotherapy: Antitumor Chemotherapy. K.H. Spitzy

and K. Karrer, eds., Part 213, Wiener Med. Akademie Publishers, Vienna, Austria, pp. 34-38, c. 1983.

27. Carr, B.I., Bertrand, M., Browning, S., Doroshow, J., Frater, L., and Pulone, B.: Metoclopromide: An

Effective Antinauseant in Cancer Chemotherapy Induced Emesis. In Proc. 13th Internat. Congress of

Chemotherapy: Antitumor Chemotherapy. K.H. Spitzy and K. Karrer, eds., Part 283, Wiener Med.

Akademie Publishers, Vienna, Austria, pp. 9-10, c. 1983.

28. Bertrand, M., Doroshow, J.H., Multhauf, P., Newman, E., Blayney, D.W., Carr, B.I., and Goldberg, D.:

Combination Chemotherapy with High-Dose Continuous Infusion Leucovorin and Bolus 5-Fluorouracil in

Patients with Advanced Colorectal Cancer. In The Current Status of 5-Fluorouracil Leucovorin Calcium

Combination. H.W. Bruckner and Y.M. Rustum, eds., Park Row Publishing Co., Inc., New York, NY, pp.

73-76, c. 1984.

29. Doroshow, J.H., Tallent, C., and Schechter, J.E.: Ultrastructural Features of Adriamycin-Induced

Skeletal and Cardiac Muscle Toxicity. Amer. J. Path. 118: 288-297, 1985.

30. Doroshow, J.H.: Role of Oxygen Radical Production in Anticancer Drug Action and Toxicity. City of

Hope Medical Center Quarterly 14: 3-6, 1985.

31. Margolin, K.A., Pak, H.Y., Esensten, M.L., and Doroshow, J.H.: Hepatic Metastasis in Granulosa Cell

Tumor of the Ovary. Cancer 56: 691-695, 1985.

32. Harris, R.N., and Doroshow, J.H.: Effect of Doxorubicin-Enhanced Hydrogen Peroxide and Hydroxyl

Radical Formation on Calcium Sequestration by Cardiac Sarcoplasmic Reticulum. Biochem. Biophys.

Res. Commun. 130: 739-745, 1985.

33. Bennett, J.J., Byrne, P., Desai, A., White, C., DeConti, R., Vogel, C., Krementz, E., Muggia, F.,

Doroshow, J., Plotkin, D., Golomb, H., Muss, H., Brodovsky, H., Gams, R., Morgan, L.R., Bryant, S.,

Weiss, A., Cartwright, K., and Dukart, G.: A Randomized Multicenter Trial of Cyclophosphamide,

Novantrone, and 5-Fluorouracil (CNF) versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil (CAF)

in Patients with Metastatic Breast Cancer. Invest. New Drugs 3: 179-185, 1985.

34. Carr, B., Bertrand, M., Browning, S., Doroshow, J.H., Presant, C., Pulone, B., and Hill, L.R.: A

Comparison of the Anti-Emetic Efficacy of Prochlorperazine and Metoclopromide for the Treatment of

Cis-Platinum-Induced Emesis: A Prospective, Randomized, Double-Blind Study. J. Clin. Oncol. 3: 1127-

1132, 1985.

35. Bertrand, M., Multhauf, P., Presant, C., Rappaport, D., Blayney, D., Carr, B., Cecchi, G., Doroshow, J.,

Emont, E., Goldberg, D., Kogut, N., Leong, L., and Margolin, K.: Phase II Trial of VP-16, Vincristine, and

High Dose Cis-Platinum in Advanced Non-Small Cell Lung Cancer. Cancer Treat. Rep. 69: 1335-1336,

1985.

33



36. Carr, B.I., Rahbar, S., Doroshow, J., Blayney, D., Goldberg, D., and Leong, L.: A Clinical Study of

the Gene Activating and Antitumor Properties of 5,6-Dihydro-5-Azacytidine. In Recent Advances in

Chemotherapy: Anticancer Section. J. Ishigami, ed., Univ. of Tokyo Press, Tokyo, Japan, pp. 590-591, c.

1985.

37. Doroshow, J.H.: Doxorubicin-Enhanced Hydroxyl Radical Production by Intact Tumor Cells. In

Recent Advances in Chemotherapy: Anticancer Section. J. Ishigami, ed., Univ. of Tokyo Press, Tokyo,

Japan, pp. 225-226, c. 1985.

38. Bennett, J.M., Byrne, P., Desai, A., Vogel, C., Krementz, E., Speyer, J., Doroshow, J., Plotkin, D.,

Bitran, J., Muss, H., Brodovsky, H., Gams, R., Morgan, L., Wolff, S., and Arlin, Z.: A Randomized

Multicenter Trial of Cyclophosphamide, Novantrone, and 5-Fluorouracil (CNF) versus Cyclophosphamide,

Adriamycin, and 5-Fluorouracil (CAF) in Patients with Metastatic Breast Cancer. In Evaluation du Risque

de Cancer Mammaire: Chimiotherapie Premiere? C. Colin, ed., pp. 323-333, c. 1985.

39. Kemeny, M.M., Goldberg, D., Beatty, J.D., Blayney, D., Browning, S., Doroshow, J., Ganteaume, L.,

Hill, R.L., Kokal, W.A., Riihimaki, D.U., and Terz, J.J.: Results of a Prospective Randomized Trial of

Continuous Regional Chemotherapy and Hepatic Resection as Treatment of Hepatic Metastases from

Colorectal Primaries. Cancer 57: 492-498, 1986.

40. Davies, K.J., and Doroshow, J.H.: Redox Cycling of Anthracyclines by Cardiac Mitochondria: I.

Anthracycline Radical Formation by NADH dehydrogenase. J. Biol. Chem. 261: 3060-3067, 1986.

41. Doroshow, J.H., and Davies, K.J.A.: Redox Cycling of Anthracyclines by Cardiac Mitochondria. II.

Formation of Superoxide Anion, Hydrogen Peroxide, and Hydroxyl Radical. J. Biol. Chem. 261: 3068-

3074, 1986.

42. Doroshow, J.H.: Prevention of Doxorubicin-Induced Killing of MCF-7 Human Breast Cancer Cells by

Oxygen Radical Scavengers and Iron Chelating Agents. Biochem. Biophys. Res. Commun. 135: 330-335,

1986.

43. Doroshow, J.H.: A Role for Hydrogen Peroxide and Hydroxyl Radical in the Killing of Ehrlich Tumor

Cells by Anticancer Quinones. Proc. Natl. Acad. Sci. U.S.A. 83: 4514-4518, 1986.

44. Newman, M., Doroshow, J., Mittman, C., and Benfield, J.: Lung Cancer. In Current Therapy of

Respiratory Disease II. R.M. Cherniack, ed., B.C. Decker Pub., Inc., Philadelphia, PA, pp. 245-249, c.

1986.

45. Blayney, D.W., Goldberg, D., Leong, L., Carr, B.I., and Doroshow, J.H.: Phase II Trial of Esorubicin

(4'Deoxydoxorubicin) in Advanced Pancreatic Adenocarcinoma. Cancer Treat. Rep. 70: 683-684, 1986.

46. Goldberg, D., Leong, L., and Doroshow, J.H.: Colorectal Cancer: Biochemical Modulation of 5-

Fluorouracil by Folinic Acid. Clinical Oncologist 1: 3-7, 1986.

34



47. Bertrand, M., Doroshow, J., Multhauf, P., Blayney, D., Carr, B., Cecchi, G., Goldberg, D., Leong, L.,

and Margolin, K.: High Dose Continuous Infusion Folinic Acid and Bolus 5-Fluorouracil in Patients with

Advanced Colorectal Cancer: A Phase II Study. J. Clin. Oncol. 4: 1058-1061, 1986.

48. Doroshow, J.H.: Stimulation of Hydroxyl Radical Production by Doxorubicin-Treated Ehrlich Tumor

Cells. In Superoxide and Superoxide Dismutase in Chemistry, Biology, and Medicine. G. Rotilio, ed.,

Elsevier Science Publishing Co., Inc., New York, NY, pp. 422-424, c. 1986.

49. Doroshow, J.H., and Schechter, J.E.: Prevention of Doxorubicin Cardiac Toxicity by Dimethyl

Sulfoxide. In Superoxide and Superoxide Dismutase in Chemistry, Biology, and Medicine. G. Rotilio,

ed., Elsevier Science Publishing Co., Inc., New York, NY, pp. 639-641, c. 1986.

50. Braly, P., Doroshow, J., and Hoff, S.: Technical Aspects of Intraperitoneal Chemotherapy in

Abdominal Carcinomatosis. Gynecol. Oncol. 25: 319-333, 1986.

51. Akman, S.A., Doroshow, J., Dietrich, M.F., Chlebowski, R.T., and Block, J.B.: Synergistic Toxicity

Between Menadione and Dicumarol Versus Murine Leukemia L1210. J. Pharmacol. Exp. Therapeutics

240: 486-491, 1987.

52. Blume, K.G., Forman, S.J., O'Donnell, M.R., Doroshow, J.H., Krance, R.A., Nademanee, A.P., Snyder,

D.S., Schmidt, G.M., Fahey, J.L., Metter, G.E., Hill, L.R., Findley, D.O., and Sniecinski, I.J.: Total Body

Irradiation and High Dose VP-16-213: A New Preparatory Regimen for Bone Marrow Transplantation of

Patients with Advanced Hematologic Malignancies. Blood 69: 1015-1020, 1987.

53. Carlson, R.W., Billingham, M.E., Kohler, M., Johnson, F.D., Doroshow, J.H., and Torti, F.: A Phase II

Study of 4'-Deoxydoxorubicin in Refractory Metastatic Carcinoma of the Breast: A Study of the Northern

California Oncology Group. Cancer Treat. Rep. 71: 427-428, 1987.

54. Carr, B.I., Rahbar, S., Doroshow, J., Blayney, D., Goldberg, D., Leong, L., and Asmeron, Y.: Fetal

Hemoglobin Gene Activation in a Phase II Study of 5,6-dihydro-5-azacytidine for Bronchogenic

Carcinoma. Cancer Res. 47: 4199-4201, 1987.

55. Carr, B., Blayney, D., Goldberg, D., Braly, P., Metter, G., and Doroshow, J.H.: Safety and Efficacy of

High Doses of Prochlorperazine for Cis-Platinum Induced Emesis: A Prospective, Randomized, Dose

Response Study. Cancer 60: 2165-2169, 1987.

56. Doroshow, J.H.: Potential Role of Intraperitoneal Cis-Platinum in the Adjuvant Chemotherapy of

Ovarian Cancer. In Occult Nodal Metastasis in Solid Carcinomata. P. Moloy and G. Nicolson, eds.,

Praeger Press, Inc., New York, NY, pp. 227-229, c. 1987.

57. Doroshow, J., Bertrand, M., Newman, E., Multhauf, P., Leong, L., Blayney, D., Goldberg, D.,

Margolin, K., Carr, B., Akman, S., and Metter, G.: Preliminary Analysis of a Randomized Comparison of

5-Fluorouracil versus 5-Fluorouracil and High Dose Continuous Infusion Folinic Acid in Disseminated

Colorectal Cancer. National Cancer Institute Monographs 5: 171-174, 1987.

35



58. Straw, J.A., Newman, E.M., and Doroshow, J.H.: Pharmacokinetics of Leucovorin (d,l-5

formyltetrahydrofolate) after I.V. Injection and Constant I.V. Infusion. National Cancer Institute

Monographs 5: 41- 45, 1987.

59. Textor, S.C., Margolin, K., Blayney, D., Carlson, J., and Doroshow, J.: Renal, Volume, and Hormonal

Changes During Therapeutic Administration of Recombinant Interleukin 2 in Man. Amer. J. Med. 83:

1055-1061, 1987.

60. Doroshow, J.H.: Role of Reactive Oxygen Production in Doxorubicin Cardiac Toxicity. In Organ

Directed Toxicities of Anticancer Drugs. M. Hacker, L. Lazo, and T. Tritton, eds., Martinus Nijhoff

Publishers, Boston, MA, pp. 31-40, c. 1988.

61. Doroshow, J.H.: Anthracycline-Enhanced Cardiac Oxygen Radical Metabolism. In Free Radicals in

the Pathophysiology of Heart Disease. P.K. Singal, ed., Martinus Nijhoff Publishers, Boston, MA, pp.

323-332, c. 1988.

62. Fisher, R.I., Coltman, C.A., Doroshow, J.H., Rayner, A., Hawkins, M.J., Mier, J.W., Wiernik, P.,

McMannis, J., Weiss, G., Margolin, K., Gemlo, B., Hoth, D., Parkinson, D., and Paietta, E.: Metastatic

Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical

Trial. Ann. Intern. Med. 108: 518-523, 1988.

63. Newman, E.M., Doroshow, J.H., Forman, S.J., and Blume, K. G.: Pharmacokinetics of High Dose

Etoposide (VP-16). Clin. Pharmacol. Ther. 43: 561-564, 1988.

64. Margolin, K., Akman, S., Carr, B., Leong, L., and Doroshow, J.: VP-16 and Cytosine Arabinoside in

the Treatment of Relapsed Small Cell Lung Cancer. Amer. J. Clin. Oncol. 11: 499-501, 1988.

65. Bennett, J.M., Muss, H., Doroshow, J., Wolff, S., Krementz, E., Cartwright, K., Dukart, G., Reisman,

A., and Schoch, I.: A Randomized Multicenter Trial Comparing Mitoxantrone, Cyclophosphamide, and 5-

Fluorouracil (CNF) to Doxorubicin, Cyclophosphamide, and 5-Fluorouracil (CAF) in the Therapy of

Metastatic Breast Carcinoma. J. Clin. Oncol. 6: 1611-1620, 1988.

66. Burke, T.G., Doroshow, J.H., and Tritton, T.R.: Membrane Interactions of the Anthracycline

Antibiotics. In Time-Resolved Laser Spectroscopy in Biochemistry. J.R. Lakowicz, ed., Proc. Int. Soc.

Optical Engin., Bellingham, WA, 909: 447-454, 1988.

67. Lown, J.W., Mossman, B.T., Doroshow, J.H., and Kensler, T.W.: Oxidants in Xenobiotic-Induced

Tissue Damage. In Oxyradicals in Molecular Biology and Pathology. P. Cerutti, I. Fridovich, and J.

McCord, eds., Alan R. Liss, Inc. Publishers, New York, NY, pp. 387-391, c. 1988.

68. Doroshow, J.H., Leong, L., Margolin, K., Flanagan, B., Goldberg, D., Bertrand, M., Akman, S., Carr,

B., Odujinrin, O., and Litchfield, T.: Effective Salvage Therapy for Refractory Disseminated Breast Cancer

with 5-Fluorouracil and High-Dose Continuous Infusion Folinic Acid.

Advances Exper. Med. Biol. 244: 245-253, 1988.

36



69. Doroshow, J.: Direct and Oxyradical-Mediated Effects of Anthracycline Antibiotics on Calcium

Uptake by Cardiac Sarcoplasmic Reticulum. In Progress in Chemotherapy. B. Berkada and H.

Kuemmerle, eds., ECOMED Publishers, W. Germany, vol. 3, pp. 203-205, c. 1988.

70. Foon, K., Doroshow, J., Bonnem, E., Fefer, A., Graham, S., Grosh, B., Narayan, P., Elias, L, Harvey,

H., Shulof, R., Williams, R., Rinehart, J., Zekan, P., Catalona, W., Dillman, R., Salmon, S., and Galasso,

F.: A Prospective Randomized Trial of α-Interferon/γ-Interferon or the Combination in Advanced

Metastatic Renal Cell Carcinoma. J. Biol. Resp. Modifiers 7: 540-545, 1988.

71. Doroshow, J.H., Leong, L., Margolin, K., Flanagan, B., Goldberg, D., Bertrand, M., Akman, S., Carr,

B., Odujinrin, O., Newman, E., and Litchfield, T.: Refractory Metastatic Breast Cancer: Salvage Therapy

with 5-Fluorouracil and High-Dose, Continuous Infusion Leucovorin Calcium.

J. Clin. Oncol. 7: 439-444, 1989.

72. Margolin, K.A., Rayner, A., Hawkins, M.J., Atkins, M.B., Dutcher, J., Fisher, R., Weiss, G.,

Doroshow, J., Jaffe, H., Roper, M., Parkinson, D., Wiernik, P., Creekmore, S., and Boldt, D.H.:

Interleukin-2 and Lymphokine Activated Killer Cell Therapy of Solid Tumors: Analysis of Toxicity and

Management Guidelines. J. Clin. Oncol. 7: 486-498, 1989.

73. Dutcher, J.P., Creekmore, S., Weiss, G.R., Margolin, K., Markowitz, A.B., Roper, M., Parkinson, D.,

Ciobanu, N., Fisher, R., Boldt, D.H., Doroshow, J., Rayner, A., Hawkins, M., and Atkins, M.: A Phase II

Study of Interleukin 2 and Lymphokine Activated Killer (LAK) Cells in Patients with Metastatic

Malignant Melanoma. J. Clin. Oncol. 7: 477-485, 1989.

74. Gandara, D., Wold, H., Perez, E., Deisseroth, A., Doroshow, J., Meyers, F., McWhirter, K., Hannigan,

J., and DeGregorio, M.W.: Cisplatin Dose Intensity in Non-Small Cell Lung Cancer: Phase II Results of a

Day 1 and Day 8 High Dose Regimen. J. Natl. Cancer Inst. 81: 790-794, 1989.

75. Burke, T.G., Israel, M., Seshadri, R., and Doroshow, J.: A Fluorescence Study Examining How 14-

Valerate Side Chain Substitution Modulates Anthracycline Binding to Small Unilamellar Phospholipid

Vesicles. Biochim. Biophys. Acta 982: 123-130, 1989.

76. Tromberg, B.J., Burke, T.G., Doroshow, J.H., and Berns, M.W.: Synchronous Fluorescence Studies of

Anthracycline Anti-tumor Drugs. In Fluorescence and Chemical Analysis: Fluorescence Detection III. T.

Vo-Dinh, ed., Proc. Internat. Soc. Optical Engin., Bellingham, WA, 1054: 152-159, 1989.

77. Burke, T.G. and Doroshow, J.H.: Plasma Membrane Lesions in Anthracycline-Resistant Tumor Cells

Probed Using a Fluorescent Dye. In Medical Applications of Lasers and Optics: New Technologies in

Cytometry. G. Salzman, ed., Proc. Internat. Soc. Optical Engin., Bellingham, WA,

1063: 161-169, 1989.

78. Doroshow, J.H.: Role of Reactive Oxygen Metabolites in the Cytotoxicity of Anticancer Quinones. In

Anticancer Drugs. H. Tapiero, J. Robert, and T. Lampidis, eds., John Libbey Eurotext Ltd., London, 191:

87-92, c. 1989.

37



79. Akman, S.A., Forrest, G., Chu, F.F., and Doroshow, J.H.: Resistance to Hydrogen Peroxide

Associated with Altered Catalase mRNA Stability in MCF-7 Breast Cancer Cells. Biochim. Biophys. Acta

1009: 70-74, 1989.

80. Newman, E., Straw, J., and Doroshow, J.H.: Pharmacokinetics of the Diastereoisomers of

(6 R,S)-Folinic Acid (Leucovorin) in Humans During Constant High-Dose Intravenous Infusion.

Cancer Res. 49: 5755-5760, 1989.

81. Sheibani, K., Traweek, T., Ben-Ezra, J., Stroup, R., Esteban, J., Rappaport, H., Battifora, H., Forman,

S., Doroshow, J., and Niland, J.: Monocytoid B-Cell Lymphoma. Amer. J. Surg. Pathol. 13: 902-904,

1989.

82. Margolin, K., Doroshow, J., Leong, L., Akman, S., Carr, B., and Odujinrin, O.: Combination

Chemotherapy with Cytosine Arabinoside and Cis-diammine-dichloroplatinum for Squamous Cancers of

the Upper Aerodigestive Tract. Amer. J. Clin. Oncol. 126: 494-497, 1989.

83. Doroshow, J.H.: Role of Oxygen Radical Metabolism in the Cardiac Toxicity of Anticancer Quinones.

In Focus on Membrane Lipid Oxidation. C. Vigo-Pelfrey, ed., CRC Press, Inc., Boca Raton, FL, vol. 1, pp.

303-314, c. 1990.

84. Odujinrin, O., Goldberg, D., Doroshow, J., Leong, L., Margolin, K., Grove, W., Carr, B., and Akman,

S.: Treatment of Metastatic Malignant Melanoma with Trimetrexate: A Phase II Study. Med. Ped. Oncol.

18: 49-52, 1990.

85. Akman, S.A., Forrest, G., Chu, F.-F., Esworthy, S., and Doroshow, J.H.: Antioxidant and Xenobiotic

Metabolizing Enzyme Gene Expression in Doxorubicin-Resistant MCF-7 Breast Cancer Cells. Cancer

Res. 50: 1397-1402, 1990.

86. Forrest, G.L., Akman, S., Krutzik, S., Paxton, R.J., Sparkes, R.S., Doroshow, J., Felsted, R.L., Glover,

C.J., Mohandas, T., and Bachur, N.R.: Induction of a Human Carbonyl Reductase Gene Located on

Chromosome 21. Biochim. Biophys. Acta 1048: 149-155, 1990.

87. Doroshow, J.H., Multhauf, P., Leong, L., Margolin, K., Litchfield, T., Akman, S., Carr, B., Bertrand,

M., Goldberg, D., Blayney, D., Odujinrin, O., DeLap, R., Shuster, J., and Newman, E.: Prospective

Randomized Comparison of 5-Fluorouracil Versus 5-Fluorouracil and High-Dose

Continuous Infusion Leucovorin Calcium for the Treatment of Advanced Measurable Colorectal Cancer In

Patients Previously Unexposed to Chemotherapy. J. Clin. Oncol. 8: 491-501, 1990.

88. Chu, F.-F., Esworthy, R.S., Akman, S., and Doroshow, J.H.: Modulation of Glutathione Peroxidase

Expression by Selenium: Effect on Human MCF-7 Breast Cancer Cell Transfectants Expressing a Cellular

Glutathione Peroxidase cDNA and Doxorubicin-Resistant MCF-7 Cells.

Nucl. Acids Res. 18: 1531-1539, 1990.

38



89. Burke, T.G., Israel, M., Seshadri, R., and Doroshow, J.H.: Abrogation of the Selectivity of

Adriamycin for Negatively-Charged Phospholipids by 14-Valerate Side Chain Substitution. Cancer

Biochem. Biophys. 11: 177-185, 1990.

90. Burke, T.G., Malak, H., and Doroshow, J.H.: Fluorescence Lifetimes of Anthracycline Drugs in

Phospholipid Bilayers Determined by Frequency-Domain Fluorometry. In Time-Resolved Laser

Spectroscopy in Biochemistry II. J.R. Lakowicz, ed., Proc. Int. Soc. Optical Engin., Bellingham, WA,

1204: 514-523, 1990.

91. Bar, M.H., Sznol, M., Atkins, M.B., Ciobanu, N., Micetich, K.C., Boldt, D.H., Margolin, K.A.,

Aronson, F.R., Rayner, A.A., Hawkins, M.J., Mier, J.W., Paietta, E., Fisher, R.I., Weiss, G.R., and

Doroshow, J.H.: Metastatic Malignant Melanoma Treated with Combined Bolus and Continuous Infusion

Interleukin-2 and Lymphokine-Activated Killer Cells.

J. Clin. Oncol. 8: 1138-1147, 1990.

92. Gaynor, E.R., Weiss, G.R., Margolin, K.A., Aronson, F.R., Sznol, M., Demchak, P., Grimer, K.M.,

Fisher, R.I., Boldt, D.H., Doroshow, J.H., Bar, M.H., Hawkins, M.J., Mier, J.W., Caliendo, G.: Phase I

Study of High Dose Continuous Infusion Interleukin-2 and Autologous Lymphokine Activated Killer Cells

in Patients with Metastatic or Unresectable Malignant Melanoma and Renal Carcinoma. J. Natl. Cancer

Inst. 82: 1397-1402, 1990.

93. Parkinson, D.R., Abrams, J.S., Wiernik, P.H., Rayner, A.A., Margolin, K.A., Van Echo, D.A., Sznol,

M., Dutcher, J.P., Aronson, F.R., Doroshow, J.H., Atkins, M.B., and Hawkins, M.J.: Interleukin-2 Therapy

in Patients with Metastatic Malignant Melanoma: A Phase II Study. J. Clin. Oncol. 8: 1650-1656, 1990.

94. Forrest, G.L., Qian, J., Ma, J.-X., Kaplan, W.D., Akman, S., Doroshow, J., and Chen, S.: Rat Liver

NAD(P)H:Quinone Oxidoreductase: cDNA Expression and Site-Directed Mutagenesis. Biochem.

Biophys. Res. Commun. 169: 1087-1093, 1990.

95. Zwelling, L.A., Slovak, M.L., Doroshow, J.H., Hinds, M., Chan, D., Parker, E., Mayes, J., Sie, K.L.,

Meltzer, P.S., and Trent, J.M.: HT1080/DR4: A P-Glycoprotein-Negative Human Fibrosarcoma Cell Line

Exhibiting Resistance to Topoisomerase II-Reactive Drugs Despite the Presence of a Drug-Sensitive

Topoisomerase II. J. Natl. Cancer Inst. 82: 1553-1561, 1990.

96. Doroshow, J.H., Akman, S.A., Chu, F.F., and Esworthy, S.E.: Role of the Glutathione-Glutathione

Peroxidase Cycle in the Cytotoxicity of the Anticancer Quinones. Pharmacol. Therapeutics 47: 359-370,

1990.

97. Margolin, K., Doroshow, J., Leong, L., Akman, S., Carr, B., Odujinrin, O., Flanagan, B., Grove, W.,

DeLap, R., and Goldberg, D.: Dezaguanine: Report of a Phase I Trial and Drug-Related Cardiac Toxicity.

Invest. New Drugs 8: 369-376, 1990.

39



98. Sznol, M., Mier, J.W., Sparano, J., Gaynor, E., Weiss, G., Margolin, K., Bar, M.H., Hawkins, M.J.,

Atkins, M., Dutcher, J.P., Fisher, R.I., Boldt, D.H., Doroshow, J.H., Louie, A., and Aronson, F.R.: A

Phase I Study of High Dose Interleukin-2 in Combination with Interferon-alpha 2B. J. Biol. Resp.

Modifiers 9: 529-537, 1990.

99. Akman, S.A., Doroshow, J.H., and Dizdaroglu, M.: Base Modifications in Plasmid DNA Caused by

Potassium Permanganate. Arch. Biochem. Biophys. 282: 202-205, 1990.

100. Carlson, R.W., Doroshow, J.H., Odujinrin, O., Flam, M.S., Malec M., and Lamborn, K.R.:

Trimetrexate in Locally Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase II Study of the

Northern California Oncology Group. Invest. New Drugs 8: 387-389, 1990.

101. Doroshow, J.H., Akman, S., Esworthy, S., Chu, F.F., and Burke, T.: Doxorubicin Resistance

Conferred by Selective Enhancement of Intracellular Glutathione Peroxidase or Superoxide Dismutase

Content in Human MCF-7 cells. Free Radical Res. Commun. 12-13: 779-781, 1991.

102. Doroshow, J.H., and Newman, E.M.: Fluoropyrimidine Biochemical Modulation in Colon Cancer:

Pharmacology Relevant in both the Laboratory and the Clinic. J. Clin. Oncol. 9: 365-367, 1991.

103. Doroshow, J.H.: Doxorubicin-Induced Cardiac Toxicity. N. Engl. J. Med. 324:843-845, 1991.

104. Somlo, G., Doroshow, J.H., Akman, S., Leong, L., Margolin, K., McNamara, M., Multhauf, P.,

Blayney, D., Morgan, R., and Raschko, J.: Phase II Study of 4'-Deoxydoxorubicin (Esorubicin) in

Advanced or Metastatic Adenocarcinoma of the Stomach. Invest. New Drugs 9: 83-85, 1991.

105. Esworthy, R.S., Chu, F.F., Paxton, R.J., Akman, S., and Doroshow, J.H.: Characterization and Partial

Amino Acid Sequence of Human Plasma Glutathione Peroxidase. Arch. Biochem. Biophys. 286: 330-336,

1991.

106. Dutcher, J.P., Gaynor, E., Boldt, D.H., Doroshow, J.H., Bar, M.H., Sznol, M., Mier, J., Sparano, J.,

Fisher, R.I., Weiss, G., Margolin, K., Aronson, F.R., Hawkins, M., and Atkins, M.: A Phase II Study of

High Dose Continuous Infusion Interleukin-2 with Lymphokine Activated Killer

Cells in Patients with Metastatic Melanoma. J. Clin. Oncol. 9: 641-648, 1991.

107. Burke, T.G., Lee, T.D., van Balgooy, J., and Doroshow, J.H.: Characterization of the Aqueous

Decomposition Products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by Liquid

Chromatographic and Mass Spectral Analysis. J. Pharmaceut. Sci. 80: 338-340, 1991.

108. Maiorino, M., Chu, F.F., Ursini, F., Davies, K.J.A., Doroshow, J.H., and Esworthy, R.S.:

Phospholipid Hydroperoxide Glutathione Peroxidase is the 18 KD Selenoprotein Expressed in Human

Tumor Cell Lines. J. Biol. Chem. 266: 7728-7732, 1991.

40



109. Vokes, E.E., Raschko, J.W., Vogelzang, N.J., Warfield, E.E., Ratain, M.J., Doroshow, J.H., and

Schilsky, R.L.: Five Day Infusion Fluorodeoxyuridine with High Dose Oral Leucovorin: A Phase I Study.

Cancer Chemother. Pharmacol. 28: 69-73, 1991.

110. Akman, S.A., Lingeman, R., Doroshow, J.H., and Smith, S.S.: Quadruplex DNA Formation in a

Region of the tRNA Gene SupF Associated with Hydrogen Peroxide-Mediated Mutations. Biochemistry

30: 8648-8653, 1991.

111. Akman, S.A., Forrest, G.L., Doroshow, J.H., and Dizdaroglu, M.: Mutation of Potassium

Permanganate and Hydrogen Peroxide-Treated Plasmid pZ189 Replicating in CV-1 Monkey Kidney Cells.

Mutat. Res. 261: 123-130, 1991.

112. Margolin, K.A., Aronson, F.R., Sznol, M., Atkins, M.B., Dutcher, J.P., Fisher, R.I., Weiss, G.R.,

Doroshow, J.H., Hawkins, M.J., Gaynor, E.P., and Boldt, D.H.: Phase II Trial of High-Dose Interleukin-2

and Lymphokine-Activated Killer Cells in Hodgkin's Disease and Non-Hodgkin's Lymphoma. J.

Immunother. 10: 214-220, 1991.

113. Forrest, G.L., Akman, S., Doroshow, J., Rivera, H., and Kaplan, W.D.: Genomic Sequence and

Expression of a Cloned Human Carbonyl Reductase Gene with Daunorubicin Reductase Activity. Molec.

Pharmacol. 40: 502-507, 1991.

114. Doroshow, J.H., Burke, T., and Akman, S.: Role of Oxygen Radical Metabolism in the Toxicity of

Anticancer Quinones for Rat Heart Myocytes In Vitro. In Oxidative Damage & Repair: Chemical,

Biological and Medical Aspects. K.J.A. Davies, ed., Pergamon Press, New York, NY, pp. 117-120, c.

1991.

115. Margolin, K.A., Doroshow, J.H., Akman, S.A., Leong, L.A., Morgan, R., Raschko, J., Somlo, G.,

Mills, B., Goldberg, D., and Sniecinski, I.: Phase I Trial of Interleukin-2 Plus Gamma-Interferon. J.

Immunother. 11: 50-55, 1992.

116. Piedbois, P., Buyse, M., Rustum, Y., Machover, D., Erlichman, C., Carlson, R.W., Valone, F.,

Labianca, R., Doroshow, J.H., and Petrelli, N.: Modulation of Fluorouracil by Leucovorin in Patients with

Advanced Colorectal Cancer: Evidence in Terms of Response Rate. J. Clin. Oncol. 10: 896-903, 1992.

117. Weiss, G.R., Margolin, K.A., Aronson, F.R., Sznol, M., Atkins, M.B., Dutcher, J., Gaynor, E.R.,

Boldt, D.H., Doroshow, J.H., Bar, M.H., Hawkins, M.J., Demchak, P.A., Gucalp, R., and Fisher, R.I.: A

Randomized Phase II Trial of Continuous Infusion Interleukin 2 or Bolus Injection Interleukin 2 Plus

Lymphokine-Activated Killer Cells for Advanced Renal Cell Carcinoma.

J. Clin. Oncol. 10: 275-281, 1992.

118. Doroshow, J.H.: Reductive Activation of Mitomycin C: A Delicate Balance. J. Natl. Cancer Inst. 84:

1138-1139, 1992.

41



119. Akman, S., Doroshow, J.H., Burke, T., and Dizdaroglu, M.: Base Modifications Induced in Isolated

Human Chromatin by NADH Dehydrogenase-Catalyzed Reduction of Doxorubicin. Biochemistry 31:

3500-3506, 1992.

120. Newman, E.M., Akman, S.A., Harrison, J.S., Leong, L.A., Margolin, K.A., Morgan, R.W., Raschko,

J.W., Somlo, G., Ahn, C.W., and Doroshow, J.H.: Pharmacokinetics and Toxicity of Continuous Infusion

(6S)-Folinic Acid and Bolus 5-Fluorouracil in Patients with Advanced Cancer.

Cancer Res. 52: 2408-2412, 1992.

121. Chu, F.-F., Esworthy, R.S., Doroshow, J.H., Doan, K., and Liu, X.-F.: Expression of Plasma

Glutathione Peroxidase in Animal Tissues and Human Cell Lines. Blood 79: 3233-3238, 1992.

122. Margolin, K.A., Doroshow, J.H., Akman, S.A., Leong, L.A., Morgan, R.J., Raschko, J.W., Somlo, G.,

and Blevins, C.: Effective Initial Therapy of Advanced Breast Cancer with 5-Fluorouracil and High-Dose,

Continuous Infusion Calcium Leucovorin. J. Clin. Oncol. 10: 1278-1283, 1992.

123. Williamson, S.K., Crowley, J.J., Livingston, R., Hantel, A., and Doroshow, J.H.: Phase II Trial of

Piroxantrone in Advanced Non-Small Cell Carcinoma of the Lung. A Southwest Oncology Group Study.

Invest. New Drugs 10: 29-30, 1992.

124. Newman, E.M., Letvak, L.A., George, M.J., and Doroshow, J.H.: Pharmacokinetics of High Dose

Continuous Infusion (6S)-Folinic Acid in Humans. Pteridines 3: 147-148, 1992.

125. Margolin, K., Doroshow, J.H., Akman, S., Leong, L.A., Morgan, R.J., Somlo, G., Raschko, J.,

Pereira, C., Yonemoto, L., and Ahn, C.: Phase II Trial of Cisplatin and α-IFN in Advanced Malignant

Melanoma. J. Clin. Oncol. 10: 1574-1578, 1992.

126. Urba, S., Doroshow, J., Cripps, C., Robert, F., Velez-Garcia, E., Dallaire, B., Adams, D., Carlson, R.,

Grillo-Lopez, A., and Gyves, J.: Multicenter Phase II Trial of Brequinar Sodium in Patients with Advanced

Squamous Cell Carcinoma of the Head and Neck. Cancer Chemother. Pharmacol. 31: 167-169, 1992.

127. Akman, S.A., Doroshow, J.H., and Kensler, T.W.: Copper-Dependent Site-Specific Mutagenesis by

Benzoyl Peroxide in the supF Gene of the Mutation Reporter Plasmid pS189. Carcinogenesis

13: 1783-1787, 1992.

128. Doroshow, J.H., and Esworthy, R.S.: The Role of Antioxidant Defenses in the Cardiac Toxicity of

Anthracyclines. In Cancer Treatment and the Heart. F.M. Muggia, M.D. Green, and J.L. Speyer, eds.,

Johns Hopkins Univ. Press, Baltimore, MD, pp. 47-58, c. 1992.

129. Singh, D., Doroshow, J.H., Leong, L., Margolin, K., Akman, S., Raschko, J., Somlo, G., Morgan, R.,

Harrison, J., and Ahn, C.: Phase II Trial of 5-Fluorouracil, High-Dose Leucovorin Calcium, and

Dipyridamole in Advanced Prostate Cancer. J. Cancer Res. Clin. Oncol. 119: 117-120, 1992.

42



130. Kraut, E.H., Bendetti, J., Balcerzak, S.P., and Doroshow, J.H.: Phase II Trial of Merberone in Soft

Tissue Sarcoma: A Southwest Oncology Group Study. Invest. New Drugs 10: 347-349, 1992.

131. Sklarin, N.T., Wiernik, P.H., Grove, W.R., Benson, L., Mittelman, A., Maroun, J.A., Stewart, J.A.,

Robert, F., Doroshow, J.H., Rosen, P.J., Jolivet, J., Ruckdeschel, J.C., Robert, N.J., Velez-Garcia, E.,

Bergsagel, D.E., Panasci, L.C., van der Merwe, A.M., Longueville, J.J., Leiby, J., and Kowal, C.D.: A

Phase II Trial of CI-921 in Advanced Malignancies. Invest. New Drugs 10: 309-312, 1992.

132. Chu, F.-F., Doroshow, J.H., and Esworthy, R.S.: Expression, Characterization, and Tissue

Distribution of a New Cellular Selenium-Dependent Glutathione Peroxidase--GSHPx-GI.

J. Biol. Chem. 268: 2571-2576, 1993.

133. Dizdaroglu, M., Olinski, R., Doroshow, J.H., and Akman, S.A.: Modification of DNA Bases in

Chromatin of Intact Target Cells by Activated Human Polymorphonuclear Leukocytes. Cancer Res.

53: 1269-1272, 1993.

134. Atkins, M.B., Sparano, J., Fisher, R.I., Weiss, G.R., Margolin, K.A., Fink, K.I., Rubinstein, L., Louie,

A., Mier, J.W., Gucalp, R., Sosman, J.A., Boldt, D.H., Doroshow, J.H., Aronson, F.R., and Sznol, M.: A

Randomized Phase II Trial of High Dose IL-2 Either Alone or in Combination with Interferon Alpha 2B in

Advanced Renal Cell Carcinoma. J. Clin. Oncol. 11: 661-670, 1993.

135. Blayney, D.W., Goldberg, D.A., Leong, L.A., Margolin, K.A., Burke, J.S., and Doroshow, J.H.: High

Risk Germ Cell Tumors in Men: High Response Rate and Severe Toxicity with Cisplatin, Vinblastine,

Bleomycin, and Etoposide. Cancer 71: 2351-2357, 1993.

136. Antman, K.A., Crowley, J., Balcerzak, S.P., Rivkin, S.E., Weiss, G.R., Elias, A., Natale, R.B.,

Cooper, R.M., Barlogie, B., Trump, D.L., Doroshow, J.H., Aisner, J., Pugh, R.P., Weiss, R.B., Cooper,

B.A., Clamond, G.H., and Baker, L.H.: An Intergroup Phase III Randomized Study of Doxorubicin and

Dacarbazine with or without Ifosfamide and Mesna in Advanced Tissue and Bone Sarcomas. J. Clin.

Oncol. 11: 1276-1285, 1993.

137. Sosman, J.A., Weiss, G.R., Margolin, K.A., Aronson, F.R., Sznol, M., Atkins, M.B., O'Boyle, K.,

Fisher, R.I., Boldt, D.H., Doroshow, J., Ernest, M.L., Fisher, S.G., Mier, J., Vachino, G., and Caliendo, G.:

Phase IB Clinical Trial of Anti-CD3 Followed by High Dose Bolus IL-2 in Patients with Metastatic

Melanoma and Advanced Renal Cell Carcinoma: Clinical and Immunological Effects. J. Clin. Oncol. 11:

1496-1505, 1993.

138. Doroshow, J.H., and Newman, E.M.: Biochemical Modulation of 5-Fluorouracil by Leucovorin in the

Treatment of Advanced Breast Cancer. J. Infusional Chemother. 3: 152-160, 1993.

139. Margolin, K.A., Doroshow, J.H., Akman, S.A., Leong, L.A., Morgan, R., Raschko, J., Somlo, G.,

Dutcher, J., Hawksworth, K., Yonemoto, L., Caliendo, G., and Cavasotto, G.: Phase I Trial of Interleukin-2

Plus Doxorubicin. J. Immunother. 14: 70-76, 1993.

43



140. Doroshow, J.H., Esworthy, R.S., Chu, F.F., and Akman, S.: Glutathione Peroxidase and Resistance to

Oxidative Stress. In Structure and Function of Glutathione Transferases, K.D. Tew, C.B. Pickett, T.J.

Mantle, B. Mannervik, and J.D. Hayes eds., CRC Press, Inc., Boca Raton, FL, pp. 269-277, c. 1993.

141. Doroshow, J.H., Margolin, K., Leong, L., Akman, S., Morgan, Jr., R., Raschko, J., Somlo, G.,

Hamasaki, V., Womack, E., Newman, E., and Ahn, C.: Fluorouracil and Leucovorin in Advanced Breast

Cancer. Advances Exper. Med. Biol. 339: 187-193, 1993.

142. Sparano, J.A., Fisher, R.I., Sunderland, M., Margolin, K., Ernest, M.L., Sznol, M., Atkins, M.B.,

Dutcher, J.P., Micetich, K.C., Weiss, G.R., Doroshow, J.H., Aronson, F.R., Rubinstein, L.V., and Mier,

J.W.: Randomized Phase III Trial of Treatment with High-Dose Interleukin-2 Either Alone or in

Combination with Interferon Alfa-2a in Patients with Advanced Melanoma. J. Clin. Oncol. 11: 1969-1977,

1993.

143. Akman, S.A., Kensler, T.W., Doroshow, J.H., and Dizdaroglu, M.: Modification of DNA Bases In

Vitro by Copper-Activated Benzoyl Peroxide. Carcinogenesis 14: 1971-1974, 1993.

144. Esworthy, R.S., Chu, F.-F., Geiger, P., Girotti, A.W., and Doroshow, J.H.: Reactivity of Plasma

Glutathione Peroxidase with Hydroperoxide Substrates and Glutathione. Arch. Biochem. Biophys. 307:

29-34, 1993.

145. Somlo, G., Doroshow, J.H., Forman, S.J., Leong, L.A., Margolin, K.A., Morgan, R.J., Jr., Raschko,

J.W., Akman, S.A., Ahn, C., and Sniecinski, I.: High-Dose Cisplatin, Etoposide, and Cyclophosphamide

with Autologous Stem Cell Reinfusion in Patients with Responsive Metastatic or High-Risk Primary

Breast Cancer. Cancer 73: 125-134, 1994.

146. Hawkins, M.J., Atkins, M.B., Dutcher, J.P., Fisher, R.I., Weiss, G.R., Margolin, K.A., Raynor, A.A.,

Sznol, M., Parkinson, D.R., Paietta, E., Gaynor, E.R., Boldt, D.H., Doroshow, J.H., and Aronson, F.R.: A

Phase II Clinical Trial of Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Colorectal

Carcinoma. J. Immunother. 15: 74-78, 1994.

147. Margolin, K., Aronson, F.R., Sznol, M., Atkins, M.B., Gucalp, R., Fisher, R.I., Sunderland, M.,

Doroshow, J.H., Ernest, M.L., Meir, J.W., Dutcher, J.P., Gaynor, E.R., and Weiss, G.R.: Phase II Studies

of Recombinant Human IL-4 in Advanced Renal Cancer and Malignant Melanoma.

J. Immunother. 15: 147-153, 1994.

148. Somlo, G., Doroshow, J.H., Forman, S.J., Leong, L.A., Margolin, K.A., Morgan, R.J.,Jr., Raschko,

J.W., Akman, S.A., Ahn, C., Nagasawa, S., and Harrison, J.: High-Dose Doxorubicin, Etoposide, and

Cyclophosphamide with Stem Cell Reinfusion in Patients with Responsive Metastatic or High-Risk

Primary Breast Cancer. Cancer 73: 1678-1685, 1994.

149. Margolin, K.A., Green, S., Osborne, K., Doroshow, J.H., Akman, S.A., Leong, L.A., Morgan, R.J.,

Raschko, J.W., Somlo, G., Hutchins, L., and Upchurch, C.: Phase II Trial of 5-Fluorouracil and High-Dose

Folinic Acid as First- or Second-Line Therapy for Advanced Breast Cancer. Amer. J. Clin. Oncol. 17: 175-

180, 1994.

44



150. Esworthy, R.S., Doan, R., Doroshow, J.H., and Chu, F.-F.: Cloning and Sequencing of the cDNA

Encoding a Human Testis Phospholipid Hydroperoxide Glutathione Peroxidase. Gene 144: 317-318, 1994.

151. Chu, F.-F., Doroshow, J.H., and Esworthy, R.S.: Tissue-Specific Expression of Members of the

Selenium-Dependent Glutathione Peroxidase (SeGSHPx) Gene Family. In New Strategies in Prevention

and Therapy: Biological Oxidants and Antioxidants. L. Packer and E. Cadenas eds., Hippokrates Verlag,

Stuttgart, pp. 153-169, c. 1994.

152. Sparano, J.A., Fisher, R.I., Weiss, G.R., Margolin, K., Aronson, F.R., Hawkins, M.J., Atkins, M.B.,

Dutcher, J.P., Gaynor, E.R., Boldt, D.H., Doroshow, J.H., Ernest, M.L., Sznol, M., and Mier, J.W.: Phase

II Trials of High-Dose IL2 and Lymphokine-Activated Killer Cells in Advanced Breast Carcinoma and

Carcinoma of the Lung, Ovary, Pancreas, and Other Tumors. J. Immunother. 16: 216-223, 1994.

153. Raschko, J.W., Akman, S.A., Leong, L.A., Margolin, K.A., Morgan, R.J., Newman, E.M., Somlo, G.,

Ahn, C.W., and Doroshow, J.H.: Phase I Study of 5-Day Continuous Infusion Fluorodeoxyuridine and

High Dose Folinic Acid with Oral Hydroxyurea. Cancer Chemother. Pharmacol. 35: 161-164, 1994.

154. Ravdin, P.M., Green, S., Doroshow, J.H., and Martino, S.: Phase II Trial of Piroxantrone in

Metastatic Breast Cancer: A Southwest Oncology Group Study. Invest. New Drugs 12: 333-336, 1994.

155. Doroshow, J.H.: Role of Reactive-Oxygen Metabolism in Cardiac Toxicity of Anthracycline

Antibiotics. In Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of

Action, W. Priebe, ed., American Chemical Society, Washington, D.C., pp. 259-267, c. 1995.

156. Erkmen, K., Egorin, M.J., Reyno, L.M., Morgan, R. Jr., and Doroshow, J.H.: Effects of Storage on

the Binding of Carboplatin to Plasma. Cancer Chemother. Pharmacol. 35: 254-256, 1995.

157. Coluzzi, P.H., Grant, M., Doroshow, J.H., Rhiner, M., Ferrell, B., and Rivera, L.: Survey of the

Provision of Supportive Care Services at National Cancer Institute Designated Cancer Centers.

J. Clin. Oncol. 13: 756-764, 1995.

158. Zhou, B.-S., Hsu, N.-Y., Pan, B.-C., Doroshow, J.H., and Yen, Y.: Overexpression of Ribonucleotide

Reductase in Transfected Human KB Cells Increases Their Resistance to Hydroxyurea: M2 but Not M1 Is

Sufficient to Increase Resistance to Hydroxyurea in Transfected Cells. Cancer Res. 55: 1328-1333, 1995.

159. Tetef, M., Margolin, K., Ahn, C., Akman, S., Chow, W., Coluzzi, P., Leong, L., Morgan, Jr., R.J.,

Raschko, J., Shibata, S., Somlo, G., and Doroshow, J.H.: Mitomycin C and Menadione for the

Treatment of Advanced Gastrointestinal Cancers: A Phase II Trial. J. Cancer Res. Clin. Oncol. 121: 103-

106, 1995.

160. Leichman,C.G., Fleming, T.R., Muggia, F.M., Tangen, C.M., Ardalan, B., Doroshow, J.H., Meyers,

F.J., Holcombe, R.F., Weiss, G.R., Mangalik, A., and Macdonald, J.S.: Phase II Study of Fluorouracil and

Its Modulation in Advanced Colorectal Cancer: A Southwest Oncology Group Study.

J. Clin. Oncol. 13: 1303-1311, 1995.

45



161. Somlo, G., Doroshow, J.H., Lev-Ran, A., Ahn, D.C., Hwang, L., Raschko, J.W., Forman, S.J.,

Margolin, K.A., Morgan, R.J., Leong, L.A., Hamasaki, V.K., Chow, W.A., Molina, A., Ahmad, B.,

Akman, S.A., Kojian, A., and Menard, P.: Effect of Low-Dose Prophylactic Dopamine on High-Dose

Cisplatin-Induced Electrolyte Wasting, Ototoxicity, and Epidermal Growth Factor Excretion: A

Randomized, Placebo-Controlled, Double-Blind Trial. J. Clin. Oncol. 13: 1231-1237, 1995.

162. Margolin, K.A., Akman, S.A., Leong, L.A., Morgan, R.J., Somlo, G., Raschko, J.W., Ahn, C., and

Doroshow, J.H.: Phase I Study of Mitomycin C and Menadione in Advanced Solid Tumors. Cancer

Chemother. Pharmacol. 36: 293-298, 1995.

163. Morgan, R.J., Jr., Speyer, J., Doroshow, J.H., Margolin, K., Raschko, J., Sorich, J., Akman, S., Leong,

L., Somlo, G., Vasilev, S., Ahn, C., Johnson, D., and Beller, U.: Modulation of 5-Fluorouracil with High

Dose Leucovorin Calcium: Limited Activity in Ovarian Cancer and Correlation with CA-125 Levels.

Gynecol. Oncol. 58: 79-85, 1995.

164. Rodriguez, H., Drouin, R., Holmquist, G.P., O'Connor, T.R., Boiteux, S., Laval, J., Doroshow, J.H.,

and Akman, S.A.: Mapping of Copper/Hydrogen Peroxide-Induced DNA Damage at Nucleotide

Resolution in Human Genomic DNA by Ligation-Mediated Polymerase Chain Reaction.

J. Biol. Chem. 270: 17633-17640, 1995.

165. Welborn, J.L., Kopecky, K.J., Meyers, F.J., Veith, R.W., Chapman, R.A., Doroshow, J.H., Balcerzak,

S.P., and Appelbaum, F.R.: Carboplatin Infusion in Relapsed and Refractory Acute Myeloid Leukemia - A

Southwest Oncology Group Trial. Leukemia 9: 1126-1129, 1995.

166. Morgan, Jr., R.J., Margolin, K., Raschko, J., Akman, S., Leong, L., Somlo, G., Scanlon, K., Ahn, C.,

Carroll, M., and Doroshow, J.H.: Phase I Trial of Carboplatin and Infusional Cyclosporine in Advanced

Malignancy. J. Clin. Oncol. 13: 2238-2246, 1995.

167. Doroshow, J.H.: Redox Cycling and the Antitumor Activity of the Anthracyclines. In The Oxygen

Paradox. K.J.A. Davies and F. Ursini, eds., CLEUP University Press, Padova, Italy,

pp. 469-477, c. 1995.

168. Doroshow, J.H., Metz, M.Z., Matsumoto, L., Winters, K.A., Sakai, M., Muramatsu, M., and Kane,

S.E.: Transduction of NIH 3T3 Cells with a Retrovirus Carrying both Human MDR1 and Glutathione S-

Transferase π Produces Broad-Range Multidrug Resistance. Cancer Res. 55: 4073-4078, 1995

169. Gonzalez, B., Akman, S., Doroshow, J., Rivera, H., Kaplan, W.D., and Forrest, G.L.: Protection

against Daunorubicin Cytotoxicity by Expression of a Cloned Human Carbonyl Reductase cDNA in K562

Leukemia Cells. Cancer Res. 55: 4646-4650, 1995.

170. Tetef, M., Doroshow, J., Akman, S., Coluzzi, P., Leong, L., Margolin, K., Morgan, R.J., Jr., Raschko,

J., Shibata, S., Somlo, G., and Ahn, C.: 5-Fluorouracil and High-Dose Calcium Leucovorin for

Hepatocellular Cancer: A Phase II Trial. Cancer Invest. 13: 460-463, 1995.

46



171. Meyskens, F.L., Kopecky, K.J., Taylor, C.W., Noyes, R.D., Tuthill, R.J., Hersh, E.M., Feun, L.G.,

Doroshow, J.H., Flaherty, L.E., and Sondak, V.K.: A Randomized Trial of Human Interferon-γ Versus

Observation in High-Risk Cutaneous Melanoma: A Southwest Oncology Group Study.

J. Natl. Cancer Inst. 87: 1710-1713, 1995.

172. Weiss, G.R., Margolin, K.A., Sznol, M., Atkins, M.B., Oleksowicz, L., Isaacs, R., Sosman, J.,

Doroshow, J.H., Trehu, E.G., Dutcher, J.P., and Fisher, R.I.: A Phase II Study of the Continuous

Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma. J. Immunother. 18: 52-56,

1995.

173. Tetef, M., Margolin, K., Ahn, C., Akman, S., Chow, W., Leong, L., Morgan, Jr., R.J., Raschko, J.,

Somlo, G., Yen, Y., and Doroshow, J.H.: Mitomycin C and Menadione for the Treatment of Lung Cancer:

A Phase II Trial. Invest. New Drugs 13: 157-162, 1995.

174. Doroshow, J.H.: Glutathione Peroxidase and Oxidative Stress. Toxicol. Lett. 82/83: 395-398, 1995.

175. Odom-Maryon, T., Niland, J.C., and Doroshow, J.: Training in Biostatistics as Part of the Clinical

Oncology Research Career Development Grant. Proc. Section On Statistical Education: Amer. Statistical

Assoc. 1: 171-175, 1995.

176. Doroshow, J.H.: Anthracyclines and Anthracenediones. In Cancer Chemotherapy and Biotherapy:

Principles and Practice, B.A. Chabner and D.L. Longo, eds., 2nd edition, Lippincott-Raven Publishers,

Philadelphia, PA, pp. 409-434, c. 1996.

177. Metz, M.Z., Matsumoto, L., Winters, K.A., Doroshow, J.H., and Kane, S.E.: Bicistronic and Two-

Gene Retroviral Vectors for Using MDR1 as a Selectable Marker and a Therapeutic Gene. Virology 217:

230-241, 1996.

178. Doroshow, J.H.: Biochemical Modulation of Fluoropyrimidines: Is There An Optimal Leucovorin

Dose and Schedule? J. Natl. Cancer Inst. 88: 393-395, 1996.

179. Muggia, F.M., Synold, T.W., Newman, E.M., Jeffers, S., Leichman, L.P., Doroshow, J.H., Johnson,

K., and Groshen, S.: Failure of Pretreatment with Intravenous Folic Acid to Alter the Cumulative

Hematologic Toxicity of Lometrexol. J. Natl. Cancer Inst. 88: 1495-1496, 1996.

180. Margolin, K., Doroshow, J.H., Hamasaki, V., Leong, L., Morgan, R., Raschko, J., Shibata, S., Somlo,

G., and Tetef, M.: Treatment of Relapsed Germ Cell Cancer with Two Cycles of High-Dose Ifosfamide,

Carboplatin and Etoposide with Autologous Stem Cell Support. J. Clin. Oncol. 14: 2631-2637, 1996.

181. Synold, T., and Doroshow, J.H.: Anthracycline Dose Intensity: Clinical Pharmacology and

Pharmacokinetics of High-Dose Doxorubicin Administered as a 96-Hour Continuous Intravenous Infusion.

J. Infusional Chemother. 6: 69-73, 1996.

47



182. Synold, T.W., Xi, B., Newman, E.M., Muggia, F.M., and Doroshow, J.H.: A Simple and Sensitive

Method for the Quantitative Analysis of Lometrexol in Plasma Using High Performance Liquid

Chromatography with Electrochemical Detection. J. Chromatog. B: Biomedical Applications 683: 245-

249, 1996.

183. Engstrom, P.F., Benson, A.B., III, Cohen, A., Doroshow, J., Kiel, K., Niederhuber, J., Roh, M., and

Tempero, M.: NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer

Network. Oncology 10: 140-175, 1996.

184. Newman, E.M., Carroll, M., Akman, S.A., Chow, W., Coluzzi, P., Hamasaki, V., Leong, L.A.,

Margolin, K.A., Morgan, R.J., Raschko, J.W., Shibata, S., Somlo, G., Tetef, M., Yen, Y., Ahn, C.W., and

Doroshow, J.H.: Pharmacokinetics and Toxicity of 120-Hour Continuous-Infusion Hydroxyurea in Patients

with Advanced Solid Tumors. Cancer Chemother. Pharmacol. 39: 254-258, 1997.

185. Sosman, J.A., Aronson, F.R., Sznol, M., Atkins, M.B., Dutcher, J.P., Weiss, G.R., Isaacs, R.E.,

Margolin, K.A., Fisher, R.I., Ernest, M.L., Mier, J., Oleksowicz, L., Eckhardt, J.R., Levitt, D., and

Doroshow, J.H.: Concurrent Phase I Trials of Intravenous Interleukin-6 in Solid Tumor Patients:

Reversible Dose-Limiting Neurologic Toxicity. Clin. Cancer Res. 3: 39-46, 1997.

186. Somlo, G., Sniecinski, I., Odom-Maryon, T., Nowicki, B., Chow, W., Hamasaki, V., Leong, L.,

Margolin, K., Morgan, R., Raschko, J., Shibata, S., Tetef, M., Molina, A., Berenson, R.J., Forman, S.J.,

and Doroshow, J.H.: Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and

Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery Following High-Dose

Chemotherapy for Breast Cancer. Blood 89: 1521-1528, 1997.

187. Margolin, K., Atkins, M., Sparano, J., Sosman, J., Weiss, G., Lotze, M., Doroshow, J., Mier, J.,

O=Boyle, K., Fisher, R., Campbell, E., Rubin, J., Federighi, D., and Bursten, S.: Prospective, Randomized

Trial of Lisofylline for the Prevention of Toxicities of High-Dose Interleukin-2 Therapy in Advanced

Renal Cancer and Malignant Melanoma. Clin. Cancer Res. 3: 565-572, 1997.

188. Dutcher, J.P., Fisher, R.I., Weiss, G., Aronson, F., Margolin, K., Louie, A., Mier, J., Caliendo, G.,

Sosman, J.A., Eckardt, J.R., Ernest, M., Doroshow, J., and Atkins, M.: Outpatient Subcutaneous

Interleukin-2 and Alpha Interferon for Metastatic Renal Cell Cancer: Five Year Follow-Up of the Cytokine

Working Group Study. Cancer J. Sci. Amer. 3: 157-162, 1997.

189. Somlo, G., Doroshow, J.H., Forman, S.J., Maryon, T., Lee, J., Chow, W., Hamasaki, V., Leong, L.,

Morgan, Jr., R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., and Molina, A.: High-Dose

Chemotherapy and Stem Cell Rescue in the Treatment of High-Risk Breast Cancer: Prognostic Indicators

of Progression-Free and Overall Survival. J. Clin. Oncol. 15: 2882-2893, 1997.

190. Lau, D.H.M., Ryu, J.K., Gandara, D.R., Morgan, R., Doroshow, J., Wilder, R., and Leigh, B.: Twice-

Weekly Paclitaxel and Radiation for Stage III Non-Small Cell Lung Cancer. Semin. Oncol. 24 (Suppl. 12):

S12-106-S12-109, 1997.

48



191. Morgan, Jr., R.J., Doroshow, J.H., Venkataraman, K., Chang, K., Raschko, J., Somlo, G., Leong, L.,

Tetef, M., Shibata, S., Hamasaki, V., Margolin, K., Forman, S., Akman, S., Coluzzi, P., Ahn, C., Weiss,

L., Gadgil, U., and Harrison, J.: High-Dose Infusional Doxorubicin and Cyclophosphamide: A Feasibility

Study of Tandem High-Dose Chemotherapy Cycles Without Stem Cell Support. Clin. Cancer Res. 3:

2337-2345, 1997.

192. Sondak, V.K., Kopecky, K.J., Smith II, J.W., Taylor, C.W., Noyes, R.D., Tuthill, R.J., Hersh, E.M.,

Feun, L.G., Doroshow, J.H., Flaherty, LE., Meyskens Jr., F.L.: Is Interferon-γ Detrimental? Results of a

Southwest Oncology Group Randomized Trial of Adjuvant Interferon-γ versus Observation in Melanoma.

In Adjuvant Therapy of Cancer VIII, S.E. Salmon, ed., Lippincott-Raven Publishers, Philadelphia, PA, pp.

259-272, c. 1997.

193. Morgan, Jr., R.J., Newman, E.M., Doroshow, J.H., McGonigle, K., Margolin, K., Raschko, J., Chow,

W., Somlo, G., Leong, L., Tetef, M., Shibata, S., Hamasaki, V., Carroll, M., Vasilev, S., Akman, S.,

Coluzzi, P., Wagman, L., Longmate, J., Paz, B., Yen, Y., and Klevecz, R.: Phase I Trial of Intraperitoneal

Iododeoxyuridine With and Without Intravenous High-Dose Folinic Acid in the Treatment of Advanced

Malignancies Primarily Confined to the Peritoneal Cavity: Flow Cytometric and Pharmacokinetic

Analysis. Cancer Res. 58: 2793-2800, 1998.

194. Yam, P.Y., Yee, J.-K., Ito, J., Sniecinski, I., Doroshow, J.H., Forman, S.J., and Zaia, J.A.:

Comparison of Amphotropic and Pseudotyped VSV-G Retroviral Transduction in Human CD34+

Peripheral Blood Progenitor Cells from Adult Donors with HIV-1 Infection or Cancer. Exper. Hematol.

26: 962-968, 1998.

195. Synold, T.W., Tetef, M.L., and Doroshow, J.H.: Antineoplastic Activity of Continuous Exposures to

Dexrazoxane: Potential New Role As a Novel Topoisomerase II Inhibitor. Semin. Oncol. 25 (Suppl. 10):

93-99, 1998.

196. Synold, T. W., Newman, E.M., Carroll, M., Muggia, F.M., Groshen, S., Johnson, K., and Doroshow,

J.H.: Cellular But Not Plasma Pharmacokinetics of Lometrexol Correlate with the Occurrance of

Cumulative Hematologic Toxicity. Clin. Cancer Res. 4: 2349-2355, 1998.

197. Lara, Jr., P.N., Gandara, D.R., Wurz, G.T., Lau, D., Uhrich, M., Turrell, C., Raschko, J.,

Edelman, M.J., Synold, T., Doroshow, J., Muggia, F., Perez, E.A., and DeGregorio, M.: High-Dose

Toremifene as a Cisplatin Modulator in Metastatic Non-Small Cell Lung Cancer: Targeted Plasma Levels

are Achievable Clinically. Cancer Chemother. Pharmacol. 42: 504-508, 1998.

198. Edelman, M.J., Meyers, F.J., Grennan, T., Lauder, J., and Doroshow, J.: Phase II Trial of Pyrazine

Diazohydroxide in Androgen-Independent Prostate Cancer. Invest. New Drugs 16: 179-182, 1998.

199. Doroshow, J.H.: Pharmacological Basis for High-Dose Chemotherapy. In Hematopoietic Cell

Transplantation, E.D. Thomas, K.G. Blume, and S.J. Forman, eds., 2nd edition, Blackwell Science, Inc.,

Malden, MA, pp. 103-122, c. 1999.

49



200. Tetef, M., Leong, L., Ahn, C., Akman, S., Chow, W., Margolin, K., Morgan, R.J. Jr., Raschko, J.,

Shibata, S., Somlo, G., and Doroshow, J.H.: Cisplatin and Infusional Cytosine Arabinoside for the

Treatment of Colorectal Adenocarcinoma: A Phase II Trial. Cancer Invest. 17: 114-117, 1999.

201. Lau, D., Ryu, J., Gandara, D., Morgan, R., Doroshow, J., Wilder, R., and Leigh, B.: Concurrent

Twice-Weekly Paclitaxel and Thoracic Irradiation for Stage III Non-Small Cell Lung Cancer. Semin.

Radiation Oncol. 9 (Suppl 1): 117-120, 1999.

202. Somlo, G., Sniecinski, I., ter Veer, A., Longmate, J., Knutson, G., Vuk-Pavlovic, S., Bhatia, R.,

Chow, W., Leong, L., Morgan, R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., Forman, S.,

Jones, D., Ashby, M., Fyfe, G., Hellmann, S., and Doroshow, J.H.: Recombinant Human Thrombopoietin

in Combination with Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood

Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic

Recovery Following High-Dose Chemotherapy. Blood 93: 2798-2806, 1999.

203. Leichman, C.G., Jacobson, J.R., Modiano, M., Daniels, J.R., Zalupski, M.M., Doroshow, J.H.,

Fletcher, W.S., and Macdonald, J.S.: Hepatic Chemoembolization Combined with Systemic Infusion of 5-

Fluorouracil and Bolus Leucovorin for Patients with Metastatic Colorectal Carcinoma: A Southwest

Oncology Group Pilot Trial. Cancer 86: 775-781, 1999.

204. Esworthy, R.S., Chu, F.-F., and Doroshow, J.H.: Analysis of Glutathione-Related Enzymes.

In Current Protocols in Toxicology, M. Maines, L. G. Costa, D.J. Reed, S. Sassa, and I.G. Sipes, eds., John

Wiley and Sons, Inc., New York, NY, pp. 7.1.1-7.1.32, c. 1999.

205. Wong, J.Y.C., Somlo, G., Odom-Maryon,T., Williams, L.E., Liu, A., Yamauchi, D., Wu, A.M.,

Yazaki, P., Wilczynski, S., Shively, J.E., Forman, S., Doroshow, J.H., and Raubitschek, A.A.: Initial

Clinical Experience Evaluating Yttrium-90-Chimeric T84.66 Anticarcinoembyonic Antigen Antibody and

Autologous Hematopoietic Stem Cell Support in Patients with Carcinoembryonic Antigen-

Producing Metastatic Breast Cancer. Clin. Cancer Res. 5: 3224s-3231s, 1999.

206. Doroshow, J.H.: Principles of Medical Oncology. In Manual of Clinical Oncology, R.Pollock ed., 7th

edition, John Wiley and Sons, Inc., New York, NY, pp. 275-292, c. 1999.

207. Morgan, R.J., Jr., Braly, P., Cecchi, G., Leong, L., Shibata, S., Margolin, K., Somlo, G., McNamara,

M., Longmate, J., Schinke, S., Raschko, J., Nagasawa, S., Kogut, N., Parker, P., Stein, A., Cho, J., Smith,

E., Coluzzi, P., Najera, L., Johnson, D., Womack, E., and Doroshow, J.H.: Phase II Trial of Intraperitoneal

Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with

Advanced Ovarian Cancer: Long-Term Follow-Up. Gynecol. Oncol. 75: 419-426, 1999.

208. Lenz, H.-J., Raghavan, D., Doroshow, J., and Gandara, D.R.: Phase I Study of Bryostatin-1 in

Combination with Cisplatin in Treating Patients with Metastatic or Unresectable Solid Tumors Including

Non-Small-Cell Lung Cancer. Clin. Lung Cancer 1: 151-152, 1999.

50



209. Jardines, L., Haffty, B.G., Theriault, R.L., and Doroshow, J.H.: Stage II Breast Cancer. In Cancer

Management: A Multidisciplinary Approach, R. Pazdur, L.R. Coia, L.D. Wagman, and W.J. Hoskins, eds.,

4th Edition, PRR, Inc., Melville, NY, pp. 171-180, c. 2000.

210. Jardines, L., Haffty, B.G., Theriault, R.L., and Doroshow, J.H.: Stages III and IV Breast Cancer. In

Cancer Management: A Multidisciplinary Approach, R. Pazdur, L.R. Coia, L.D. Wagman, and W.J.

Hoskins, eds., 4th Edition, PRR, Inc., Melville, NY, pp. 183-200, c. 2000.

211. Tetef, M.L., Margolin, K.A., Doroshow, J.H., Akman, S., Leong, L. A.,, Morgan, R.J.,Jr., Raschko,

J.W., Slatkin, N., Somlo, G., Longmate, J., Carroll, M., and Newman, E.M.: Pharmacokinetics and

Toxicity of High Dose Intravenous Methotrexate in the Treatment of Leptomeningeal Carcinomatosis.

Cancer Chemother. Pharmacol. 46: 19-26, 2000.

212. Morgan, R.J., Jr., Braly, P., Leong, L., Shibata, S., Margolin, K., Somlo, G., McNamara, M.,

Longmate, J., Schinke, S., Raschko, J., Nagasawa, S., Kogut, N., Najera, L., Johnson, D., and Doroshow,

J.H.: Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated

Patients with Advanced Ovarian Cancer: Long-Term Follow-Up. Gynecol. Oncol.77: 433-438, 2000.

213. Raschko, J.W., Synold, T.W., Chow, W., Coluzzi, P., Hamasaki, V., Leong, L.A., Margolin, K.A.,

Morgan, R.J., Shibata, S.I., Somlo, G., Tetef, M.L., Yen, Y., and Doroshow, J.H.: Phase I Study of

Carboplatin and Etoposide Administered in Conjunction with Dipyridamole, Prochlorperazine and

Cyclosporine A. Cancer Chemother. Pharmacol. 46: 403-410, 2000.

214. Wong, J.Y.C., Chu, D.Z., Yamauchi, D., Williams, L.E., Liu, A., Wilcynski, S., Wu, A.M., Shively,

J.E., Doroshow, J.H., and Raubitschek, A.A.: A Phase I Radioimmunotherapy Trial Evaluating 90

Yttrium

Labeled Anti-CEA Chimeric T84.66 in Patients with Metastatic CEA-Producing Malignancies. Clin.

Cancer Res. 6: 3855-3863, 2000.

215. Benson, A.B., Choti, M.A., Cohen, A.M., Doroshow, J.H., Fuchs, C., Kiel, K., Martin, E.W.,

McGinn, C., Petrelli, N.J., Posey, J.A., Skibber, J.M., Venook, A., and Yeatman, T.J.: NCCN Practice

Guidelines for Colorectal Cancer. Oncology 14: 203-212, 2000.

216. Lau, D., Leigh, B., Gandara, D., Edelman, M., Morgan, R., Israel, V., Lara, P., Wilder, R., Ryu, J.,

and Doroshow, J.: Twice-Weekly Paclitaxel and Weekly Carboplatin with Concurrent Thoracic

Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non-Small Cell Lung Cancer: A

California Cancer Consortium Phase II Trial. J. Clin. Oncol. 19: 442-447, 2001.

217. Morgan, R.J., Synold, T.W., Carr, B.I., Doroshow, J.H., Womack, E.P., Shibata, S., Somlo, G.,

Raschko, J.W., Leong, L., McNamara, M., Chow, W., Tetef, M.L., Margolin, K., Akman, S., and

Longmate, J.: Continuous Infusion Prochlorperazine: Pharmacokinetics, Anti-emetic Efficacy, and

Feasibility of High-Dose Therapy. Cancer Chemother. Pharmacol. 47: 327-332, 2001.

218. Doroshow, J. and Tiller, P.: Cardiotoxicity. In Outline of Oncology Therapeutics, M.J. Ratain, M.

Tempero, and C. Skosey, eds., W.B. Saunders, Inc., Philadelphia, PA, pp. 140-141, c. 2001.

51




Principles and Practice, B.A. Chabner and D.L. Longo, eds., 3rd edition, Lippincott, Williams, and Wilkins

Publishers, Philadelphia, PA, pp. 500-537, c. 2001.

220. Doroshow, J.H., Synold, T.W., Somlo, G., Akman, S.A., and Gajewski, E.: Oxidative DNA Base

Modifications in Peripheral Blood Mononuclear Cells of Patients Treated with High-Dose Infusional

Doxorubicin. Blood 97: 2839-2845, 2001.

221. Somlo, G., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan, Jr., R., Sniecinski, I., Frankel,

P., Reardon, D., Longmate, J., Raschko, J., Shibata, S., O=Donnell, M., Smith, E., Tetef, M., Forman, S.,

Yen, Y., Molina, A., and Doroshow, J.H.: Tandem-Cycle High-Dose Melphalan and Cisplatin with

Peripheral Blood Progenitor Cell Support in Patients with Breast Cancer and Other Malignancies. Biol.

Blood Marrow Transplant. 7: 284-293, 2001.

222. Tetef, M.L., Synold, T.W., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S.,

Somlo, S., Yen, Y., Groshen, S., Johnson, K., Lenz, H.-J., Gandara, D., and Doroshow, J.H.: Phase I Trial

of Ninety-Six Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies. Clin.

Cancer Res. 7: 1569-1576, 2001.

223. Somlo, G., Doroshow, J.H., Synold, T., Longmate, J., Reardon, D., Chow, W., Forman, S.J., Leong,

L.A., Margolin, K.A., Morgan, Jr., R.J., Raschko, J.W., Shibata, S.I., Tetef, M.L., Yen, Y., Kogut, N.,

Schriber, J., and Alvarnas, J.: High-Dose Paclitaxel in Combination with Doxorubicin, Cyclophosphamide

and Peripheral Blood Progenitor Cell Rescue in Patients with High-Risk Primary and Responding

Metastatic Breast Carcinoma: Toxicity Profile, Relationship to Paclitaxel Pharmacokinetics, and Short-

Term Outcome. Brit. J. Cancer 84: 1591-1598, 2001.

224. Jardines, L., Haffty, B.G., Doroshow, J.H., Fisher, P., Weitzel, J., and Theriault, R.L.: Breast Cancer

Overview: Risk Factors, Screening, Genetic Testing, and Prevention. In Cancer Management: A

Multidisciplinary Approach, R. Pazdur, L.R. Coia, L.D. Wagman, and W.J. Hoskins, eds., 5th Edition,

PRR, Inc., Melville, NY, pp. 137-159, c. 2001.

225. Jardines, L., Haffty, B.G., Doroshow, J.H., and Theriault, R.L.: Stages 0 and I Breast Cancer. In



226. Jardines, L., Haffty, B.G., Doroshow, J.H., and Theriault, R.L.: Stage II Breast Cancer. In Cancer

Management: A Multidisciplinary Approach, R. Pazdur, L.R. Coia, L.D. Wagman, and W.J. Hoskins, eds.,


227. Jardines, L., Haffty, B.G., Doroshow, J.H., and Theriault, R.L.: Stages III and IV Breast Cancer. In



228. Margolin, K., Longmate, J., Synold, T., and Doroshow, J.H.: Methodologic Guidelines for the Design

of High-Dose Chemotherapy Regimens. Biol. Blood Marrow Transplant. 7: 414-432, 2001.

52



229. Lara, P.N., Jr., Gandara, D.R., Longmate, J., Gumerlock, P.H., Lau, D.H.M., Edelman, M.J.,

Gandour-Edwards, R., Mack, P.C., Israel, V., Raschko, J., Frankel, P., Perez, E.A., Lenz, H.J., and

Doroshow, J.H.: Activity of High Dose Toremifene Plus Cisplatin in Previously Platinum-Treated Non-

Small Cell Lung Cancer: A Phase II California Cancer Consortium Trial. Cancer Chemother. Pharmacol.

48: 22-28, 2001.

230. Kane, S.E.,, Matsumoto, L., Metz, M.Z., Donohue, C.A., Lingeman, R.G., Lin, S.W. and Doroshow,

J.H.: MDR1 Biscistronic Vectors: Analysis of Selection Stringency, Amplified Gene Expression, and

Vector Stability in Cell Lines. Biochem. Pharmacol. 62: 693-704, 2001.

231. Esworthy, R.S., Aranda, R., Martin, M.G., Doroshow, J.H., Binder, S.W., and Chu, F.-F.:

Mice With Combined Disruption of GPX1 and GPX2 Genes Have Colitis. Amer. J. Physiol. Gastrointest.

Liver Physiol. 281: G848-G855, 2001.

232 . Margolin, K., Longmate, J., Synold, T.W., Gandara, D.R., Weber, J., Gonzalez, R., Johansen, M.J.,

Newman, R., Baratta, T., and Doroshow, J.H.: Dolastatin-10 in Metastatic Melanoma: A Phase II and

Pharmacokinetic Trial of the California Cancer Consortium. Invest. New Drugs 19: 335-340, 2001.

233. List, A.F., Kopecky, K.J., Willman, C.L., Head, D.R., Persons, D.L., Slovak, M.L., Dorr, R., Karanes,

C., Hynes, H.E., Doroshow, J.H., Shurafa, M., and Appelbaum, F.R.: Benefit of Cyclosporine Modulation

of Drug Resistance in Patients with Poor-Risk Acute Myeloid Leukemia: A Southwest Oncology Group

Study. Blood 98: 3212-3220, 2001.

234. Morgan, R.J., Jr., Doroshow, J.H., Leong, L., Schriber, J., Shibata, S., Forman, S., Hamasaki, V.,

Margolin, K., Somlo, G., Alvarnas, J., McNamara, M., Longmate, J., Raschko, J., Chow, W., Vasilev, S.,

McGonigle, K., and Yen, Y.: Phase II Trial of High-Dose Intravenous Doxorubicin, Etoposide, and

Cyclophosphamide with Autologous Stem Cell Support in Patients with Residual or Responding Recurrent

Ovarian Cancer. Bone Marrow Transplant. 28: 859-863, 2001.

235. Jardines, L., Haffty, B.G., Doroshow, J.H., Fisher, P., and Weitzel, J.: Breast Cancer Overview: Risk

Factors, Screening, Genetic Testing, and Prevention. In Cancer Management: A Multidisciplinary

Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, eds., 6th Edition, PRR, Inc., Melville,

NY, pp. 149-172, c. 2002.

236. Jardines, L., Haffty, B.G., and Doroshow, J.H.: Stages 0 and I Breast Cancer. In Cancer Management:

A Multidisciplinary Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, and, eds., 6th

Edition, PRR, Inc., Melville, NY, pp. 173-184, c. 2002.

237. Jardines, L., Haffty, B.G., and Doroshow, J.H.: Stage II Breast Cancer. In Cancer Management: A

Multidisciplinary Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, eds., 6th Edition,

PRR, Inc., Melville, NY, pp. 185-194, c. 2002.

238. Jardines, L., Haffty, B.G., and Doroshow, J.H.: Stages III and IV Breast Cancer. In Cancer

Management: A Multidisciplinary Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, eds.,


53



239. Lara, P.N.Jr., Meyers, F.J., Gray, C.R., Edwards, R.G., Gumerlock, P.H., Kauderer, C., Tichauer, G.,

Twardowski, P., Doroshow, J.H., and Gandara, D.R.: HER-2/neu Is Infrequently Overexpressed in Patients

with Prostate Cancer: Results from the California Cancer Consortium Screening Trial. Cancer 94: 2584-

2589, 2002.

240. Somlo, G., Simpson, J.F., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J.,

Shibata, S., Forman, S., Kogut, N., McNamara, M., Molina, A., Somlo, E., and Doroshow, J.H.: Predictors

of Long-Term Outcome Following High-Dose Chemotherapy in High-Risk Primary Breast Cancer. Brit. J.

Cancer 87: 281-288, 2002.

241. Yen, Y., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, G.,

Twardowski, P., Frankel, P., Longmate, J., Synold, T., Newman, E.M., Lenz, H.-J., Gandara, D., and

Doroshow, J.H.: Phase I Pharmacodynamic Study of Time and Sequence Dependency of Hydroxyurea in

Combination with Gemcitabine: A California Cancer Consortium Trial. Cancer Chemother. Pharmacol. 50:

353-359, 2002.

242. Morgan, R.J., Jr., Newman, E., Sowers, L., Scanlon, K., Harrison, J., Akman, S., Leong, L., Margolin,

K., Niland, J., Raschko, J., Somlo, G., Carroll, M., Chow, W., Tetef, M., Hamasaki, V., Yen, Y., and

Doroshow, J.H.: Phase I Study of Cis-diamminedichloroplatinum in Combination with Azidothymidine in

the Treatment of Patients with Advanced Malignancies. Cancer Chemother. Pharmacol. 51: 459-464, 2003.

243. Takimoto, C.H., Remick, S.C., Sharma, S., Mani, S., Ramanathan, R.K., Doroshow, J., Hamilton, A.,

Mulkerin, D., Graham, M., Lockwood, G.F., Ivy, P., Egorin, M., Schuler, B., Greenslade, D., Goetz, A.,

Knight, R., Thomas, R., Monahan, B.P., Dahut, W., and Grem, J.L.: A Dose Escalating and

Pharmacological Study of Oxaliplatin in Adult Cancer Patients with Impaired Renal Function: A National

Cancer Institute Organ Dysfunction Group Study. J. Clin. Oncol. 21: 2664-2672, 2003.

244. Juhasz, A., Cheng, C., Rivera, H., Vishwanath, R., Chiu, A., Margolin, K., Yen, Y., Newman, E.M.,

Synold, T., Wilczynski, S., Lenz, H.-J., Gandara, D., Albain, K., Longmate, J., Frankel, P., and Doroshow,

J.H.: Quantification of Chemotherapeutic Target Gene mRNA Expression in Human Breast Cancer

Biopsies: Comparison of Real-Time Reverse Transcription-PCR Versus Relative Quantification Reverse

Transcription-PCR Utilizing DNA Sequencer Analysis of PCR Products. J. Clin. Lab. Analysis 17: 184-

194, 2003.

245. Esworthy, R.S., Binder, S.W., Doroshow, J.H., and Chu, F.-F.: Microflora Trigger Colitis in Mice

Deficient in Selenium-Dependent Glutathione Peroxidase and Induce Gpx2 Gene Expression.

Biol. Chem. 384: 597-607, 2003.



Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, eds., 7th Edition, SCP

Communications, Inc., New York, NY, pp. 163-188, c. 2003.

54



247. Jardines, L., Haffty, B.G., and Doroshow, J.H.: Stages 0 and I Breast Cancer. In Cancer Management:

A Multidisciplinary Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, eds., 7th Edition,

SCP Communications, Inc., New York, NY, pp. 189-204, c. 2003.



SCP Communications, Inc., New York, NY, pp. 205-214, c. 2003.



7th Edition, SCP Communications, Inc., New York, NY, pp. 215-234, c. 2003.

250. Doroshow, J.H., Synold, T., Gandara, D., Mani, S., Remick, S., Mulkerin, D., Hamilton, A., Sharma,

S., Ramanathan, R., Lenz, H.-J., Graham, M., Longmate, J., Takimoto, C., and Ivy, P.: Pharmacology of

Oxaliplatin in Solid Tumor Patients with Hepatic Dysfunction: A Preliminary Report of the National

Cancer Institute Organ Dysfunction Working Group. Semin. Oncol. 30 (Suppl. 15): 14-19, 2003.

251. Ten Tije, A.J., Synold, T.W., Spicer, D., Verweij, J., Doroshow, J.H., and Sparreboom, A.: Effect of

Valspodar on the Pharmacokinetics of Unbound Paclitaxel. Invest. New Drugs 21: 291-298, 2003.

252. Takimoto, C.H., Remick, S.C., Sharma, S., Mani, S., Ramanathan, R.K., Doroshow, J., Hamilton, A.,

Mulkerin, D., Graham, M., Lockwood, G.F., Ivy, P., Egorin, M., Greenslade, D., Goetz, A., and Grem,

J.L.: Administration of Oxaliplatin to Patients with Renal Dysfunction: A Preliminary Report of the

National Cancer Institute Organ Dysfunction Working Group. Semin. Oncol. 30 (Suppl. 15): 20-25, 2003.

253. Lara, P.N., Jr., Frankel, P., Mack, P.C., Gumerlock, P.H., Galvin, I., Martel, C.L., Longmate, J.,

Doroshow, J.H., Lenz, H.-J., Lau, D.H.M., and Gandara, D.R.: Tirapazamine Plus Carboplatin and

Paclitaxel in Advanced Solid Tumors: A California Cancer Consortium Phase I and Molecular Correlative

Study. Clin. Cancer Res. 9: 4356-4362, 2003.

254. Lara, P.N., Jr., Quinn, D.I., Margolin, K., Meyers, F.J., Longmate, J., Frankel, P., Mack, P.C., Turrell,

C., Valk, P., Rao, J., Buckley, P., Wun, T., Gosselin, R., Galvin, I., Gumerlock, P.H., Lenz, H.-J.,

Doroshow, J.H., and Gandara, D.R. SU5416 Plus Interferon Alfa in Advanced Renal Cell Carcinoma: A

Phase II California Cancer Consortium Study with Biologic and Imaging Correlates of Angiogenesis

Inhibition. Clin. Cancer Res. 9: 4772-4781, 2003.

255. Morgan, R.J., Jr., Doroshow, J.H., Synold, T., Lim, D., Shibata, S., Margolin, K., Schwarz, R., Leong,

L., Somlo, G., Twardowski, P., Yen, Y., Chow, W., Lin, P., Paz, B., Chu, D., Frankel, P., and Stalter, S.:

Phase I Trial of Intraperitoneal Docetaxel in the Treatment of Advanced Malignancies Confined to the

Peritoneal Cavity: Dose-Limiting Toxicity and Pharmacokinetics. Clin. Cancer Res. 9: 5896-5901, 2003.

256. Wong, J.Y.C., Shibata, S., Williams, L.E., Kwok, C., Liu, A., Chu, D.Z., Yamauchi, D., Wilczynski,

S., Wu, A.M., Yazaki, P., Shively, J.E., Doroshow, J.H., and Raubitschek, A.A.: A Phase I Trial of 90

Y-

Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy with 5-Fluorouracil in Patients with

Metastatic Colorectal Cancer. Clin. Cancer Res. 9: 5842-5901, 2003.

55



257. Doroshow, J.H., and Synold, T.: Pharmacological Basis for High-Dose Chemotherapy. In Thomas=

Hematopoietic Cell Transplantation, K.G. Blume, S.J. Forman, and F.R. Applebaum, eds., 3rd

edition,

Blackwell Publishing, Ltd., Malden, MA, pp. 130-157, c. 2004.

258. Openshaw, H., Beamon, K., Synold, T.W., Longmate, J., Slatkin, N.E., Doroshow, J.H., Forman, S.,

Margolin, K., Morgan, R., Shibata, S., and Somlo, G.: Neurophysiological Study of Peripheral Neuropathy

after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine. Clin. Cancer Res. 10: 461-467,

2004.

259. Liu, G., Gandara, D.R., Lara, P., Jr., Raghavan, D., Doroshow, J.H., Twardowski, P., Kantoff, P., Oh,

W., Kim, K., and Wilding, G.: A Phase II Trial of Flavopiridol (NSC# 649890) in Patients with Previously

Untreated Metastatic Androgen Independent Prostate Cancer. Clin. Cancer Res.10: 924-928, 2004.

260. Chu, F.-F., Esworthy, R.S., Chu, P.G., Longmate, J., Huycke, M.M., Wilczynski, S., and Doroshow,

J.H.: Bacteria-Induced Intestinal Cancer in Mice with Disrupted Gpx1 and Gpx2 Genes. Cancer Res. 64:

962-968, 2004.

261. Lara, P.N., Jr., Laptalo, L., Longmate, J., Lau, D.H.M., Gandour-Edwards, R., Gumerlock, P.H.,

Doroshow, J.H., and Gandara, D.R.: Trastuzumab Plus Docetaxel in HER-2/neu-Positive Non-Small Cell

Lung Cancer: A California Cancer Consortium Screening and Phase II Trial. Clin. Lung Cancer 5: 231-

236, 2004.

262. Kimura, T., Holland, W.S., Kawaguchi, T., Williamson, S.K., Chansky, K., Crowley, J.J., Doroshow,

J.H., Lenz, H.-J., Gandara, D.R., and Gumerlock, P.H.: Mutant DNA in Plasma of Lung Cancer Patients:

Potential for Monitoring Response to Therapy. Ann. N.Y. Acad. Sci. 1022: 1-7, 2004.

263. Lara, P.N., Chee, K.G., Longmate, J., Ruel, C., Meyers, F.J., Gray, C.R., Gandour-Edwards, R.,

Gumerlock, P.H., Twardowski, P., Doroshow, J.H., and Gandara, D.R.: Trastuzumab Plus Docetaxel in

HER-2/neu-Positive Prostate Carcinoma: Final Results from the California Cancer Consortium Screening

and Phase II Trial. Cancer 100: 2125-2131, 2004.

264. Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Jr., Shibata, S., Chu, P.,

Forman, S., Lim, D., Twardowski, P., Weitzel, J., Alvarnas, J., Kogut, N., Schriber, J., Fermin, E., Damon,

L., and Doroshow, J.H.: Favorable Outcome in Patients with Stage IIIB Inflammatory Breast Carcinoma

Following Dose-Intense Chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.

265. Chu, F.-F., Esworthy, R.S., and Doroshow, J.H.: Role of Se-Dependent Glutathione Peroxidases in

Gastrointestinal Inflammation and Cancer. Free Radical Biol. Med. 36: 1481-1495, 2004.

266. Shibata, S.I., Pezner, R., Chu, D., Doroshow, J.H., Chow, W.A., Leong, L.A., Margolin, K.A.,

McNamara, M.V., Morgan, R.J., Jr., Raschko, J.W., Somlo, G., Tetef, M.L., Yen, Y., Synold, T.W.,

Wagman, L., Vora, N., Carroll, M., Lin, S., and Longmate, J.: A Study of Radiotherapy Modalities

Combined with Continuous 5-FU Infusion for Locally Advanced Gastrointestinal Malignancies. Eur. J.

Surg. Oncol. 30: 650-657, 2004

56



267. Yen, Y., Margolin, K., Doroshow, J., Fishman, M., Johnson, B., Clairmont, C., Sullivan, D., and

Sznol, M.: A Phase I Trial of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone in Combination

with Gemcitabine for Patients with Advanced Cancer. Cancer Chemother. Pharmacol. 54: 331-342, 2004.

268. Chow, W.A., Synold, T.W., Tetef, M.L., Longmate, J., Frankel, P., Lawrence, J., Al-Kadimi, Z.,

Leong, L., Lim, D., Margolin, K., Morgan, R.J., Jr., Raschko, J., Shibata, S., Somlo, G., Twardowski, P.,

Yen, Y., and Doroshow, J.H.: Feasibility and Pharmacokinetic Study of Infusional Dexrazoxane and Dose-

Intensive Doxorubicin Administered Concurrently Over 96 Hours for the Treatment of Advanced

Malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.

269. Morgan, R.J., Jr., Synold, T.W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K.,

Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Y., Chow,

W., Somlo, G., Carroll, M., and Doroshow, J.H.: Phase II Trial of Carboplatin and Infusional Cyclosporine

in Platinum-Resistant Recurrent Ovarian Cancer. Cancer Chemother. Pharmacol. 54: 283-289, 2004.



Approach, R. Pazdur, L.R. Coia, W.J. Hoskins, and L.D. Wagman, eds., 8th Edition, CMP Healthcare

Media, Manhasset, NY, pp. 165-190, c. 2004.

271. Jardines, L., Haffty, B.G., and Doroshow, J.H.: Stages 0 and I Breast Cancer. In Cancer


8th Edition, CMP Healthcare Media, Manhasset, NY, pp. 191-204, c. 2004.



CMP Healthcare Media, Manhasset, NY, pp. 205-214, c. 2004.



8th Edition, CMP Healthcare Media, Manhasset, NY, pp. 215-232, c. 2004.

274. Lara, P.N., Jr., Gumerlock, P.H., Mack, P.C., Lau, D.H.M., Gandour-Edwards, R., Edelman, M.J.,

Albain, K.S., Law, L.Y., Longmate, J., Frankel, P., Reddy, G.P., Israel, V., Doroshow, J.H., and Gandara,

D.R.: Gemcitabine in Non-Small Cell Lung Cancer Patients Previously Treated with Platinum-Based

Chemotherapy: A Phase II California Cancer Consortium Trial. Clin. Lung Cancer 6: 102-107, 2004.

275. Doroshow, J.H.: Principles of Medical Oncology. In UICC Manual of Clinical Oncology, R.E.

Pollock, ed., 8th

Edition, John Wiley & Sons, Inc., Hoboken, NJ, pp. 245-262, c. 2004.

276. Lim, D., Morgan, Jr., R.J., Akman, S., Margolin, K., Carr, B.I., Leong, L., Odujinrin, O., and

Doroshow, J.H.: Phase I Trial of Menadiol Diphosphate (Vitamin K3) in Advanced Malignancy. Invest.

New Drugs 23: 235-239, 2005.

57



277. Lara, P.N. Jr., Law, L.Y., Wright, J.J., Frankel, P., Twardowski, P., Lenz, H.-J., Lau, D.H.,

Gumerlock, P.H., Doroshow, J.H., and Gandara, D.R.: Intermittent Dosing of the Farnesyl Transferase

Inhibitor Tipifarnib (R115777) in Advanced Malignant Solid Tumors: A Phase I California Cancer

Consortium Trial. Anticancer Drugs 16: 317-321, 2005.

278. Doroshow, J.: The Role of the National Cancer Institute in Drug Development. Clinical Advances in

Hematol. & Oncol. 3: 257-258, 2005.

279. Lara, P.N., Jr., Mack, P.C., Synold, T., Frankel, P., Longmate, J., Gumerlock, P.H., Doroshow, J.H.,

and Gandara, D.R.: The Cyclin-Dependent Kinase (CDK) Inhibitor UCN-01 (7-Hydroxy Staurosporine)

Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and

Molecular Correlative Trial. Clin. Cancer Res. 11: 4444-4450, 2005.

280. Doroshow, J.H.: Targeting EGFR in Non-Small-Cell Lung Cancer. N. Engl. J. Med. 353:

200-202, 2005.

281. Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I.,

Gandara, D., and Doroshow, J.H.: CCI-779 in Metastatic Melanoma: A Phase II Trial of the California

Cancer Consortium. Cancer 104: 1045-1048, 2005.

282. Margolin, K.A., Doroshow, J.H., Frankel, P., Chow, W., Leong, L.A., Lim, D., McNamara, M.,

Morgan, R.J., Shibata, S., Somlo, G., Twardowski, P., Yen, Y., Kogut, N., Schriber, J., Alvarnas, J., and

Stalter, S.: Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed

Germ Cell Cancer. Biol. Blood Marrow Transplant. 11: 903-911, 2005.

283. Acharya, M.R., Sparreboom, A., Sausville, E.A., Conley, B.A., Zwiebel, J., Doroshow, J.H., Venitz,

J., and Figg, W.D.: Interspecies Differences in Plasma Protein Binding of MS-275, A Novel Histone

Deacetylase Inhibitor. Cancer Chemother. Pharmacol. 57: 275-281, 2006.

284. Doroshow, J.H.: Redox Modulation of Chemotherapy-Induced Tumor Cell Killing and Normal Tissue

Toxicity. J. Natl. Cancer Inst. 98: 223-225, 2006.

285. Lara, P.N., Jr., Stadler, W., Longmate, J., Quinn, D.I., Wexler, J., Van Loan, M., Twardowski, P.,

Gumerlock, P.H., Vogelzang, N.J., Vokes, E.E., Lenz, H.-J., Doroshow, J.H., and Gandara, D.R.: A

Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory

Prostate Cancer Patients with Bone Metastases. Clin. Cancer Res. 12: 1556-1563, 2006.

286. Kummar, S., Gutierrez, M., Doroshow, J.H., and Murgo, A.J.: Drug Development in Oncology:

Classical Cytotoxics and Molecularly Targeted Agents. Brit. J. Clin. Pharmacol. 62: 15-26, 2006.

287. Lara, P. N., Jr., Kocyzwas, M., Quinn, D.I., Lenz, H.J., Davies, A., Lau, D.H.M., Gumerlock, P.H.,

Longmate, J., Doroshow, J.H., Scheinkein, D., Kashala, O., and Gandara, D.R.: Bortezomib Plus

Docetaxel in Advanced Non-Small-Cell Lung Cancer and Other Solid Tumors: A Phase I California

Cancer Consortium Trial. J. Thoracic Oncol.1: 126-134, 2006.

58



288. Hesketh, P.J., Chansky, K., Lau, D.H.M., Doroshow, J.H., Moinpour, C.M., Chapman, R.A.,

Goodwin, J.W., Gross, H.M., Crowley, J.J., and Gandara, D.R.: Sequential Vinorelbine and Docetaxel in

Advanced Non-Small Cell Lung Cancer Patients Over Age 70, and/or with a Performance Status of 2; A

Phase II Trial of the Southwest Oncology Group (S0027). J. Thoracic Oncol.1: 537-544, 2006.

289. Doroshow, J.H., McCoy, S., Macdonald, J.S., Issell, B.F., Patel, T., Cobb, P.W., Yost, K.J., and

Abbruzzese, J.L.: Phase II Trial of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic

Adenocarcinoma of the Stomach: A Southwest Oncology Group Study. Invest. New Drugs 24: 537-542,

2006

290. Tan, A.R., Moore, D.F., Hidalgo, M., Doroshow, J.H., Poplin, E.A., Goodin, S., Mauro, D., and

Rubin, E.H.: Pharmacokinetics of Cetuximab after Administration of Escalating Single Dosing and

Weekly Fixed Dosing in Patients with Solid Tumors. Clin. Cancer Res. 12: 6517-6522, 2006.

291. Mukhopadhyay, I., Sausville, E.A., Doroshow, J.H., and Roy, K.K.: Molecular Mechanism of

Adaphostin-Mediated G1 Arrest in Prostate Cancer (PC-3) Cells: Signaling Events Mediated by

Hepatocyte Growth Factor Receptor, c-Met, and p38 MAPK Pathways. J. Biol. Chem. 281:

37330-37344, 2006.


Principles and Practice, B.A. Chabner and D.L. Longo, eds., 4th edition, Lippincott, Williams, and Wilkins

Publishers, Philadelphia, PA, pp. 414-450, c. 2006.

293. Kummar, S., Kinders, R., Rubinstein, L., Parchment, R., Murgo, A., Collins, J., Pickeral, O., Low, J.,

Steinberg, S., Gutierrez, M., Yang, S., Helman, L., Wiltrout, R., Tomaszewski, J., and Doroshow, J.H.:

Compressing Drug Development Timelines in Oncology Using Phase ‘0’ Trials. Nature Rev. Cancer 7:

131-139, 2007.

294. Shibata, S., Chow, W., Frankel, P., Juhasz, A., Koczywas, M., Leong, L., Lim, D., Margolin, K.,

McNamamara, M., Morgan, R., Newman, E., Somlo, G., Twardowski, P., Yen, Y., Synold, S., and

Doroshow, J.: A Phase I Study of Oxaliplatin in Combination with Gemcitabine: Correlation of Clinical

Outcome with Gene Expression. Cancer Chemother. Pharmacol. 59: 549-557, 2007.

295. Morgan, R.J. Jr., Synold, T.W., Xi, B., Lim, D., Shibata, S., Margolin, K., Schwarz, R., Leong, L.,

Somlo, G., Twardowski, P., Yen, Y., Chow, W., Tetef, M., Lin, P., Paz, B., Koczywas, M., Wagman, L.,

Chu, D., Frankel, P., Stalter, S., and Doroshow, J.H.: Phase I Trial of Intraperitoneal Gemcitabine in the

Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Dose-Limiting

Toxicity and Pharmacokinetics. Clin. Cancer Res. 13: 1232-1237, 2007.

296. Morgan, R.J., Jr., Synold, T.W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K.,

Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Y., Chow,

W., Somlo, G., Carroll, M., and Doroshow, J.H.: Phase II Trial of Carboplatin and Infusional Cyclosporine

with Alfa-Interferon in Recurrent Ovarian Cancer: A California Cancer Consortium Trial. Int. J. Gynecol.

Cancer 17: 373-378, 2007.

59



297. Gajewski, E., Gaur, S., Akman, S.A., Matsumoto, L., van Balgooy, J.N.A., and Doroshow, J.H.:

Oxidative DNA Base Damage in MCF-10A Breast Epithelial Cells at Clinically Achievable

Concentrations of Doxorubicin. Biochem. Pharmacol. 73: 1947-1956, 2007.

298. Synold, T.W., Takimoto, C.H., Doroshow, J.H., Gandara, D., Mani, S., Remick, S.C., Mulkerin, D.L.,

Hamilton, A., Sharma, S., Ramanathan, R.K., Lenz, H.-J., Graham, M., Longmate, J., Kaufman, B.M., and

Ivy, P.: Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients with Impaired

Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. Clin. Cancer

Res. 13: 3660-3666, 2007.

299. Kinders, R., Parchment, R.E., Ji, J., Kummar, S., Murgo, A.J., Gutierrez, M., Collins, J., Rubinstein,

L., Pickeral, O., Steinberg, S.M., Yang, S., Hollingshead, M., Chen, A., Helman, L., Wiltrout, R.,

Simpson, M., Tomaszewski, J.E., and Doroshow, J.H.: Phase 0 Clinical Trials in Cancer Drug

Development: From FDA Guidance to Clinical Practice. Molec. Interventions 7: 325-334, 2007

300. Takimoto, C.H., Graham, M.A., Lockwood, G., Ng, C.M., Goetz, A., Greenslade, D., Remick, S.C.,

Sharma, S., Mani, S., Ramanathan, R.K., Synold, T.W., Doroshow, J.H., Hamilton, A., Mulkerin, D., Ivy,

P., Egorin, M., and Grem, J.L.: Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer

Patients with Impaired Renal Function. Clin. Cancer Res. 13: 4832-4839, 2007.

301. Kummar, S., Gutierrez, M., Gardner, E.R., Hwang, K., Chung, E.J., Lee, M.-J., Maynard, K.,

Kalnitskiy, M., Donovan, E., Chen, A., Melillo, G., Ryan, Q., Conley, B., Figg, W.D., Trepel, J.B.,

Zweibel, J., Doroshow, J.H., and Murgo, A.J.: Phase I Trial of MS-275, a Histone Deacetylase Inhibitor,

Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. Clin. Cancer Res. 13:

5411-5417, 2007.

302. Tomaszewski, J.E., and Doroshow, J.H.: Preclinical Development of Molecularly Targeted Agents in

Oncology. In Cancer Drug Discovery and Development: Molecular Targeting in Oncology, H.L.

Kaufman, S. Wadler, and K. Antman, eds., Humana Press, Totowa, NJ, pp. 703-718, c. 2008.

303. Ramanathan, R.K., Egorin, M.J., Takimoto, C.H.M., Remick, S.C., Doroshow, J.H., LoRusso, P.A.,

Mulkerin, D.L., Grem, J.L., Hamilton, A., Murgo, A.J., Potter, D.M., Belani, C.P., Hayes, M.J., Peng, B.,

and Ivy, S.P.: Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients with Advanced

Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ

Dysfunction Working Group. J. Clin. Oncol. 26: 563-569, 2008.

304. Beumer, J.H., Parise, R.A., Newman, E.M., Doroshow, J.H., Synold, T.W., Lenz, H.-J., and Egorin,

M.E.: Concentrations of the DNA Methyltransferase Inhibitor 5-Fluoro-2’-Deoxycytidine (FdCyd) and its

Cytotoxic Metabolites in Plasma of Patients Treated with FdCyd and Tetrahydrouridine (THU). Cancer


305. Abrams, J.S., Christian, M., and Doroshow, J.: Structures Supporting Cancer Clinical Trials. In

Abeloff’s Clinical Oncology, M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, and W.G.

McKenna, eds., 4th

edition, Churchill Livingstone, Philadelphia, PA, pp. 327-335, c. 2008.

60



306. Murgo, A.J., Kummar, S., Gutierrez, M., Tomaszewski, J.E., and Doroshow, J.: Principles of

Molecularly Targeted Therapy: Present and Future. In Abeloff’s Clinical Oncology, M.D. Abeloff, J.O.

Armitage, J.E. Niederhuber, M.B. Kastan, and W.G. McKenna, eds., 4th

edition, Churchill Livingstone,

Philadelphia, PA, pp. 485-500, c. 2008.

307. Murgo, A.J., Kummar, S., Rubinstein, L., Gutierrez, M., Collins, J., Kinders, R., Parchment, R.E., Ji,

J., Steinberg, S.M., Yang, S., Hollingshead, M., Chen, A., Helman, L., Wiltrout, R., Tomaszewski, J.E.,

and Doroshow, J.H.: Designing Phase 0 Clinical Trials. Clin. Cancer Res. 14: 3675-3682, 2008.

308. Doroshow, J.H. and Parchment, R.E.: Oncologic Phase 0 Trials Incorporating Clinical

Pharmacodynamics: From Concept to the Patient. Clin. Cancer Res. 14: 3658-3663, 2008.

309. Doroshow, J.H.: Publishing Cancer Clinical Trial Results: A Scientific and Ethical Imperative.

The Oncologist 13: 930-932, 2008.

310. Kummar, S., Rubinstein, L., Kinders, R., Parchment, R.E., Gutierrez, M.E., Murgo, A.J., Ji, J.,

Mroczkowski, B., Pickeral, O.K., Simpson, M., Hollingshead, M., Yang, S.X., Helman, L., Wiltrout, R.,

Collins, J., Tomaszewski, J.E., and Doroshow, J.H.: Phase 0 Clinical Trials: Conceptions and

Misconceptions. The Cancer Journal 14: 133-137, 2008.

311. Somlo, G., Chu, P., Frankel, P., Ye, W., Groshen, S., Fermin, E., Doroshow, J.H., Danenberg, K., and

Danenberg, P.: Molecular Profiling Including Epidermal Growth Factor Receptor and p21 Expression in

High-Risk Breast Cancer Patients as Indicators of Outcome. Ann. Oncol. 19: 1853-1859, 2008.

312. Kinders, R.J., Hollingshead, M., Khin, S., Rubinstein, L., Tomaszewski, J.E., Doroshow, J.H., and

Parchment, R.E.: Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic

Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts. Clin. Cancer Res. 14:

6877-6885, 2008.

313. Luu, T., Morgan, R.J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D.D.,

Doroshow, J.H., Gandara, D.R., Aparicio, A., Somlo, G., and Wong, C.: A Phase II Trial of Vorinostat

(Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study.

Clin. Cancer Res. 14: 7138-7142, 2008.

314. Kummar, S., Doroshow, J.H., Tomaszewski, J.E., Calvert, A.H., Lobbezoo, M., and Giaccone, G.:

Phase 0 Clinical Trials: Recommendations from the Task Force on Methodology for the

Development of Innovative Cancer Therapies. Eur. J. Cancer 45: 741-746, 2009.

315. Kummar, S., Doroshow, J.H., and Murgo, A.J.: Phase 0 Trials: An Early Lesson in Trial Teamwork.

Good Clin. Pract. J. 16: 12-14, 2009.

316. Doroshow, J.H., Croyle, R.T., and Niederhuber, J.E.: Five Strategies for Accelerating the War on

Cancer in an Era of Budget Deficits. The Oncologist 14: 110-116, 2009.

61



317. Doroshow, J.H., and Synold, T.W.: Pharmacologic Basis of High-Dose Chemotherapy. In Thomas=

Hematopoietic Cell Transplantation, F.R. Appelbaum, S.J. Forman, R.S. Negrin, and K.G. Blume, eds., 4th

edition, Wiley-Blackwell Publishing, Ltd., Hoboken, NJ, pp. 289-315, c. 2009.

318. Chew, H.K., Frankel, P., Margolin, K., Lenz, H.-J., Gordon, M., Zhang, W., Yang, D., Spicer, D.,

Synold, T., Gandara, D., Albain, K., and Doroshow, J.H.: A Phase II Study of Gemcitabine and Cisplatin

in the Treatment of Metastatic Breast Cancer: A California Cancer Consortium Study. J. Clin. Oncol. 27:

2163-2169, 2009.

319. Kummar, S., Kinders, R., Gutierrez, M.E., Rubinstein, L., Parchment, R.E., Phillips, L.R., Ji, J.,

Monks, A., Low, J.A., Chen, A., Murgo, A.J., Collins, J., Eliopoulos, H., Giranda, V.L., Gordon, G.,

Helman, L., Wiltrout, R., Tomaszewski, J.E., and Doroshow, J.H.: Phase 0 Clinical Trial of the Poly

(ADP-ribose) Polymerase (PARP) Inhibitor ABT-888 in Patients with Advanced Malignancies.

J. Clin. Oncol. 27: 2705-2711, 2009.

320. Juhasz, A., Ge, Y., Markel, S., Chiu, A., Matsumoto, L., van Balgooy, J., Roy, K., and Doroshow,

J.H.: Expression of NADPH Oxidase Homologues and Accessory Genes in Human Cancer Cells,

Tumours, and Adjacent Normal Tissues. Free Radical Res. 43: 1-10, 2009.

321. Pfister, T.D., Reinhold, W., Agama, K., Gupta, S., Khin, S.A., Kinders, R., Parchment, R.E.,

Tomaszewski, J.E., Doroshow, J.H., and Pommier, Y.: Topoisomerase I Levels in the NCI-60 Cell Line

Panel: Comparison of Enzyme Levels Determined by a Validated ELISA and Microarray mRNA Levels

with Indenoisoquinoline Sensitivity. Molec. Cancer Ther. 8: 1878-1884, 2009.

322. Shibata, S., Chow, W., Frankel, P., Leong, L., Lim, D., Margolin, K., Morgan, R., Somlo, G., Yen,

Y., Synold, T., Doroshow, J., Gandara, D., Lenz, H.-J., and Newman, E.: Phase I Trial of GTI-2040,

Oxaliplatin, and Capecitabine in the Treatment of Advanced Metastatic Solid Tumors. Cancer Chemother.

Pharmacol. 64: 1149-1155, 2009.

323. Yang, S.X., Kummar, S., Steinberg, S.M., Murgo, A.J., Gutierrez, M., Rubinstein, L., Nguyen, D.,

Kaur, G., Chen, A.P., Giranda, V.L., Tomaszewski, J.E., and Doroshow, J.H.: Immunohistochemical

Detection of Poly (ADP-ribose) Polymerase Inhibition by ABT-888 in First Oncology Phase 0 Trial.

Cancer Biology and Therapy 8: 1-6, 2009.

324. Doroshow, J.H., and Kummar, S.: Role of Phase 0 Trials in Drug Development. Future Medicinal

Chemistry 1: 1375-1380, 2009.

325. Kummar, S., Gutierrez, M.E., Gardner, E.R., Figg, W.D., Melillo, G., Dancey, J., Sausville, E.A.,

Conley, B.A., Murgo, A.J., and Doroshow, J.H.: A Phase I Trial of UCN-01 and Prednisone in Patients

with Refractory Solid Tumors and Lymphomas. Cancer Chemother. Pharmacol. 65: 383-389, 2010.

326. Wang, L.H., Pfister, T.D., Parchment, R.E., Kummar, S., Rubinstein, L., Evrard, Y.A., Gutierrez,

M.E., Murgo, A.J., Tomaszewski, J.E., Doroshow, J.H., and Kinders, R.J.: Monitoring Drug-Induced

γH2AX Changes as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells.

Clin. Cancer Res. 16 : 1073-1084, 2010.

62



327. Kummar, S., Gutierrez, M.E., Gardner, E.R., Chen, X., Figg, W.D., Zajac-Kaye, M., Chen, M.,

Steinberg, S.M., Muir, C.A., Yancey, M.A., Horneffer, Y.R., Juwara, L., Melilo, G., Ivy, S.P., Merino, M.,

Neckers, L., Steeg, P.S., Conley, B.A., Giaccone, G., Doroshow, J.H., and Murgo, A.J.: Phase I Trial of

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a Heat Shock Protein Inhibitor,

Administered Twice Weekly in Patients with Advanced Malignancies. Eur. J. Cancer 46: 340-347, 2010.

328. Curt, G., Dornan, J., Prindiville, S.A., and Doroshow, J.H.: Bringing New Options to Cancer Patients

Faster. J. BioLaw & Business 13:1, 2010.

329. Luu, T., Chow, W., Lim, D., Koczywas, M., Frankel, P., Cristea, M., Margolin, K., Doroshow, J.H.,

Somlo, G., Gaur, S., Yen, Y., and Morgan, R.J.: Phase I Trial of Fixed-Dose-Rate Gemcitabine in

Combination with Bortezomib in Patients with Advanced Solid Tumors. Anticancer Res. 30: 167-174,

2010.

330. Reinhold, W.C., Mergny, J.-L., Liu, H., Ryan, M., Pfister, T.D., Kinders, R., Parchment, R.,

Doroshow, J., Weinstein, J.N., and Pommier, Y.: Exon Array Analyses Across the NCI-60 Reveals

Potential Regulation of TOP1 by Transcription Pausing at Guanosine Quartets in the First Intron.

Cancer Res. 70: 2191-2203, 2010.

331. Rubinstein, L., Steinberg, S., Kummar, S., Kinders, R., Parchment, R., Murgo, A., Tomaszewski, J.,

and Doroshow, J.: Statistics of Phase 0 Designs. Statist. Med. 29: 1072-1076, 2010.

332. Holbeck, S.L., Collins, J.M., and Doroshow, J.H.: Analysis of Food and Drug Administration-

Approved Anti-cancer Agents in the NCI60 Panel of Human Tumor Cell Lines. Molec. Cancer Ther. 9:

1451-1460, 2010.

333. Doroshow, J.H., Dilts, D., and Schilsky, R.L.: Streamlining the Cancer Clinical Trials Process,

American Society of Clinical Oncology 2010 Education Book, R. Govindan, ed., Alexandria, VA, pp. 81-

85, c. 2010.

334. Speranza, G., Doroshow, J.H., and Kummar, S.: Adenocarcinoma of the Small Bowel: Changes in the

Landscape? Curr. Opin. Oncol. 22: 387-393, 2010.

335. Abrams, J., and Doroshow, J.H.: Clinical Trial. In Encyclopedia Britannica. 2010. Retrieved June 25,

2010, from Encyclopedia Britannica Online:

http://www.britannica.com/EBchecked/topic/1498744/clinical-trial.

336. Khleif, S.N., Doroshow, J.H., and Hait, W.N.: AACR-FDA-NCI Cancer Biomarkers Collaborative:

Advancing the Use of Biomarkers in Cancer Drug Development. Clin. Cancer Res. 16: 3299-3318, 2010.

337. Doroshow, J.: The National Cancer Institute Experimental Therapeutics Program. Clinical

Advances in Hematol. & Oncol. 8: 403-404, 2010.

63



338. Morgan, R.J., Jr., Synold, T., Mamelak, A., Lim, D., Al-Kadhimi, Z., Twardowski, P., Leong, L.,

Chow, W., Margolin, K., Shibata, S., Somlo, G., Yen, Y., Frankel, P., and Doroshow, J.H.: Plasma and

Cerebrospinal Fluid Pharmacokinetics of Topotecan in a Phase I Trial of Tamoxifen, Carboplatin, and

Topotecan in the Treatment of Recurrent or Refractory Brain or Spinal Cord Tumors. Cancer Chemother.

Pharmacol. 66: 927-933, 2010.

339. Redon, C.E., Nakamura, A.J., Zhang, Y., Ji, J., Bonner, W.M., Kinders, R., Parchment, R., Doroshow,

J.H., and Pommier, Y.: Histone γH2AX and Poly(ADP ribose) as Clinical Pharmacodynamic Biomarkers.

Clin. Cancer Res. 16: 4532-4542, 2010.

340. Kummar, S., Chen, H.X., Wright, J., Holbeck, S., Davis-Millin, M., Tomaszewski, J.E., Zweibel, J.,

Collins, J., and Doroshow, J.H.: Utilizing Targeted Cancer Therapeutic Agents in Combination: Novel

Approaches and Urgent Requirements. Nature Rev. Drug Devel. 9: 843-856, 2010.

341. Doroshow, J.H.: Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for

Molecular Profiling of Individual Patients with Advanced Solid Tumors? J. Clin. Oncol. 28: 4869-4871,

2010.

342. Dilts, D.M., Cheng, S.K., Crites, J.S., Sandler, A.B., and Doroshow, J.H.: Phase III Clinical Trial

Development: A Process of Chutes and Ladders. Clin. Cancer Res. 16: 5381-5289, 2010.

343. Freedman, A.N., Sansbury, L.B., Figg, W.D., Potosky, A.L., Smith, S.R.W., Khoury, M.J., Nelson,

S., Weinshilboum, R.M., Ratain, M.J., McLeod, H., Epstein, R.S., Ginsburg, G.S., Schilsky, R.L., Liu, G.,

Flockhart, D.A., Ulrich, C.M., Davis, R.L., Lesko, L.J., Zineh, I., Randhawa, G., Ambrosone, C.B.,

Relling, M.V., Rothman, N., Xie, H., Spitz, M., Ballard-Barbash, R., Doroshow, J.H., and Minasian, L.:

Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate

Translation. J. Natl. Cancer Inst. 102: 1698-1705, 2010.

344. Kinders, R.J., Hollingshead, M., Lawrence, S., Ji, J., Tabb, B., Bonner, W.E., Pommier, Y.,

Rubinstein, L., Parchment, R.E., Tomaszewski, J., and Doroshow, J.H.: Development of a Validated

Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor

Activity. Clin. Cancer Res. 16: 5447-5457, 2010.

345. Kummar, S., and Doroshow, J.H.: Phase 0 Trials: Expediting the Development of Chemoprevention

Agents. Cancer Prev. Res. 4: 288-292, 2011.

346. Doroshow, J.H.: Topoisomerase II Inhibitors: Anthracyclines. In Cancer Chemotherapy and

Biotherapy: Principles and Practice, B.A. Chabner and D.L. Longo, eds., 5th

edition, Lippincott, Williams,

and Wilkins Publishers, Philadelphia, PA, pp. 356-391, c. 2011.

347. Kummar, S., Gutierrez, M., Chen, A., Turkbey, I.B., Allen, D., Horneffer, Y.R., Juwara, L., Cao, L.,

Yu, Y., Kim, Y.S., Trepel, J., Chen, H., Choyke, P., Melillo, G., Murgo, A.J., Collins, J., and Doroshow,

J.H.: Phase I Trial of Vandetanib and Bevacizumab Evaluating the VEGF and EGF Signal Transduction

Pathways in Adults with Solid Tumors and Lymphomas. Eur. J. Cancer 47: 997-1005, 2011.

64



348. Wu, Y., Antony, S., Juhasz, A., Lu, J., Ge, Y., Jiang, G., Roy, K., and Doroshow, J.H.: Up-regulation

and Sustained Activation of Stat1 Are Essential for IFN-γ Induced Duox2/DuoxA2 Expression in Human

Pancreatic Cancer Cell Lines. J. Biol. Chem. 286: 12245-12256, 2011.

349. Kummar, S., Gutierrez, M.E., Maurer, B.J., Reynolds, C.P., Kang, M., Singh, H., Crandon, S., Murgo,

A.J., and Doroshow, J.H.: Phase I Trial of Fenretinide Lym-X-Sorb Oral Powder in Adults with Solid

Tumors and Lymphomas. Anticancer Res. 31: 961-966, 2011.

350. Zhang, Y.-W., Regairaz, M., Seiler, J., Agama, K.K., Doroshow, J.H., and Pommier, Y.: Poly(ADP-

ribose) polymerase and XPF-ERCC1 Participate in Distinct Pathways for the Repair of Topoisomerase I-

Induced DNA Damage in Mammalian Cells. Nucl. Acids Res. 39: 3607-3620, 2011.

351. Somlo, G., Lashkari, A., Bellamy, W., Zimmerman, T.M., Tuscano, J., O’Donnell, M., Mohrbacher,

A., Forman, S., Frankel, P., Chen, H., Doroshow, J., and Gandara, D.: Phase II Randomized Trial of

Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma.

Brit. J. Haematol. 154: 533-535, 2011.

352. Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Steinberg, S.M., Rapisarda, A., Figg, W.D.,

Turkbey, I.B., Choyke, P., Murgo, A.J., Doroshow, J.H., and Melillo, G.: Multihistology, Target-Driven

Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia Inducible Factor-1α (HIF-1α) in Advanced Solid

Tumors. Clin. Cancer Res. 17: 5123-5131, 2011.

353. Humphrey, R.W., Brockway-Lunardi, L.M., Bonk, D.T., Dohoney, K.M., Doroshow, J.H., Meech,

S.J., Ratain, M.J., Topalian, S.L., and Pardoll, D.M.: Opportunities and Challenges in the Development of

Experimental Drug Combinations for Cancer. J. Natl. Cancer Inst. 103: 1222-1226, 2011.

354. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J.M., Ames, M., Jia, L., Weil, M., Speranza, G.,

Murgo, A.J., Kinders, R., Wang, L., Parchment, R.E., Carter, J., Stotler, H., Rubinstein, L., Hollingshead,

M., Melillo, G., Pommier, Y., Bonner, W., Tomaszewski, J.E., and Doroshow, J.H.: Phase I Study of

PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and

Lymphomas. Cancer Res. 71: 5626-5634, 2011.

355. Ji, J., Kinders, R.J., Zhang, Y., Rubinstein, L., Kummar, S., Parchment, R.E., Tomaszewski, J.E., and

Doroshow, J.H.: Modeling Pharmacodynamic Response to the Poly (ADP-Ribose) Polymerase Inhibitor

ABT-888 in Human Peripheral Blood Mononuclear Cells. PLoS ONE 6(10): e26152.

doi:10.1371/journal.pone.0026152, 2011.

356. Martin, M.M., Ryan, M., Kim, R., Zakkas, A.L., Fu, H., Lin, C.M., Reinhold, W.C., Davis, S.R.,

Bilke, S., Liu, H., Doroshow, J.H., Reimers, M.A., Valenzuela, M.S., Pommier, Y., Meltzer, P.S., and

Aladjem, M.I.: Genome-wide Depletion of Replication Inititation Events in Highly Transcribed Regions.

Genome Res. 21: 1822-1832, 2011.

357. Kummar, S., and Doroshow, J.H.: Phase 0 Trials in Cancer Drug Development. In Drug Discovery

and Clinical Research, S.K. Gupta, ed., Jaypee Brothers Medical Publishers, Ltd., New Delhi, India, pp.

170-181, c. 2011.

65



358. Nguyen, D., Zajac-Kaye, M., Rubinstein, L., Voeller, D., Tomaszewski, J.E., Kummar, S., Chen,

A.P., Pommier, Y., Doroshow, J.H., and Yang, S.X.: Poly(ADP-ribose) Polymerase Inhibition Enhances

P53-Dependent and –Independent DNA Damage Responses Induced by DNA Damaging Agents.

Cell Cycle 10: 4074-4082, 2011.

359. Doroshow, J.H.: A Vision for the Development of Molecularly Targeted Therapies for Colon Cancer

in 2012. J. Clin. Oncol. 30 (suppl. 4): 40-41, 2012.

360. Speranza, G., Gutierrez, M.E., Kummar, S., Strong, J.M., Parker, R.J., Collins, J., Yunkai, Y., Cao,

L., Murgo, A.J., Doroshow, J.H., and Chen, A.: Phase I Study of the Synthetic Triterpenoid, 2-Cyano-3,

12-Dioxoolean-1, 9-Dien-28-Oic Acid (CDDO) in Advanced Solid Tumors. Cancer Chemother.

Pharmacol. 69: 431-438, 2012.

361. Zoppoli, G., Solier, S., Reinhold, W.C., Liu, H., Connelly, Jr., J.W., Monks, A., Shoemaker, R.H.,

Abaan, O.D., Davis, S.R., Meltzer, P.S., Doroshow, J.H., and Pommier, Y.: CHEK2 Genomic and

Proteomic Analyses Reveal Genetic Inactivation or Endogenous Activation Across the 60 Cell Lines of the

US National Cancer Institute. Oncogene 31: 403-418, 2012.

362. Morgan, R.J., Leong, L., Chow, W., Gandara, D., Frankel, P., Fleming, G., Garcia, A., Lenz, H.-J.,

and Doroshow, J.H.: Phase II Trial of Bryostatin-1 in Combination with Cisplatin in Patients with

Recurrent or Persistent Ovarian Cancer: A California Cancer Consortium Study. Invest. New Drugs 30:

723-728, 2012.

363. Doroshow, J.H., Juhasz, A., Ge, Y., Holbeck, S., Antony, S., Wu, Y., Lu, J., Jiang, G., and Roy, K.:

Antiproliferative Mechanisms of Action of the Flavin Dehydrogenase Inhibitors Diphenylene Iodonium

and Di-2-thienyliodonium Based on Molecular Profiling of the NCI-60 Human Tumor Cell Panel.

Biochem. Pharmacol. 83: 1195-1207, 2012.

364. Kummar, S., Chen, A., Parchment, R.E., Kinders, R., Ji, J., Tomaszewski, J.E., and Doroshow, J.H.:

Advances in Using PARP Inhibitors to Treat Cancer. BMC Medicine 10: 25, 2012 (doi:10.1186/1741-

7015-10-25).

365. Kummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S.L., Belani, C.P., Gandara, D.R., Allen, D.,

Kiesel, B., Beumer, J.H., Newman, E.M., Rubinstein, L., Chen, A., Zhang, Y., Wang, L., Kinders, R.J.,

Parchment, R.E., Tomaszewski, J.E., and Doroshow, J.H.: A Phase I Study of Veliparib in Combination

with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas.

Clin. Cancer Res. 18: 1726-1734, 2012.

366. Schilsky, R.L., Doroshow, J.H., LeBlanc, M., and Conley, B.A.: Development and Use of Integral

Assays in Clinical Trials. Clin. Cancer Res. 18: 1540-1546, 2012.

367. Do, K., Doroshow, J.H., and Kummar, S.: Antiangiogenic Approaches for the Treatment of Advanced

Synovial Sarcomas. Curr. Opin. Oncol. 24: 425-430, 2012.

66



368. Reinhold, W.C., Sunshine, M., Liu, H., Varma, S., Kohn, K.W., Morris, J., Doroshow, J., and

Pommier, Y.: Cell Miner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript

and Drug Patterns in the NCI-60. Cancer Res. 72: 3499-3511, 2012.

369. Doroshow, J. H.: Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation

Injury from the Anthracycline Antibiotics. Curr. Pharmaceut. Biotech. 13: 1949-1956, 2012.

370. Vanderwalde, A., Ye, W., Frankel, P., Asuncion, D., Leong, L., Luu, T., Morgan, R., Twardowski, P.,

Koczywas, M., Pezner, R., Paz, I.B., Margolin, K., Wong, J., Doroshow, J., Forman, S., Shibata, S., and

Somlo, G.: Long-term Survival after High-Dose Chemotherapy Followed by Peripheral Blood Stem Cell

Rescue for High-Risk, Locally Advanced/Inflammataory, and Metastatic Breast Cancer. Biol. Blood

Marrow Transplant. 18: 1273-1280, 2012.

371. Esworthy, R.S., Kim, B.-W., Rivas, G.E., Leto, T.L., Doroshow, J.H., and Chu, F.-F.: Analysis of

Candidate Colitis Genes in the Gdac1 Locus of Mice Deficient in Glutathione Peroxidase-1 and -2.

PLoS ONE 7(9): e44262, 2012. doi:10.1371/journal.pone.0044262.

372. Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W.C., Varma, S., Ballestrero, A., Doroshow, J.H., and

Pommier, Y.: The Putative DNA/RNA Helicase SLFN-11 Sensitizes Cancer Cells to DNA Damaging

Agents. Proc. Natl. Acad. Sci. USA 109: 15030-15035, 2012.

373. Teicher, B.A., and Doroshow, J.H.: The Promise of Antibody-Drug Conjugates. New Engl. J. Med.

367: 1847-1848, 2012.

374. Murai, J., Huang, S.N., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S., and

Pommier, Y.: Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res.

72: 5588-5599, 2012.

375. Speranza, G., Doroshow, J.H., and Kummar, S.: Pharmacodynamic Endpoints in Early Phase

Oncology Trials. Clin. Invest. 2: 679-687, 2012.

376. Pfister, T.D., Hollingshead, M., Kinders, R.J., Zhang, Y., Evrard, Y.A., Ji, J., Khin, S.A., Borgel, S.,

Stotler, H., Carter, J., Divelbiss, R., Kummar, S., Pommier, Y., Parchment, R.E., Tomaszewski, J.E., and

Doroshow, J.H.: Development and Validation of an Immunoassay for Quantification of Topoisomerase I in

Solid Tumor Tissues. PLoS ONE 7(12): e50494, 2012. doi:10.1371/journal.pone.0050494.

377. Jaspers, J.E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S.A.L., Ji, J., Aly, A.,

Doroshow, J., Cranston, A., Martin, N.M.B., Lau, A., O’Connor, M., Ganesan, S., Borst, P., Jonkers, J.,

and Rottenberg, S.: Loss of 53BP1 Causes PARP Inhibitor Resistance in BRCA1-Mutated Mouse

Mammary Tumors. Cancer Disc. 3: 68-81, 2013.

378. Wu, Y., Lu, J., Antony, S., Juhasz, A., Liu, H., Jiang, G., Meitzler, J.L., Roy, K., and Doroshow, J.H.:

Interferon-γ-Induced Toll-Like Receptor 4 Is Required for the Synergistic Induction of Dual Oxidase 2 and

Dual Oxidase A2 by Lipopolysaccharide and Interferon-γ in Human Pancreatic Cancer Cell Lines.

J. Immunol. 190: 1859-1872, 2013.

67



379. Park, S.R., Davis-Millin, M., Doroshow, J.H., and Kummar, S.: Safety and Feasibility of Targeted

Agent Combinations in Solid Tumours. Nature Rev. Clin. Oncol. 10: 154-168, 2013.

380. Doroshow, J.H., Gaur, S., Markel, S., Lu, J., van Balgooy, J., Synold, T.W., Xi, B., Wu, X., and

Juhasz, A.: Effects of Iodonium-Class Flavin Dehydrogenase Inhibitors on Growth, Reactive Oxygen

Production, Cell Cycle Progression, NADPH Oxidase 1 Levels, and Gene Expression in Human Colon

Cancer Cells and Xenografts. Free Rad. Biol. Med. 57: 162-175, 2013.

381. Wu, Y., Antony, S., Hewitt, S.M., Jiang, G., Yang, S., Meitzler, J.L., Juhasz, A., Lu, J., Liu, H.,

Doroshow, J.H., and Roy, K.: Functional Activity and Tumor-Specific Expression of Dual Oxidase 2 in

Pancreatic Cancer Cells and Human Malignancies Characterized with a Novel Monoclonal Antibody.

Int. J. Oncol. 42: 1229-1238, 2013.

382. Kummar, S., Anderson, L., Hill, K., Majerova, E., Allen, D., Horneffer, Y., Ivy, S. P., Rubinstein, L.,

Harris, P., Doroshow, J.H., and Collins, J.M.: First-in-Human Phase 0 Trial of Oral 5-Iodo-2-

pyrimidinone-2’-deoxyribose (IPdR) in Patients with Advanced Malignancies. Clin. Cancer Res. 19:

1852-1857, 2013.

383. Park, S.R., Speranza, G., Piekarz, R., Wright, J.J., Kinders, R.J., Wang, L., Pfister, T., Trepel, J.B.,

Lee, M.-J., Alarcon, S., Steinberg, S.M., Collins, J., Doroshow, J.H., and Kummar, S.: A Multi-histology

Trial of Fostamatinib in Patients with Advanced Colorectal, Non-Small Cell Lung, Head and Neck,

Thyroid, and Renal Cell Carcinomas, and Pheochromocytomas. Cancer Chemother. Pharmacol. 71: 981-

990, 2013.

384. Kummar, S., Allen, D., Monks, A., Polley, E.C., Hose, C.D., Ivy, S.P., Turkbey, I.B., Lawrence, S.,

Kinders, R.J., Choyke, P., Simon, R., Steinberg, S.M., Doroshow, J.H., and Helman, L.: Cediranib for

Metastatic Soft Part Sarcoma. J. Clin. Oncol. 31: 2296-2302, 2013.

385. Kummar, S., and Doroshow, J.H.: Molecular Targets in Cancer Therapy. Expert Rev. Anticancer

Ther. 13: 267-269, 2013.

386. Abrams, J.S., Mooney, M., Zwiebel, J., Korn, E.L., Friedman, S., Finnigan, S., Schettino, P.,

Denicoff, A., Kruhm, M., Montello, M., Misra, R., Ansher, S., DiPiazza, K., Souhan, E., Wickerham, L.,

Giantonio, B.J., O’Donnell, R., Sullivan, D.M., Soto, N., Flemin, G., Prindiville, S., Petryshyn, R.A.,

Hautala, J., Grad, O., Zuckerman, B.L., Meyer, R.M., Yao, J.C., Baker, L.A., Buckner, J., Hortobagyi, G.,

and Doroshow, J.H.: Implementation of Timeline Reforms Significantly Speeds Up Initiation of NCI-

Sponsored Trials. J. Natl. Cancer Inst. 105: 954-959, 2013.

387. Bhattacharyya, S., Kurdziel, K., Wei, L., Riffle, L., Kaur, G., Hill, G.C., Jacobs, P.M., Tatum, J.L.,

Doroshow, J.H., and Kalen, J.D.: Zirconium-89 Labeled Panitumumab: A Potential Immuno-PET Probe

for HER1-Expressing Carcinomas. Nucl. Med. Biol. 40: 451-457, 2013.

388. Doroshow, J.H., Sleijfer, S., Stupp, R., and Anderson, K.: Cancer Clinical Trials: Do We Need a New

Algorithm in the Age of Stratified Medicine? The Oncologist 18: 651-652, 2013.

68



389. Abaan, O.D., Davis, S.R., Zhu, Y.J., Bilke, S., Polley, E.C., Walker, R.L., Pineda, M., Ginden, Y.,

Jiang, Y., Reinhold, W., Holbeck, S.L., Doroshow, J.H., Simon, R., Pommier, Y., and Meltzer, P.S.: The

Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology.

Cancer Res. 73: 4372-4382, 2013.

390. Jeong, W., Doroshow, J.H., and Kummar, S.: United States Food and Drug Administration Approved

Oral Kinase Inhibitors for the Treatment of Malignancies. Curr. Probl. Cancer 37: 110-144, 2013.

391. Antony, S., Wu, Y., Hewitt, S.M., Anver, M.R., Butcher, D., Jiang, G., Meitzler, J.L., Liu, H., Juhasz,

A., Lu, J., Roy, K.K., and Doroshow, J.H.: Characterization of NADPH Oxidase 5 Expression in Human

Tumors and Tumor Cell Lines with a Novel Mouse Monoclonal Antibody. Free Rad. Biol. Med.

65: 497-508, 2013.

392. Doroshow, J.H.: Timely Completion of Scientifically-Rigorous Cancer Clinical Trials: An Unfilfilled

Priority. J. Clin. Oncol. 31: 3312-3314, 2013.

393. Do, K., Doroshow, J.H., and Kummar, S.: Wee Kinase as a Target for Cancer Therapy.

Cell Cycle 12: 3159-3164, 2013.

394. Kummar, S., Gutierrez, M.E., Anderson, L.W., Klecker, Jr., R.W., Chen, A., Murgo, A.J., Doroshow,

J.H., and Collins, J.M.: Pharmacologically-Driven Patient Selection for a First-in-Human Phase I Trial of

Batracylin in Patients with Advanced Solid Tumors and Lymphomas. Cancer Chemother. Pharmacol.

72: 917-923, 2013.

395. McShane, L.M., Cavenagh, M.M., Lively, T.G., Eberhard, D.A., Bigbee, W.L., Williams, P.M.,

Mesirov, J.P., Polley, M.C., Kim, K.Y., Tricoli, J.V., Taylor, J.M.G., Shuman, D. J., Simon, R.M.,

Doroshow, J.H., and Conley, B.A.: Criteria for the Use of Omics-Based Predictors in Clinical Trials.

Nature 502: 317-320, 2013.

396. McShane, L.M., Cavenagh, M.M., Lively, T.G., Eberhard, D.A., Bigbee, W.L., Williams, P.M.,

Mesirov, J.P., Polley, M.C., Kim, K.Y., Tricoli, J.V., Taylor, J.M.G., Shuman, D. J., Simon, R.M.,

Doroshow, J.H., and Conley, B.A.: Criteria for the Use of Omics-Based Predictors in Clinical Trials:

Explanation and Elaboration. BMC Medicine 11: 220, 2013.

397. Dodd, L.E., Korn, E.L., Freidlin, B., Gu, W., Abrams, J.S., Bushnell, W.D., Canetta, R., Doroshow,

J.H., Gray, R.J., and Sridhara, R.: An Audit Strategy for Time-To-Event Outcomes Measured with Error:

Application to Five Randomized Controlled Trials in Oncology. Clin. Trials 10: 754-760, 2013.

398. Weil, M.K., Kummar, S., Doroshow, J.H., and Chen, A.: BRCA Mutation and PARP Inhibitors. In

Handbook of Therapeutic Biomarkers in Cancer, S. Yang, J. Dancey, eds., Pan-Sanford Publishing,

Singapore, pp. 417-448, c. 2013.

399. Esworthy, R.S., Kim, B.-W., Doroshow, J.H., Leto, T.L., and Chu, F.-F.: The Gdac1 Locus Modifies

Spontaneous and Salmonella-Induced Colitis in Mice Deficient in Either Gpx2 or Gpx1 Genes, submitted

for publication. Free Rad. Biol. Med. 65: 1273-1283, 2013.

69



400. Doroshow, J.H.: Overcoming Resistance to Targeted Anticancer Drugs. N. Engl. J. Med. 369:

1852-1853, 2013.

401. Abrams, J.S., Mooney, M., Zwiebel, J.A., Christian, M.C., and Doroshow, J.H.: Structures Supporting

Cancer Clinical Trials. In Abeloff’s Clinical Oncology, J.E. Niederhuber, J.O. Armitage, J.H. Doroshow,

M.B. Kastan, and J.E. Tepper, eds., 5th

edition, Elsevier, Philadelphia, PA, pp. 294-301, c. 2014.

402. Kummar, S., Murgo, A.J., Tomaszewski, J.E., and Doroshow, J.H.: Therapeutic Targeting of Cancer

Cells: Era of Molecularly Targeted Agents. In Abeloff’s Clinical Oncology, J.E. Niederhuber, J.O.

Armitage, J.H. Doroshow, M.B. Kastan, and J.E. Tepper, eds., 5th

edition, Elsevier, Philadelphia, PA, pp.

423-433, c. 2014.

403. Kummar, S., and Doroshow, J.H.: Phase 0 Trials in Oncology. In Handbook of Anticancer

Pharmacokinetics and Pharmacodynamics, M.A. Rudek, C.H. Chau, W.D. Figg, and H.L. McLeod, eds.,

2nd

edition, Springer Science and Business Media, LLC, New York, NY, pp. 89-97, c. 2014.

404. Jeong, W., Rapisarda, A., Kinders, R., Chen, A., Melilo, G., Turkbey, B., Steinberg, S.M., Choyke,

P., Doroshow, J.H., and Kummar, S.: Pilot Trial of EZN-2968, an Antisense Oligonucleotide Inhibitor of

Hypoxia-Inducible Factor-1 Alpha (HIF-1α), in Patients with Refractory Solid Tumors. Cancer


405. Murai, J., Huang, S.N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow,

J.H., and Pommier, Y.: Stereospecific Trapping of PARP-DNA Complexes by BMN-673 and Comparison

with Olaparib and Rucaparib. Molec. Cancer Ther. 13: 433-443, 2014.

406. Esworthy, R.S., Kim, B.-W., Chow, J., Shen, B., Doroshow, J.H., and Chu, F.-F.: NOX1 Causes

Ileocolitis in Mice Deficient in Glutathione Peroxidase-1 and -2. Free Rad. Biol. Med. 68: 315-325, 2014.

407. Meitzler, J.L., Antony, S., Wu, Y., Juhasz, A., Liu, H., Lu, J., Jiang, G., Roy, K., and Doroshow, J.H.:

NADPH Oxidases: A Perspective on ROS Production in Tumor Biology. Antioxid. Redox Signal. 20:

2873-2889, 2014.

408. Wu, Y., Antony, S., Meitzler, J.L., and Doroshow, J.H.: Molecular Mechanisms Underlying Chronic

Inflammation-Associated Cancers. Cancer Lett. 345: 164-173, 2014.

409. Jeong, W., Park, S.R., Rapisarda, A., Fer, N., Kinders, R., Chen, A., Melilo, G., Turkbey, B.,

Steinberg, S.M., Choyke, P., Doroshow, J.H., and Kummar, S.: Weekly EZN-2208 (PEGylated SN-38) in

Combination with Bevacizumab in Patients with Refractory Solid Tumors. Invest. New Drugs 32: 340-

346, 2014.

410. Murai, J., Marchand, C., Shahane, S.A., Sun, H., Huang, R., Zhang, Y., Chergui, A., Ji, J., Doroshow,

J.H., Jadhav, A., Takeda, S., Xia, M., and Pommier, Y.: Identification of Novel PARP Inhibitors Using a

Cell-Based TDP1 Inhibitory Assay in a Quantitative High-Throughput Screening Platform. DNA Repair

21: 177-182, 2014.

411. Conley, B.A., and Doroshow, J.H.: Molecular Analysis for Therapy Choice: NCI MATCH. Semin.

Oncol. 41: 297-299, 2014.

70



412. Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J.H., and Pommier, Y.: Rationale for

Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or

Temozolomide Based On PARP Trapping Versus Catalytic Inhibition. J. Pharmacol. Exper. Ther. 349:

408-416, 2014.

413. Lee, J.-M., Hays, J.L., Annunziata, C.M., Noonan, A., Minasian, L., Zujewski, J., Yu, M., Ji, J.,

Steinberg, S.M., Sissung, T., Figg, W.D., Wood, B., Doroshow, J., and Kohn, E.C.: Phase I/Ib Study of

Olaparib and Carboplatin in BRCA 1/2MUT

-Associated Breast or Ovarian Cancer with Biomarker

Analyses. J. Natl. Cancer Inst. doi: 10.1093/jnci/dju089, 2014.

414. Park, S.R., Kinders, R.J., Khin, S., Hollingshead, M., Antony, S., Parchment, R.E., Tomaszewski,

J.E., Kummar, S., and Doroshow, J.H.: Validation of a Hypoxia-Inducible Factor-1 Alpha Specimen

Collection Procedure and Quantitative ELISA in Solid Tumor Tissues. Anal. Biochem. 459: 1-11, 2014.

415. Abrams, J., Conley, B., Mooney, M., Zwiebel, J., Chen, A., Welch, J., Takebe, N., Malik, S.,

McShane, L., Korn, E., Williams, M., Staudt, L., and Doroshow, J.: National Cancer Institute’s Precision

Medicine Initiatives for the New National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 34:

71-76, 2014.

416. Reinhold, W.C., Varma, S., Sousa, F., Sunshine, M., Abaan, O., Davis, S., Reinhold, S.W., Kohn,

K.W., Moris, J., Meltzer, P., Doroshow, J.H., and Pommier, Y.: NCI-60 Whole Exome Sequencing and

Pharmacological CellMiner Analyses. PloS ONE 9(7): e101670. Doi:10.1371/journal.pone.0101670.

417. Doroshow, J.H., and Kummar, S.: Translational Research in Oncology: 10 Years of Progress and

Future Prospects. Nature Rev. Clin. Oncol. 11: 649-662, 2014.

418. Josse, R., Martin, S.E., Guha, R., Ormanoglu, P., Pfister, T.D., Reaper, P.M., Barnes, C.S., Jones, J.,

Charlton, P., Pollard, J.R., Morris, J., Doroshow, J.H., and Pommier, Y.: ATR Inhibitors VE-821 and VX-

970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and

Fork Elongation Responses. Cancer Res. 74: 6968-6979, 2014.

419. Abrams, J., Kramer, B., Doroshow, J.H., and Varmus, H.: National Cancer Institute-Supported

Clinical Trials Networks. J. Clin. Oncol. 33: 293-294, 2015.

420. Roy, K., Wu, Y., Meitzler, J.L., Juhasz, A., Liu, H., Jiang, G., Antony, S., and Doroshow, J.H.:

NADPH Oxidases (NOXs), Cytokines, and Cancer. Clin. Science, in press.

421. Kummar, S., Do, K., Chen, A., Ji, J., Rubinstein, L., and Doroshow, J.H.: Assessing Target

Modulation in Early-Phase Clinical Trials. Semin. Oncol., in press.

422. Kummar, S., and Doroshow, J.H.: Phase 0 Clinical Trials. In Phase 1 Cancer Clinical Trials—A

Practical Guide, E. Eisenhauer, C. Twelves, and M. Buyse, eds., 2nd

edition, Oxford University Press, New

York, NY, in press.

423. Do, K., Kummar, S., Doroshow, J.H., and Pommier, Y.: Topoisomerase-Interacting Agents. In

Cancer: Principles and Practice of Oncology, V.T. DeVita, Jr., T.S. Lawrence, and S.A. Rosenberg, eds.,

10th

edition, Wolters Kluwer Health, Philadelphia, PA, pp. 218-227, c. 2015.

71



424. Doroshow, J.H.: Approach to the Patient with Cancer. In Cecil-Goldman Textbook of Medicine, L.

Goldman and A. Schafer, eds., 25th

edition, Elsevier, Philadelphia, PA, in press.

425. Doroshow, J.H. and Demetri, G.: Malignant Tumors of Bone, Sarcomas, and Other Soft Tissue

Neoplasms. In Cecil-Goldman Textbook of Medicine, L. Goldman and A. Schafer, eds., 25th

edition,

Elsevier, Philadelphia, PA, in press.

426. Newman, E.M., Morgan, R.J., Kummar, S., Beumer, J.H., Blanchard, M.S., Ruel, C., El-Khoueiry,

A.B., Carroll, M.I., Hou, J.M., Li, C., Lenz, H.-J., Eiseman, J.L., and Doroshow, J.H.: A Phase I,

Pharmacokinetic, and Pharmacodynamic Evaluation of the DNA Methyltransferase Inhibitor 5-Fluoro-2’-

deoxycytidine Administered with Tetrahydrouridine. Cancer Chemother. Pharmacol., in press.

427. Kummar, S., Williams, M., Lih, C.-J., Polley, E.C., Chen, A.P., Rubinstein, L.V., Zhao, Y., Simon,

R.M., Conley, B.A., and Doroshow, J.H.: Application of Molecular Profiling in Clinical Trials for

Advanced Metastatic Cancers. J. Natl. Cancer Inst. doi:10.1093/jnci/djv003, 2015.

428. Zhao, Y., Polley, E.C,, Li, M.-C., Lih, C.-J., Palmisano, A., Sims, D.J., Rubinstein, L.V., Conley,

B.A., Chen, A.P., Williams, P.M., Kummar, S., Doroshow, J.H., and Simon, R.M.: GeneMed: An

Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision

Oncology Clinical Trials. Cancer Infomatics, in press.

429. Nguyen, D., Rubinstein, L., Takebe, N., Miele, L., Tomaszewski, J.E., Ivy, P., Doroshow, J.H., and

Yang, S.X.: Notch1 Phenotype and Clinical Stage Progression in Non-Small Cell Lung Cancer. J.

Hematol. Oncol., in press.

430. Kummar, S., Oza, A.M., Fleming, G.F., Sullivan, D.M., Gandara, D.R., Naughton, M.J., Villalona-

Calero, M.A., Morgan Jr., R.J., Szabo, P.M. Youn, A., Chen, A.P., Ji, J., Allen, D.E., Lih, C.-J., Mehaffey,

M.G., Walsh, W.D., McGregor III, P.M., Steinberg, S.M., Williams, P.M., Kinders, R.J., Conley, B.A.,

Simon, R.M., and Doroshow, J.H.: Randomized Trial of Cyclophosphamide and the Oral Poly (ADP-

ribose) Polymerase Inhibitor Veliparib in Patients with Advanced High-Grade Serous Ovarian, Primary

Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin. Cancer Res., in press.

431. Do, K., Speranza, G., Bishop, R., Khin, S., Rubinstein, L., Datiles, M., Jeong, W., Eugeni, M., Doyle,

A., Kinders, R., Doroshow, J.H., and Kummar, S.: Biomarker-Driven Phase 2 Trial of the Akt Inhibitor,

MK-2206, in Combination with the MEK Inhibitor, Selumetinib (AZD6244), in Patients with Advanced

Colorectal Carcinoma. Invest. New Drugs, in press.

432. Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R.J., Collins, J., Chen, A.P., Doroshow,

J.H., and Kummar, S.: Phase I Study of Single Agent AZD1775 (MK-1775), a WEE1 Inhibitor, in Patients

with Refractory Solid Tumors. J. Clin. Oncol., in press.

433. Sousa, F.G., Matuo, R., Tang, S.W., Rajapakse, V.N., Luna, A., Sander, C., Varma, S., Simon,

P.H.G., Doroshow, J.H., Reinhold, W.C., and Pommier, Y.: Alterations of DNA Repair Genes in the NCI-

60 Cell Lines and Their Predictive Value for Anticancer Drug Activity. DNA Repair, in press.

72



434. Do, K., Cao, L., Kang, Z., Turkbey, B., Lindenberg, M.L., Larkins, E., Holkova, B., Steinberg, S.M.,

Raffeld, M., Peer, C.J., Figg, W.D., Eugeni, M., Jacobs, P., Choyke, P., Wright, J.J., Doroshow, J.H., and

Kummar, S.: A Phase 2 Study of Sorafenib in Combination with Cetuximab in EGFR-Expressing, KRAS-

Mutated Metastatic Colorectal Cancer. Clin. Colorectal Cancer, in press.

435. Carnesecchi, S., Rougemont, A.-L., Doroshow, J.H., Nagy, M., Mouche, S., Gumy-Pause, F., and

Szanto, I.: The NADPH Oxidase NOX5 Protects Against Apoptosis in ALK-Positive Anaplastic Large

Cell Lymphoma Cell Lines. Free Rad. Biol. Med., in press.

436. Srivastava, A.K., Hollingshead, M.G., Weiner, J., Navas, T., Evrard, Y.A., Khin, S., Ji, J., Zhang, Y.,

Borgel, S., Pfister, T.D., Kinders, R.J., Bottaro, D. P., Linehan, W. M., Tomaszewski, J.E., Doroshow,

J.H., and Parchment, R.E.: Assessment of Pharmacodynamic Response of Full-Length MET Using

Validated Immunoassays, submitted for publication.

437. Lih, C.-J., Sims, D., Harrington, R., Polley, E., Zhao, Y., Mehaffey, M., Forbes, T., Das, B., Walsh,

W., Datta, V., Simon, R., Conley, B., Chen, A., Kummar, S., Doroshow, J., and Williams, P.M.: Analytical

Validation of a Targeted Next Generation Sequencing Assay for the MPACT (Molecular Profiling Based

Assignment of Cancer Therapy) Clinical Trial (NCT01827384), submitted for publication.

438. Juhasz, A., Markel, S., Gaur, S., Liu, H., Lu, J., Jiang, G., Wu, X., Antony, S., Wu, Y., Melillo, G.,

Meitzler, J.L., Roy, K., and Doroshow, J.H.: NADPH Oxidase 1 Expression Plays an Essential Role in

Human Colon Cancer Proliferation, Cell Cycle Progression, and Angiogenesis by Modulating Reactive

Oxygen Species-Dependent Signal Transduction, submitted for publication.

439. Marrero, A.M., Wilsker, D., Lawrence, S.M., Hollingshead, M., Butcher, D., Cerna, D., Pommier, Y.,

Parchment, R.E., Tomaszewski, J.E., Doroshow, J.H., and Kinders, R.J.: Quantitative Assessment of DNA

Damage in Tumors by Multiplex Immunofluorescence Assay, submitted for publication.

440. Doroshow, J.H., Matsumoto, L., Van Balgooy, J., Lin, S., Juhasz, A., and Akman, S.A.:

Modulation of Selenium-Dependent Glutathione Peroxidase Activity Enhances Doxorubicin-Induced

Apoptosis, Tumor Cell Killing, and Hydroxyl Radical Production in Human MCF-7Adr

Breast Cancer Cells

Despite High-Level P-Glycoprotein Expression, submitted for publication.

441. Kinders, R.J., Wang, L., Hollingshead, M., Zhu, W., Khin, S.A., Balasubramanian, P., Evrard, Y.A.,

Newman, E., Byun, H., Yang, A., Rubinstein, L., Kummar, S., Parchment, R.E., Tomaszewski, J.E., and

Doroshow, J.H.: Effects of the DNA Methyltransferase Inhibitor 5-Fluoro-2’-Deoxycytidine (FdCyd) on

DNA Methylation in Vitro and in Patients with Solid Tumors, submitted for publication.

442. Doroshow, J.H.,Winters, K.A., Matsumoto, L., Chu, F.-F., Metz, M.Z., and Kane, S.E.: Co-

Expression of the Human MDR1 and Glutathione Peroxidase Genes in NIH 3T3 Cells After Retroviral

Transduction Enhances Doxorubicin Resistance Beyond that Expected from MDR1 Overexpression Alone,

submitted for publication.

443. Holleran, J.L., Beumer, J.H., McCormick, D.L., Johnson, W.D., Newman, E.M., Doroshow, J.H.,

Kummar, S., Collins, J.M., Covey, J.M., Davis, M., and Eiseman, J.L.: Oral and Intravenous

Pharmacokinetics of 5-Fluoro-2’-deoxycytidine and THU in Cynomolgus Monkeys and Humans,


73



444. Kinders, R., Balasubramanian, P., Kummar, S., Gupta, V., Hasegawa, D., Menachery, A., Lawrence,

S., Davis, D., Parchment, R., Tomaszewski, J., and Doroshow, J.H.: Validation and Clinical Readiness of

the Apostream® Prototype Instrument for Isolation of Circulating Tumor Cells from Sarcoma Patient

Blood Specimens, submitted for publication.

445. Srivastava, A.K., Jaganathan, S., Stephen, L., Hollingshead, M.G., Layhee, A., Damour, E.,

Govindharajulu, J.P., Donohue, J., Esposito, D., Mapes, J.P., Kinders, R.J., Takebe, N., Tomaszewski, J.E.,

Kummar, S., Doroshow, J.H., and Parchment, R.E.: A Multiplex Immunoassay to Quantify 15

Pharmacodynamic Biomarkers of Apoptosis for Clinical Evaluation of a Smac mimetic and Other Classes

of Pro-Apoptotic Drugs, submitted for publication.

446. Do, K., Speranza, G., Chang, L.-C., Polley, E.C., Bishop, R., Khin, S., Trepel, J.B., Lee, S., Lee, M.-

J., Kinders, R.J., Phillips, L, Collins, J., Antony, R., Chen, A.P., Neckers, L., Doroshow, J.H., and

Kummar, S.: Phase I Study of the Heat Shock Protein 90 (Hsp90) Inhibitor, AT113387, Administered on a

Daily for 2 Consequtive Days per Week Dosing Schedule, in Patients with Advanced Solid Tumors,


447. Reinhold, W.C., Sunshine, M., Varma, S., Doroshow, J.H., and Pommier, Y.: Using CellMiner 1.6 for

Systems Pharmacology and Genomic Analysis of the NCI-60, submitted for publication.

448. Cristofaro, J., Ansher, S.S., Abrams, J., Mooney, M., Zwiebel, J., and Doroshow, J.H.: Intellectual

Property in the Era of Molecular Marker-Driven Cancer Therapeutic Trials: A View from the National

Cancer Institute, submitted for publication.

Date post:	09-Aug-2018
Category:	Documents
Upload:	ledan
View:	219 times
Download:	0 times

CURRICULUM VITAE - Harvard Medical School · Chair, Search Committee for Director, Office of Cancer...

Documents